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Breast carcinoma is the most commonly diagnosed malignancy in females, accounting for 
23% of all of new cancer cases worldwide. It is currently the leading cause of cancer 
death among women and accouns for 14% of all cancer death worldwide in 2008. Ductal 
breast carcinoma is one of the most common types of breast malignancies and is 
categorized into two subtypes, ductal carcinoma in situ (DCIS) and invasive ductal 
carcinoma (IDC). DCIS is the most frequent type of non-infiltrating breast carcinoma 
accounting for 10-20% of all breast malignancies. IDC is the most frequent type of breast 
carcinoma, accounting for 60-80% of all breast malignancies. 
 
Heparan sulfate is a linear-structured polysaccharide that is covalently attached to various 
core proteins, and is expressed ubiquitously in human cells, and is found at the cell 
surface and in the extracellular matrix. It has interactions with several proteins and 
mediates a variety of cellular and biological processes. These interactions, which are 
critically dependent on the O-sulfation  patterns within heparan sulfate chains could 
define binding sites for proteins and regulate key events in embryonic development and 
in homeostasis, including the regulation of growth factor signaling, proliferation, cell 
adhesion, coagulation and mobility. Sulfation pattern of heparan sulfate chains is a 
significant factor that critically determines the interactions between heparan sulfate and 




One of the most important sulfation modifiers of heparan sulfate is 6-O-sulfotransferase 
(HS6ST) that specifically transfers sulfate groups from 3’-phosphoadenosine 5’- 
phosphosulfate (PAPS) to the C6 position of N-acetylglucosamine (GlcNAc) residues of 
heparan sulfate. Three 6-O-sulfotransferase isoforms have been described in humans. 
Several studies have demonstrated that HS6ST isoforms are involved in important 
cellular and biological processes such as embryonic organogenesis, postnatal growth and 
development. 
 
Endosulfatases (SULFs) are other sulfation modifying enzymes which specifically edit 6-
O-sulfation on the cell membrane and extracellular matrix by removing the sulfate group 
from the C6 position of N-acetylglucosamine in heparan sulfate chains, thereby 
modulating the biological activity of heparan sulfate. SULF1 and SULF2 are two 
isoforms of endosulfatases which have been identified in humans. Recently, a growing 
body of research has focused on expression patterns of SULF1 and SULF2 in several 
malignancies, and it was identified that the expression of these enzymes are deregulated 
in a number of human malignancies including breast cancer. Although some studies 
proposed that alteration of the expression of 6-O-sulfation editing enzymes may be 
involved in the carcinogenesis process, there is limited information on the function of 
HS6ST(s) and SULF(s) in the tumorigenesis process. 
 
The aim of this study is to elucidate the functional roles of HS6ST3 in breast cancer cell 
lines. HS6ST3 was silenced using siRNA and then functional and genomics studies were 
Summary  
xv  
performed. The immunohistochemical expression of HS6ST3 and SULF1 were examined 
on clinical samples of ductal breast carcinoma by using immunohistostaining techniques. 
 
Our study found that HS6ST3 could modulate the growth and progression of breast 
cancer by directly regulating the expression of critical genes, as well as influencing the 
interactions between heparan sulfate and several growth factors on the cell surface. In 
addition, it was shown that HS6ST3 has an important regulatory role in biosynthesis of 
heparan sulfate on the cell surface of the tumor cells. HS6ST3 was also found to modulate 
cellular response to the cytotoxic effects of Cisplatin and 5-Fluorouracil in breast cancer. 
On the other hand, the immunohistochemical findings on heparan sulfate editing enzymes 
using HS6ST3 and SULF1 antibodies in breast cancer showed that the expression of 
SULF1 and HS6ST3 were dysregulated in breast cancer. Besides, the analysis showed 
that HS6ST3 could be used as a novel diagnostic and prognostic tool for breast cancer, 
while SULF1 could be used as a prognostic factor in breast carcinoma.    
 
These finding are of considerable significance in implicating HS6ST3 in breast cancer. 
The significance of the current study is not limited to the regulatory role of HS6ST3 in 
cellular processes because it could also be used as a novel prognostic and diagnostic 
biomarker in breast cancer. In addition, HS6ST3 might be a possible therapeutic target 
for treating breast cancer as well as other oncogenic malignancies. 
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1.1 Introduction to breast cancer 
Breast is a common location for development of benign and malignant pathologies in 
females. However, in a rare condition, less than 1% of males may develop breast cancer. 
(Mouna et al. 2011) Breast cancer is a term used for a variety of malignant pathologies 
arising in breast. This cancer may develop from several tissues of breast, thus having a 
basic knowledge about anatomy and developmental process of a normal breast is 
essential to have a better understanding about its pathologies such as malignancies. The 
malignancies of breast are classified into different groups which will be discussed in next 
sections. Although the etiology of breast cancer is considered multifactorial, there are 
several known risk factors which may increase the chance of developing a breast cancer 
during a woman’s life such as genetic predisposition, age, family history, diet and 
medication (American, Cancer Society, Breast Cancer Facts and Figures, 2009-2010).  
 
Innovative improvement in medicine brought many advantages for breast cancer as well 
as other cancers. One of these innovations is the early screening methods that enable the 
clinicians to make an early diagnosis. For example, mammography is a common method 
that is wildly used all over the world for screening purposes. Surgical therapies, 
chemotherapy, radiotherapy and hormonal treatments have been other important 





1.1.1Anatomy of normal breast  
Breast is a circular organ located in front of pectoralis major muscle of the chest wall in a 
fertile woman. Superioinferiorly, it extends from second to fifth rib and laterally, extends 
from the external border of sternum to anterior auxiliary line. Breast consists of ducts and 
lobular system which are surrounded by connective tissues. 
 
Each breast is composed of about 15-20 structural units, called lobes which radiate out 
from nipple. Lobes are separated out from each other by fibrous septa which function as 
suspensory ligaments. Lobes are embedded in connective tissue and divided into several 
lobules by fibrous connective tissue. Each lobule is further divided into several alveoli 
which considered as milk secreting units in breast. The milk secreted from alveoli of the 
lobules flows into the ducts which are collecting tubes. All ducts of each lobe connect to 
each others to form a major duct of the lobe. Then, the ducts dilate at their terminating 
location where they connect to the nipple, called ampulla or lactiferous duct. Finally, the 
milk flows from 15-20 opening in the nipple. The nipple is surrounded by a pigmented 
area, called areola which contains a lot of sebaceous glands (Figure.1.1).  
 
Clinically breast is divided to four quadrants: upper lateral, upper medial, lower lateral 
and lower medial.  The lymph drainage of the breast has of great importance since they 
are the common routs for development and spreading of a variety of breast malignancies. 
The lymph of lateral quadrants of breast drains into anterior auxiliary and pectoral lymph 
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nodes. The medial quadrants drain their lymph into internal and posterior thoracic lymph 
nodes (Figure 1.2).  
 
Figure 1.1. Gross structural anatomy of the breast. 
 
Figure 1.2. Lymphatic drainage of the breast.  
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1.1.2 Development of the breast 
Breast is a dynamic specialized glandular organ that produces and secretes the milk. They 
present in a pair in both male and female; however, in male it is immature, while in 
female they develop during puberty and adulthood. In fetus, maternal and placental 
hormones ignite the proliferation of the ducts and connective tissues. Therefore, breast 
bud could be seen in both sexes in newborns (Howard and Gusterson 2000).  
 
During puberty, ovarian hormones influence the breasts to form a circular enlargement. 
In this process, the ductal system elongates and the margins of breast extend; however, 
this enlargement is mainly due to the deposition of adipose tissue than elongation of 
ducts. In a fertile woman, breast has more enlargements and tends to protrude forward. 
Thus, during each menstrual cycle the size of the breast may vary under the influence of 
estrogen and progesterone level of secretion (Knight and Sorensen 2001).  
 
During the early pregnancy, ductal system starts branching while they elongate. The 
secreting alveoli which are located at the end of small ducts expand and filled a major 
volume in breast. The vascularity of connective tissue of breast considerably increases in 
this period. The nipple enlarges and the areola expands and darkens due to more 
pigmentation of this area. In late pregnancy, although enlargement of the breast continue 
due to the distention of secretory alveoli, the speed of growth process decrease. During 
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lactation period, secretory alveoli are very active to produce the milk (Russo and Russo 
2008; Howard and Gusterson 2000).  
 
After lactation period, the breasts tend to turn back to their inactive condition. Therefore, 
the secretory alveoli start shrinking and then disappearing and the space between the 
lobes fill with a thick connective tissue. The nipples also shrink into their original size 
and the pigmentation of the areola diminishes. During the menopause state, the secreting 
alveoli start vanishing and the breasts shrink and become more pendulous due to the 
absence of ovarian secreting hormones (Estrogen and progesterone), a process which is 
called breast atrophy (Jose Russu, 2011(Russo and Russo 2004). 
 
1.1.3 Epidemiology of breast cancer 
Breast carcinoma is the most commonly diagnosed malignancy in females accounting for 
23% of all of new cancer cases. In males, lung cancer is the most frequently diagnosed 
malignancy which has been the first top-ranked cause of cancer death. In the United state, 
12% of females experience invasive type of breast cancer during their life (American 
Cancer Society, 2011a).   
 
The incidence rate of breast cancer rate is generally higher in developed countries 
compared to developing country; however, the mortality rates remains nearly similar.  
Thus, the incidence rate of breast cancer was estimated to be the highest among females 
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living in West and North of the Europe as well as in North of the US and also Australia, 
while the lowest incidence rate was reported from Sub Saharan district of Africa and 
Asia. The incidence rates of other countries were ranked as intermediate. This variation 
might be firstly attributable to the different physical and hormonal factors of a variety of 
people living in different conditions, and secondly due to the availability of the screening 
methods such as mammography. In fact, the high incidence rate of breast cancer in 
Western countries has been mainly due to the intensive screening programs, hormone 
therapy during menopausal period and the increased awareness of their people (Althuis et 
al. 2005; Ravdin et al. 2007; Cronin, Ravdin and Edwards 2009; Edwards et al. 2010; 
Parkin 2009; Séradour et al. 2009; Canfell et al. 2008). On the other hand, in countries 
such as US, UK, Australia and France the incidence rates were diminished which was 
relatively because of limited usage of combinational hormone therapy during the 
menopausal period (Figure 1.3: A). Although the incidence rate of breast cancer was 
generally increased, the death rate was remarkably decreased in many European countries 





Figure 1.3. Incidence rate of breast cancer after age-adjustment (A) mortality rate of 
breast cancer after age-adjustment (B) (Jemal et al. 2011). 
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Breast cancer is currently the top cause of cancer mortality among females specifically in 
developing societies accounting for 14% of cancer death in 2008, while cancer of cervix 
was the leading cause of cancer death during the 1990s. Nearly, half of breast cancers 
happen in developing societies, but sixty percent of breast cancer mortalities were 
reported in these societies. The breast cancer mortality had a decreasing trend in the 
North of US and also many European countries over the last decades (Jemal et al. 2010). 
On the other hand, this trend has been increasing in several African and some Asian 
countries such as India and Uganda mainly due to their lifestyle changes (Parkin et al. 
2010; Ito et al. 2009; Jemal et al. 2011; Colditz, Sellers and Trapido 2006) (Figure 1.3: 
B). The decreasing trend of death rate in developed countries was mainly because of 
early screening for cancer detection as well as newly improved treatment. Overall, the 
five year survival of the breast carcinoma has increased from fifty percent to more than 
seventy five percent (Jemal et al. 2011; Autier et al. 2010). 
 
In Singapore, breast carcinoma has been the most frequent malignancy affecting females 
and accounting for 29.2% of all cancers among females of various ethnic groups 
(Chinese, Malay and Indian) during 2005-2009 (Figure 1.4). Similar to many other 
countries, breast cancer has been the top cause of cancer death in Singapore accounting 
















Figure 1.4. Percentage of the most frequent malignancies in Singapore women during 
2005 – 2009. (Singapore National Registry of Diseases Office, 2011). 
 
 
1.1.4 Risk factors of Breast Cancer 
Many factors were identified as risk factor for breast cancer. Although the main cause of 
breast cancer is still unknown, exposing to at least one of risk factors could increase the 
chance of developing breast cancer during a female’s life. Thus, increasing awareness of 
females about risk factors and the importance of timely screening may lead to reducing 
the incidence as well as mortality of breast cancer. These risk factors may be classified as 
genetic and environmental; however, many of them seem to be not separable. In the next 


















1.1.4.1 Age and Ethnicity 
The chance of developing breast cancer increases by aging in females. The median age of 
the breast cancer cases at the time of diagnosis was estimated at 61. About 95 percent of 
new breast cancer cases and also 97 percent of breast cancer mortalities happened in 
females who were below 40 years old during 2002 to 2006. Although developing breast 
cancer is not a rare phenomenon in female below 40 years old, its risk is considerably 
lower than higher ages. The lowest rate was reported for the age of 20 to 24, while 
women between 75 to 79 years old had the highest incidence rate for developing this 
carcinoma. However, the decrease in the incidence trend of breast cancer over 80 years 
old might be due to imperfect screening. White females who are more than 40 years old 
are at higher risk of breast carcinoma compared to African American at the similar ages. 
On the other hand, African American females who are under 40 years old are in a higher 
risk for developing and dying of breast cancer than American white women of the same 
ages. Breast carcinoma is also ranked on the top of the causes of cancer mortalities in the 
females between 35 to 54 years old (American Cancer Society, 2011a; Horner et al. 
2009). 
 
1.1.4.2 Family history of breast cancer 
 
Females whose first-degree family such as mother, sister and/ or daughter had a history 
of breast cancer are at a higher risk for developing breast carcinoma. This risk will be 
increase in females when more than one of their first degree family are affected or when 
disease occurs in a member of their close relatives at young ages (Collaborative Group on 
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Hormonal Factors in Breast Cancer 2001). In specific syndromes, having a history of 
ovarian carcinoma in close family could increase the chance of developing breast cancer. 
Genetic inheritance is said to be responsible for about nearly five to ten percent of breast 
cancer’s occurrence (National Cancer Institute 2009). This genetic predisposition was 
reported when mutations happen in BRACA1 and BRACA2 genes. These mutations are 
rare (1 %) (Ford et al. 1998); however, when they occur, the chance of developing breast 
carcinoma before the age of seventy is 57% and 49% in BRACA1 and BRACA2 
respectively (Chen and Parmigiani 2007; Bonaïti-Pellié et al. 2009). However, scientist 
believed that lifestyle is a determining factor which could influence the inheritance 
(Lichtenstein et al. 2000). 
 
1.1.4.3 Hormonal factors 
Endogenous sex hormones such as Estrogen and Progesterone always influence the 
growth and development of the breast. They are specifically adjusting the stimulation of 
cell proliferation and inducing the cell death, apoptosis. Thus, they play a critical role in 
predisposing a female to develop a breast cancer. Early menarche or late menopause are 
two important condition that increase the exposure time of a female to sex hormones, and 
therefore could predispose a female to breast carcinoma (Hulka and Moorman 2008; 
Hulka and Moorman 2001). Multiparous women and those who were pregnant below 30 
years old are at lower risk for breast cancer. However, pregnancies at older ages have 
been associated with slight rise in risk of the disease (Lambe et al. 1994; Albrektsen et al. 
2005). In addition, breast feeding showed to remarkably decreased the risk of developing 
this cancer (Collaborative Group on Hormonal Factors in Breast Cancer 2002). 
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Exogenous sex hormones which are used in contraceptives or combined in hormone 
replacement therapy (post-menopausal prescriptions) have been reported to increase the 
risk of developing breast cancer (Johnson and Millard 1996; Bjelic-Radisic and Petru 
2010). Thus, the longer time a women used these exogenous hormones, the higher is the 
risk of breast cancer occurrence; however, stop using of these hormones was showed to 
decrease the risk after five years (Breast cancer and hormone replacement therapy 1997 
(Calle et al. 2009; Heiss et al. 2008). 
 
1.1.4.4 Obesity, physical activity and Diet 
Body weight is a significant adjustable risk factor for breast carcinoma. Gaining weight 
which might be due to unhealthy diet, hormone replacement therapy and/ or physical 
inactivity could enhance the chance of developing breast cancer after the menopause.  
Production of endogenous estrogen occurs in adipose tissue after the menopausal period; 
thus gaining more fat in this period enhance the level of this estrogen in circulation and 
predispose the female to breast cancer. Although body mass and weight gain are 
generally associated with each other, weight gain seems to be an important determining 
factor that positively increase the risk of the breast cancer (Feigelson et al. 2004; 
Morimoto et al. 2002; Eliassen et al. 2006). 
 
Several studies have focused on the role of physical exercise on breast cancer. It was 
shown that those females who do physical exercise regularly are at lower risk physical of 
breast cancer. This effect was well observed in females with normal body mass index 
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(BMI) after the menopause; however, the mechanism of this effect is still unclear 
(Ballard-Barbash et al. 2009; Neilson et al. 2009; Friedenreich and Cust 2008; Peters et 
al. 2009; Schmidt et al. 2009).  
Alcohol intake is an important dietary risk factor that positively increases the risk of 
breast cancer. This risk was enhanced the risk rate up to 21% in those who had more than 
24 g of ethanol consumption per day. Other studies showed that even when the daily 
alcohol intake is below this level, the risk of breast cancer may slightly increase. One 
possible reason might be the effect of ethanol on generating of endogenous sex hormones 
such as estrogen and androgen (Allen et al. 2009; Singletary and Gapstur 2001; Lew et al. 
2009). Overall, it seems that adjusting the body mass by having a balance between energy 
intake and physical exercise could be beneficial to prevent breast cancer.  
 
1.1.4.5 Other risk factors of breast cancer 
 Many studies have reported the association between tobacco smoking and breast cancer. 
Active and passive smoker both may be at higher risk for breast cancer than none 
smokers. However, apart from breast cancer smokers are at higher risk of developing 
other cancers; therefore, non-smokers could benefit from a healthier physical condition 
(Kasim et al. 2005; Lee and Hamling 2006; Miller et al. 2007; Takezaki et al. 1996). 
 
Exposure to a high dose radiation is also suggested to be a potential risk factor 
specifically in adulthood. This event was reported mainly in those survivors who were 
experienced the atomic bomb in Japan. Exposure to low-dose radiation during diagnostic 
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and therapeutic procedures has been also associated with breast cancer; therefore, risk 
assessment before performing these procedures seems to be necessary for physicians  
(Boice et al. 1979; Nekolla, Griebel and Brix 2008; Ma et al. 2008). 
 
1.1.5 Symptoms of breast cancer 
When the tumor is big enough, it would be palpable in physical examination or self 
examination, but generally there is no pain unless inflammation or space occupying mass 
develops. Lymph node metastasis may leads to lymphadenopathy in some cases, while 
the local tumor is still small and/ or painless. Although not frequent but some other times 
a carcinoma of breast give a feeling of heaviness to the breast. Other signs and symptoms 
include pain, asymmetry in breast’s bulk, nipple discharge or bleeding, skin retraction, 
redness and/ or thickening. Once a female found any of these signs or symptoms, she 
should seek for consulting with a physician.  In some cases, breast carcinomas are 
asymptomatic specifically when the tumor is not big enogh to be palpable. Thus, 
awareness of timely screening systems would be very significant to detect the breast 
cancer in earlier stages (American Cancer society, Breast Cancer Facts and Figures 
2011a). 
 
1.1.6 Classification of breast cancer 
Breast cancer classification is critical for physician to decide on treatment as well as 
determine the prognosis of the patients. For this purpose two important system was 
developed, grading and staging. Grading classification is performed on the basis of 
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tumoral cellular structures compared to the normal differentiated cells by a pathologist. 
Thus, the tumors classify into three grades (Grade I, Grade II and Grade III) based on the 
microscopic structure of the tumor cells and cellular growth.  
 
Staging is another important classification for breast cancer. Staging defines how much 
the tumor extended from its original location into other parts of the body. By staging, 
physician could estimate the survival of the breast cancer patients and therefore decide on 
the optimal treatment that the patients may needs. The American Joint Committee on 
Cancer (AJCC) introduced a standardized staging strategy for clinical physicians, called 
TNM system. T is state tumor size ranging from 0 to 4, N state the number of lymph 
node(s) which are involved and ranging from 0 to 3 and M stands for the existence of 
metastasis to other organs which is 0 or 1 ( Escobar et al. 2007; Arnone et al. 2010). The 
details of TNM staging system are as following: 
Stage 0: Carcinoma in-situ, the cancer cells are limited to the original location without 
invasion. 
Stage I: Tumor size ≤ 2cm with no lymph node involvement. 
Stage II: Tumor size ≤ 2cm with metastasis to the adjacent lymph nodes OR tumor size 
is between 2-5 cm with OR without metastasis to the lymph nodes OR tumor size ≥ 5 cm 
without cancer spread. 
Stage III: Tumor is any size with metastasis to the auxiliary lymph nodes (stage IIIA) 
OR the tumor is any size with spread to the breast’s skin or the chest wall (stage IIIB) OR 
the tumor is any size with metastasis to the chest wall, breast’s skin and spread into the 
infraclavicular nodes (stage IIIC). 
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Stage IV: Tumor is at any size and the cancer spreads beyond of the breast into the other 
organs such as lung, liver or brain (American Cancer Society, 2011c). 
Histologically, breast cancer is categorized into several types. This classification includes 
Ductal carcinoma (Invasive or In-Situ), Lobular carcinoma (Invasive or In-Situ), 
Medullary breast carcinoma, Tubular carcinoma, Mucinous carcinoma (colloid), 
Inflammatory breast carcinoma, Scirrhous carcinoma, Papillary carcinoma, Paget disease 
and Undifferentiated carcinomas. Other tumors such as Phyllodes, Angiosarcoma and 
Primary lymphoma may occur in breast but they are not histologically classified as sub-
types of the breast cancer (Edge SB et al. 2010; Carter and Page 2004; Yeatman et al. 
1995; Chaney et al. 2000; Piñero-Madrona et al. 2008). In this classification, some types 
are common such as ductal and lobular carcinoma, while some others are rare such as 
Paget disease. Since ductal carcinoma was used in this study, it will be discussed in the 
next section (American Cancer Society, 2011c; Egyed, Járay and Péntek 2006). 
 
1.1.6.1 Ductal breast carcinoma 
Ductal breast carcinoma is one of the most common types of breast malignancies. In this 
carcinoma, the tumor cells originate from epithelial cells lining the inner layer of the milk 
ducts. Ductal breast carcinomas are categorized into two subtypes based on the location 
and invasion of the tumor cells into basement membrane of the ducts. 
 
Invasive or infiltrating ductal carcinoma (IDC) is the most frequent subtype of breast 
carcinoma and accounting for 60- 80% of all breast malignancies. Thus, IDC develops in 
ducts and then invades the basement membrane of the ducts and finally may spread to the 
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adjacent lymph nodes and tissues as well as other organs (American Cancer Society, 
2011c; Lee et al. 2010; Harris et al. 1984; Wasif et al. 2010). If the tumor cells are limited 
to the basement membrane of the ducts it is called ductal carcinoma In-Situ (DCIS) 
which is the most frequent types of non-infiltrating breast carcinoma accounting for 10-
20% of all breast malignancies. DCIS by itself is not fatal, but it may increase the chance 
of developing IDC in a female Thus, the probability of recurring after 5 to 10 years is 
about 30% specifically if the breast cancer patient was not undergone the radiotherapy. 
However, if radiotherapy performs in combination with other optimal therapies, the risk 
of recurring drops to nearly half (Moriya and Silverberg 1994; Farese and Aebi 2009; 
Jansen 2011; Betsill et al. 1978; Kerlikowske 2010; Barth et al. 1995; Leonard and Swain 
2004).  
 
1.1.7 Diagnosis of breast cancer 
As noted breast cancer may or may not have an apparent signs or symptoms. However, in 
some cases lumps may be detected by patient in self-examination or by physician. Other 
symptoms such as skin redness, rash, retraction or nipple discharges should be taken as a 
serious matter until prove otherwise by examining physician. However, once a female 
seek a physician there could be several diagnostic steps for detecting a breast cancer that 
will be discussed in next sections.  
 
1.1.7.1 Physical examination 
The clinical physician may find some potential abnormalities in breast examination. 
These findings may include asymmetry of breasts, skin inflammation, discharge or 
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retraction of the nipple, lumps or bump in breast, lymphadenopathy in auxiliary, infra or 
supra clavicular lymph nodes. Although normal clinical examination is promising, it 
could not completely rule out the existence of any malignancy in the breast specifically in 
females more than 40 years old. Thus, a regular screening system is recommended to 
perform on females older than 40 years old. 
 
1.1.7.2 Mammography 
Mammography is a medical procedure in which the breast image is taken by x-ray. 
American National Cancer Institute recommends females to do mammography every 1-2 
years in those who are above 40 as a screening method. However, if a clinical physician 
is suspicious to any abnormality in the breast’s breast, it is recommended to perform 
mammography as a first diagnostic step for females at any ages. In fact, the exposure 
time of the x-ray and its precision is higher in diagnostic mammography than screening 
mammography. Sometimes mammography could detect abnormalities which are not 
palpable for patient or physician. In addition, micro calcifications are easily detected in 
mammography which could be an important sign of malignant cancer. However, 
mammography has some false negative or false positive results which should be 
considered by examining physician for further evaluation (Golinger et al. 1979; Borràs, 
Espinàs and Castells 2003; Vidal and Cozzi 1970; Ostapenko et al. 2004; Shetty 2011). 
 
1.1.7.3 Ultrasonography  
Ultrasonography is a non invasive imaging method could scan internal parts of breast as 
well as other soft tissues by using high frequency sound waves. Therefore, this method 
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enables the physicians to have a real time image of internal parts of breast. Solid and 
cystic masses could be detected and discriminated in the breast by ultrasonography. 
Following this step, the clinical physician could decide about the next diagnostic step. 
However, the interpretation of ultrasound in some cases is difficult or even unreliable 
specifically in dense breasts. Some time the real time ultrasonography is used as a good 
guide for taking biopsy from the breast (Guarneri et al. 2011; Le-Petross and Shetty 
2011; Shin et al. 2011; Garcia-Ortega et al. 2011). 
 
1.1.7.4 Magnetic Resonance Imaging (MRI) 
MRI is another non-invasive screening test which is more sensitive than mammography 
ultrasound as it could detect the abnormalities even in dense breasts; however, it is nat 
sensitive for detecting micro calcifications. In this method, cross sectional images of the 
internal organs could be taken by using magnet and radio waves. MRI could be used for 
different purposes such as screening for those who are at high risk of breast cancer, 
reevaluating the suspicious area of the breast and also used for following up of the breast 
cancer patients after treatment (McLaughlin and Hylton 2011; Jansen 2011; Monticciolo 
2011; Miller, Abbott and Tuttle 2011; Postma et al. 2011; Fakkert et al. 2011; Guarneri et 
al. 2011; Le-Petross and Shetty 2011).  
 
1.1.7.5 Positron emission tomography (PET-scan) 
PET scan is generally used for evaluating breast cancer patient in stage II, IIIA, IIIB and 
IV in order to detect any potential metastasis specifically after treatment. Thus, 
radiopharmaceutical [18F] 2-deoxyglucose is intravenously injected to the patient and 
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then patient will be scanned for 90 minutes. Changing of the metabolism of glucose by 
tumor cell could be indicative of metastasis. On the other hand, this method is expensive 
and has a higher rate of false positive results compared to other methods (Park et al. 
2011; Champion et al. 2011; Clapp, Peller and Subramaniam 2011; Warning et al. 2011; 
Choi et al. 2011; Niikura et al. 2011). 
 
1.1.7.6 Fine needle aspiration (FNA) and breast biopsy 
FNA is an easy and rapid test which is done on breast lumps by using a fine needle. FNA 
is a less invasive diagnostic method that enables a physician to discriminate a cystic mass 
from a solid mass found in the breast after screening. In addition, FNA provides a small 
sample of breast’s lumps for further laboratory evaluations. 
Biopsy is basically a definite gold standard way for diagnosis of the breast abnormality. 
Thus, the breast’s abnormality will be partially or totally removed by a surgeon. 
However, based on the surgeon’s decision, obtaining the sample may be performed by 
using different less invasive or invasive procedures. In some cases, biopsy will be done 
under a guide of ultrasound. Then, the obtained sample would be microscopically 
evaluated by a pathologist to make a diagnosis based on histopathology and cytological 
features of the specimen(Hong et al. 2011; Miyake et al. 2011; Lianidou and Markou 
2011; Canavese et al. 2011; Simsir, Rapkiewicz and Cangiarella 2009; Zhao, 2009 







1.1.8 Treatment of breast cancer 
1.1.8.1 Surgery 
 Surgery is a common therapeutic method for breast cancer that may be used in 
combination with other treatments. For example, in ductal carcinoma in-situ the 
combination of surgery and radiotherapy are recommended. Most of the time, surgery is 
considered as a diagnostic and prognostic procedure. There are different types of surgery 
depending on the tumor grading and staging as well as the patient general health 
condition. The type of surgery ranges from local lumpectomy and partial (segmental) 
mastectomy to radical mastectomy depending on above conditions. In the latter, in 
addition to the breast, auxiliary or surrounding lymph nodes and sometimes the 
underlying muscles are also removed by surgeon (American Cancer Society, 2011c).  
 
1.1.8.2 Radiation therapy 
Radiotherapy is a therapeutic method used for breast cancer by using high energy x-ray. 
This method induces the apoptosis and also inhibits uncontrolled proliferation in cancer 
cells. Depending on the type and stage of the breast cancer external or internal therapy 
may be hired. External radiotherapy emit x-ray on the external surface of the cancer 
region, while in internal method, radioactive chemicals are directly guided into the cancer 
location via a needle or catheter. This method is usually used in combination with other 
methods such as surgery or chemotherapy. Thus, radiotherapy may apply pre or post-
operatively in breast cancer patients. Performing radiation therapy together with surgery 
was associated with a less recurrence rate as well as a better survival for breast cancer 
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patients (Ragaz 1990; Ragaz, Spinelli and Coldman 2000; Woodward et al. 2010; Clarke 
et al. 1985; Clarke et al. 2005; Early Breast Cancer Trialists' Collaborative Group 
(EBCTCG) et al. 2010; Miyake et al. 2011; Lianidou and Markou 2011).  
 
Systemic treatment is referred to using a wide variety of the chemical (chemotherapy), 
hormonal (hormonal therapy) or targeted-agent (biological therapy) medication on breast 
cancer patients via systemic circulation. These medications are generally used in 
combination with surgical operations; thus they are used before surgery (called neo-
adjutant) to kill the tumor cells and reduce the tumor size or used after surgery (adjutant) 
to decrease the recurrence rate. Using either of these methods depends on the cancer 
stage, patient’s condition and the presence of specific biomarkers. In addition, based on 
the clinical status of the patients different protocols may be used for combining several of 
these systemic medications. Although these therapeutic medications were associated with 
improved survival of the patients, they might exhibit undesired side effects due to their 
influence on the normal cells (Sakr and Dizon 2011; Bantema-Joppe et al. 2011; Glasziou 
and Houssami 2011; Hall et al. 2011). 
 
1.1.8.3 Systemic therapy 
1.1.8.3.1 Chemotherapy 
Chemotherapeutic drugs generally inhibit the growth and/ or induce cell death in cancer. 
A combination of these drugs was shown to be more effective than single chemotherapy; 
and thus they routinely used in a 2 or 3 combinational protocols. Their frequent 
successful combinations are shown in Table 1.1. Although using these drugs are basically 
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shown to be beneficial for decreasing the relapse rate and also increasing the patient’s 
survival, several undesired side effects may appear such as nausea, vomiting, 
constipation, diarrhea, hair loss and fatigue (Kimmick 2011; Yin et al. 2011; Horio et al. 
2011; Yagata, Kajiura and Yamauchi 2011; Choi, Craft and Geraci 2011; Fitzal et al. 
2011; Müller et al. 2011; Vera-Ramirez et al. 2011).  
 
Table 1.1. Common chemotherapeutic combinations used for breast cancer. 
Abbreviation Combinational chemotherapy 
AC Doxorubicin, cyclophosphamide 
AC-T AC followed by paclitaxel 
EC Epirubicin, cyclophosphamide  
EC-T EC followed by paclitaxel 
CMF Cyclophosphamide, methotrexate, 5-fluorouracil  
TC Docetaxel, cyclophosphamide  
TCH Docetaxel, carboplatin, trastuzumab 
 
1.1.8.3.2 Hormonal therapy 
The proliferation of the tumor cells in some of the breast carcinomas is closely rely on the 
existence of estrogen or progesterone. The hormonal therapy mainly blocks or inhibits 
the influence of the estrogen or progesterone on their corresponding receptors. Therefore, 
the hormonal therapy may be useful on cancer cells that exhibit estrogen or progesterone 
receptors. Before the menopause, patients may benefit from estrogen receptor blockers 
such as Tamoxifen. In addition, estrogen receptor blockers may be used in combination 
with ovarian suppressor drugs such as Leuperolide or Goserlin, Aromidex, Aromasin. 
Aromatase inhibitors are shown to be beneficial after menopause. They inhibit the 
endogenous production of estrogen in the body. The well known members of this group 
are Anastrazol, Letrozole and Exemestane. Fulvestrant is a member of estrogen receptor 
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blockers which is recommended to be used after menopause. On the other hand, using 
hormonal therapy may cause some undesired side effects such as hot flash feeling, 
infertility and irregular menses (Mouridsen et al. 2003; Poole and Paridaens 2007; von 
Minckwitz et al. 2001; Eiermann et al. 2001; de Haes and Olschewski 1998; Barker 2003; 
Bohnet and Bertram 1989; Spinelli et al. 2008; Vrbanec et al. 1998). 
 
1.1.8.3.3 Targeted therapy (Biological therapy) 
In biological therapy, the drugs target certain critical molecules which are responsible for 
growth and progression of the tumor cells. For instance, over expression of HER2/neu 
gene in some breast cancer may lead to rapid proliferation as well as progression of the 
tumor cells in the body. Trastuzumab is a monoclonal antibody that is able to bind into 
HER2 protein on the cell membrane of cancer cells and thus, inhibits the cell signaling 
which cause cellular proliferation as well as invasion. Biological therapy is usually given 
in combination with other anti tumor treatments. Bevacizumab is another monoclonal 
antibody which is able to inhibit angiogenesis in tumor tissues and therefore, limits the 
cancer growth and progression. Undesired side effects may happen during the biological 
therapy such as rash, fever, chill, diarrhea, hypertension, heart, liver or kidney 
dysfunction (Ferreira et al. 2011; Munagala, Aqil and Gupta 2011; Syrigos et al. 2011; 
Kümler and Nielsen 2011; Polyzos et al. 2011; Petrelli et al. 2011; Pivot et al. 2011; 
Burris 2011; Spano et al. 2011; Fang et al. 2011; Rack et al. 2011; Denkert et al. 2011; 




1.2 Introduction to glycosaminoglycans (GAGs) 
Glycosaminoglycans (GAGs) are long unbranched polysaccharides macromolecules 
comprising of an alternating disaccharide subunit of uronic acid isoforms such as L-
iduronic acid or D-glucuronic acid and an N-acetyl-hexosamine such as N-
acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc). They range from 
sulfated macromolecules with a highly negative charge (heparin) to unsulfated molecules 
(Hyaluronan). GAGs could not only be found on the cell surface but they are forming the 
important components of extracellular matrix of a variety of the human tissues. The main 
members of GAGs super family are heparan sulfate, dermatan sulfate, chondroitin 
sulfate, keratan sulfate and hyluronan (Figure 1.5). Except hyluronan, other 
glycosaminoglycans chains might be bounded to a variety of the core protein by covalent 




Figure 1.5. The structure of disaccharides of different glycosaminoglycans (GAGs). 




Figure 1.6. The backbone structure of Proteoglycans (PGs). Glycosaminoglycans 
covalently attach to core proteins via a serine residue. 
 
Heparan sulfate (HS) is a long sulfated negatively charged GAG that composed of 
alternating subunit of D-glucuronic acid and N-acetylglucosamine disaccharides or L-
iduronic acid and N-acetylglucosamine. Heparan sulfate is an unbranched macromolecule 
that could be abundantly found on the cell surfaces as well as in extracellular matrix. 
Heparin, a well known highly sulfated type of heparan sulfate is recognized as the most 
negatively charged molecule in the nature which abundantly found in mast cell granules 
and has an anticoagulant function in human body. HS molecules are involved in a variety 
of cellular and physiological mechanisms in living organism from invertebrate to human. 
It is of great importance since it has critical role in many biological and pathological 
conditions in human such as growth development and carcinogenesis (Whitelock and 
Melrose 2011; Rabenstein 2002). In the next sections, the types and functions of these 
macromolecules will be discussed in detail.  
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Chondroitin sulfate (CS) and Dermatan sulfate (DS) are sulfated linear GAGs which have 
a similar precursor in their biosynthesis. Chondroitin sulfate is composed of repeating 
subunits of glucuronic acid and N-acetylgalactosamine (GalNAc), while dermatan sulfate 
is structured by repeating L-iduronic acid N-acetylgalactosamine (GalNAc) 
disaccharides. CS and DS are heterogeneous molecules due to their various O-sulfation 
patterns and could be found in many mammals. Dermatan sulfate could be abundantly 
found in the human skin and the wall of the vessels, while chondroitin sulfate is mainly 
found in the articular cartilage and in nervous system. CS and DS play important roles in 
development, wound healing, differentiation, cardiovascular diseases, carcinogenesis, 
inflammation, infection and anticoagulation and fibrosis (Shirk et al. 2000; Maimone and 
Tollefsen 1990; Cöster 1991; Trowbridge and Gallo 2002; Kozma, Olczyk and Głowacki 
2001; Watanabe, Yamada and Kimata 1998; McGee and Wagner 2003; Głowacki, 
Koźma and Olczyk 2004; Maeda et al. 2011; Calabrese et al. 2004). 
 
Keratan sulfate (KS) is a short unbranched glycosaminoglycans constituted of an N-
acetylglucosamine as well as galactose instead of uronic acid in its repeating 
disaccharides. KS could be mainly found in extracellular matrix of several tissues; 
however, it is majorly found in cornea, cartilage as well as central nervous system. 
Similar to other GAGs, KS involved in various cellular and biological processes such as 
development, osteoarticular disorders, corneal diseases and neurodegenerative disorders 
(Lester et al. 2001; Funderburgh, Caterson and Conrad 1986; Funderburgh et al. 1991; 
Lindahl et al. 1996; Funderburgh 2002; Greiling 1994). 
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Hyaluronan (HA) is large unsulfated negatively charged GAGs with high molecular 
weight that composed of repeating D-glucuronic acid and N-acetylglucosamine 
disaccharides. This molecule has an excellent lubricating characteristic as they could 
keep a large volume of fluid in extracellular matrix (ECM).  Hyaluronan is a major 
component of synovial fluid, saliva, vitreous humor and extracellular matrix of loose 
connective tissues. These macromolecules are involved in some other important functions 
such as cell proliferation, wound healing, inflammation, immunity, angiogenesis and 
cancer progression (Gao et al. 2010; Slavkovsky et al. 2010; Maeshima et al. 2011; 
Bharadwaj et al. 2011; Meran et al. 2011; Swann et al. 1984; Pogrel, Lowe and Stern 
1996; Cascone, Fonzi Dagger and Aboh 2002; Lu, Levick and Wang 2005; Cöster 1991; 
Maimone and Tollefsen 1990; Lindahl et al. 1996).  As shown in Table 1.2, 
Proteoglycans are classified into several categories based on their core protein as well as 
their specific localization (Waddington and Embery 2001). 
Table 1.2 Classification of proteoglycan (PGs) based on their core protein and 
localization (Waddington et al. 2001). 
 
 
Localization Glycosaminoglycan chain 
Mr of the core 
protein (kD) Main members 
ECM HA, CS, KS 225-250 Aggrecan, versican 
Collagen-




membrane HS 120 Perlecan 






granules Heparin, CS 17-19 Serglycin 
 





1.3 Heparan Sulfate Proteoglycans (HSPG)  
1.3.1 Introduction to Heparan Sulfate (HS) 
As stated above, heparan sulfate is a highly sulfated macromolecule which expresses 
ubiquitously on the cell membrane as well as extracellular matrix of all mammals. This 
linear polysaccharide with a highly negative charge composed of repetitive disaccharide 
and covalently attaches to the serine residue of various core proteins. HSPGs are 
categorized to several classes based on their core protein. On the cell surface, heparan 
sulfate majorly bind with two main families of core proteins: Syndecan (Syndecan 1-4) 
and Glypican (Glypican 1-6). Syndecan are transmembrane proteins whose C- terminal 
domains are highly conserved. HS connect to syndecan via a serine residue in the distal 
part of the core protein. Chondroitin sulfate (CS) chains sometime accompany the HS on 
the syndecan and bounds to the proximal part of the core protein. Glypican core proteins 
are globular proteins stabilized by disulfide links on the cell surface and attach to cell 
membrane via Glycophosphatidylinositol (GPI) linkage. HS attaches to the glypican core 
protein near the plasma membrane. Secreted syndecan or glypican into the extracellular 
matrix are called Perlecans and Agrin which could be found in extracellular matrix 
(ECM) (Figure 1.7). Despite syndecans, glypicans and perlecans merely accompany 




Figure 1.7. Main types of heparan sulfate proteoglycans (HSPGs). Syndecans composed 
of a transmembrane core protein (red), while the core globular protein (red) of glypicans 
attaches to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage. 
Chondroitin sulfate (CS) chains sometime accompany the HS on the syndecan and 
bounds to the proximal part of the core protein. Blue dots represent disulfide bond in 
glypican core protein. Perlecans are shedded heparan sulfate proteoglycans (HSPGs). 
 
Heparan sulfate is the most biologically active GAG in human and thus play a significant 
role in several biological and cellular processes. It interacts with several growth factors 
and cytokines and therefore mediates a variety of the complicated biological processes in 
cellular events such as proliferation, adhesion, migration and differentiation. The heparan 
sulfate may function as a receptor or co-receptor to mediate these cellular processes by 
internalizing the cell signals (Bernfield et al. 1999). Therefore, the level of expression of 
heparan sulfate may potentially influence the signal transduction. It was reported that 
expression of the HS on cell surface could critically regulate the development of different 
organs during embryonic period. This regulation may start from early blastula to the 
latest stages of organogenesis (Tumova, Woods and Couchman 2000; Sutherland et al. 
1991; Litwack et al. 1998). Therefore, any change in the expression pattern of heparan 
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sulfate might lead to a variety of the growth and developmental disorders (Silveri et al. 
1991; Cano-Gauci et al. 1999; Ng et al. 2009).  
 
On the other hand, the quantitative changes of heparan sulfate expression may contribute 
in tumorogenesis process; because these changes could potentially alter the interaction 
between the cell membrane heparan sulfate and several ligands such as cytokines and 
growth factors. Heparan sulfate expression was reported to be involved in the malignant 
process of several cancers such as breast cancer, pancreatic cancer, colorectal cancer, 
brain cancer and lung cancer. For example, a high expression of syndecan 1 in breast 
cancer was shown to be associated with more aggressive nature of tumor cells 
(Vlodavsky et al. 1988; Iozzo 1988; Naor, Sionov and Ish-Shalom 1997; Lo et al. 2011; 
Suzuki et al. 2010; Umezu et al. 2010; Barbareschi et al. 2003; Tátrai et al. 2010; Lv et 
al. 2007; Chatzinikolaou et al. 2008; Raman and Kuberan 2010).  
 
Heparanase is an enzyme that cleaves the cell surface and extracellular heparan sulfate. 
Studies has shown that over-expression of heparanase may result in various malignancies 
such as breast cancer, leukemia and brain cancer (Nadir, Vlodavsky and Brenner 2008; 
Theodoro et al. 2007). Other studies showed that shedding of syndecan 1 that is enhanced 
by heparanase, could significantly stimulate the growth and metastasis of the breast 
cancer cells (Su et al. 2007).   
 
Apart from quantitative changes, qualitative alterations in the structure of HS could 
significantly affect the interaction between the heparan sulfates on the cell surface with 
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several growth factors. Hence, having a deep understanding about the structure of the 
heparan sulfate and its modification during biosynthesis seems to be necessary. 
 
1.3.2 Heparan sulfate biosynthesis 
Heparan sulfate is a heterogeneous macromolecule which consists of repeating 
disaccharide subunits of uronic acid and glucosamine and produces in Golgi apparatus 
inside the cells (Yang et al. 2007). Thus, heparan sulfate biosynthesis is a highly complex 
process that starts from the location in which it connects to the core protein. The 
attachment location usually composed of 2-4 Serine-Glycine sequence on the core 
protein.  
 
The biosynthesis of HS is a sequential process which begins with chain initiation, 
continued by chain polymerization, and finally completed with chain modification. These 
steps are done by several enzymes such as glycosyltransferases, sulfotransferases, 
epimerase and acetylase. In the first step, assembly of a tetrasaccharide which is called 
linkage region on the serine residue of a core protein is started. The linkage region of 
heparin heparan sulfate, dermatan sulfate and chondroitin sulfate has similar structure. 
The catalysis of this step is sequentially accomplished by Xylose transferase (Xy1T), 
Galactose transferase I (GalIT), II (GalIIT) and Glucoronic acid transferase by adding 
each sugar to non-reducing side of the chain. By the end of first step, the tetrasaccharide 





Polymerization of heparan sulfate specifically begins with addition of at least one α1, 4 
glucuronic acid to the linkage region by α -glucoronic acid transferase II (GlcAT-II) and 
then followed by inserting N-acetylglucosamine by GlcNAc transferase II (GlcNAcT II). 
Thus, polymerization continues with addition of alternating disaccharide units (up to 200 
disaccharides) by glycosyltransferases (EXTs) to form the backbone of HS in the Golgi 
apparatus (Esko and Selleck 2002; Lamanna et al. 2007).  
 
By completing the polymerization, modification of heparan sulfate chain starts. These 
modifications happen in sequence, starting from Glucuronic acid N-deacetylation and N-
sulfation to C5 epimerization of glucuronic acid into iduronic acid and then several O-
sulfations. The latter is done by Sulfotransferases, the enzymes which specifically 
transfer the sulfate group from 3′-phosphoadenosyl-5′-phosphosulfate (PAPS) as a donor 
of sulfate group to the particular position in the sugar residues.  O-sulfation begins at C2 
of Iduronic acid (L-IdoA) and glucuronic acid (D-GlcA) residues (2-O-sulfation) with 
more preference for L-IdoA and then continued to C6 sulfation in glucuronic acid and N-
acetylglucosamine (6-O-sulfation) and may finally end with C3 sulfation in glucuronic 
residues (3-O-sulfation).  
 
Three isoforms have been recognized for heparan sulfate 6-O-sulfotransferases (HS6ST1-
3). HS6ST isoforms have different substrate specificities. Thus, they may transfer the 
sulfate group to either GlcNSO3 or GlcNAc residues; additionally, HS6ST1 
predominately act on C6 of GLcNOS3 residue of the HexA-GlcNOS3, but HS6ST2 
prefer C6 of GlcNOS3 residue of the IdoA (2SO4)-GlcNO3 and HS6ST3 may act on 
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both depending on the substrate concentration. Furthermore, HS6ST isoforms express in 
a tissue-specific manner because HS6ST1 express in epithelial and neural-derived tissues, 
while HS6ST2 mainly expresses in mesenchymal tissues and HS6ST3 may express in a 
restricted manner during the later stages of embryonic period. (McCormick et al. 2000; 
Lin 2004; Kramer and Yost 2003; Izumikawa et al. 2006; Esko and Lindahl 2001; 
Hagner-McWhirter et al. 2004; Gorsi and Stringer 2007; Habuchi, Habuchi and Kimata 
2004).  
 
There are other important enzymes which are able to modify the heparan sulfate 6-O-
sulfation in human; called endosulfatases (SULFs). Human SULF1 and SULF2 are 
enzymes known by their arylsulfatase activities that specifically remove sulfate group 
from C6 in heparan sulfate chain. SULFs are able to desulfate the HS both intracellular 
(Golgi apparatus) and extracellular (cell membrane and ECM). It was shown that 
trisulfated IdoA2S-GlcNS6S disaccharide in the heparan sulfate chain is a preferred 
substrate for both of the endosulfatases (Sedita, Izvolsky and Cardoso 2004; Frese et al. 
2009; Ai et al. 2006).  
 
All of the mentioned modifications provide a wide heterogeneity in heparan sulfate 
macromolecules. Sulfation pattern of heparan sulfate chain is a significant factor that 
determines the interactions between HS and variety of the ligands such as cytokines, and 
growth factors and therefore, the function of HS is critically dependent on its sulfation 
pattern (Morimoto-Tomita et al. 2002; Gama et al. 2006; Jastrebova et al. 2010; Allen, 
Filla and Rapraeger 2001).  The sulfation seems to play a crucial role in cell signaling 
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which results in growth and development in mammals. Failure of any of these 
modifications may result in growth disorders or fatal developmental abnormalities during 
the embryonic period (Sugaya et al. 2008; Lin et al. 2000; Stickens et al. 2005; Carlsson 
et al. 2008; Habuchi et al. 2007; Habuchi, Habuchi and Kimata 2004; Kobayashi et al. 
2007; Garg et al. 2003; Ford-Perriss et al. 2002; Habuchi and Kimata 2010; Pratt et al. 
2006).  
 
On the cellular basis, most of the biologically active growth factors need heparan sulfate 
to regulate the cellular processes such as proliferation, adhesion and migration. For this 
purpose, heparan sulfation pattern plays a critical role in determining the spatial 
configuration and the binding site of HS for interacting with growth factors. Recently, 
researcher showed that dysregulation of the heparan sulfation pattern may involve the 
cells in the malignant process of carcinogenesis (Sousa et al. 2008; Kozlowski and Pavao 
2011; Tátrai et al. 2010; Jastrebova et al. 2010; Sanderson et al. 2005). Other researchers 
demonstrated that the heparan sulfation pattern could actively promote or inhibit tumor 
invasion as well as its metastasis (Kozlowski and Pavao 2011; Gama et al. 2006).  
 
1.3.3 Heparan sulfate 6-O-sulfation and cancer 
In the following section, enzymes which are involved in 6-O-sulfation of heparan sulfate 
chain and their significance in tumorogenesis are reviewed. Thus, we firstly will focus on 
critical role of 6-O-sulfotransferases (HS6STs) which transfer sulfate group into C6 
position of N-acetylglucosamine (GlcNAc) residues of heparan sulfate. Then, 
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endosulfatases (SULFs) which remove sulfate group from the similar position will be 
discussed.   
One of the most important sulfation modifiers of heparan sulfate is 6-O-sulfotransferase 
(HS6ST) that specifically transfers sulfate group from 3’-phosphoadenosine 5’- 
phosphosulfate (PAPS) to C6 position of N-acetylglucosamine (GlcNAc) residues of HS. 
As discussed, three HS6ST isoforms have been described in humans with differences in 
their tissue distribution. Each isoform plays an important role in modifying a tissue-
specific 6-O-sulfation in heparan sulfate chain (Habuchi et al. 2000). Changes of the 
expression of each HS6ST isoforms were shown to be associated with an altered HS 
domain structure that may affect the molecular interactions and signaling processes (Do 
et al. 2006). Several studies have demonstrated that HS 6-O-sulfotransferases are 
involved in important biological processes such as embryonic organogenesis, postnatal 
growth and development (Kamimura et al. 2001; Sedita, Izvolsky and Cardoso 2004; 
Habuchi et al. 2007; Izvolsky et al. 2008). Tissue-specific expression of HS6ST isoforms 
at different time points of embryonic period indicates that their timely expression is 
significantly required for growth factor-related development during organogenesis 
(Sedita, Izvolsky and Cardoso 2004). In addition, to the embryonic development, HS6ST 
isoforms seem to influence the anticoagulant characteristic of heparan sulfate during its 
biosynthesis (Zhang et al. 2001). Of the few studies, remarkable over-expression of 
HS6ST2 has been demonstrated in serous, papillary, clear cell carcinoma of ovary as well 
as cervical and corpus cancer of uterine (Kanoh et al. 2006; Seko et al. 2009). Song et al. 
recently found that down-regulation of HS6ST2 could inhibit the growth and progression 
of the pancreatic cancer (Song et al. 2011). Therefore, a new insight has been provided 
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for identifying the potential role of HS6ST isoforms in tumorogenesis, but limited efforts 
were performed to clarify their function in the malignant process of tumorogenesis. 
Endosulfatases (SULFs) are other potent sulfation modifying enzymes which specifically 
edit 6-O-sulfation on the cell surface and extracellular matrix by removing the sulfate 
group from C6 position of N-acetylglucosamine in heparan sulfate chain and thereby 
modulating the biological activity of heparan sulfate (Holst et al. 2007). SULF1 and 
SULF2 are two isoforms of endosulfatases which have been identified in humans.  
Recently, a growing body of research has focused on expression pattern of SULF1 and 
SULF2 in a variety of malignancies, since it was identified that the expression of these 
two enzymes were dysregulated in a number of human malignancies including breast 
cancer. It has also been distinguished that up or down regulation of human endosulfatases 
modulates the cellular behavior of many cancers by inducing an alteration in sulfation 
pattern of carbon C6 in heparan sulfate chain. This means that the sulfation pattern of C6 
position in N-acetylglucosamine residues has an important role that crucially determines 
the binding site and interaction of heparan sulfate chain with various growth factors. 
Several researchers observed a remarkable suppression in tumor proliferation, invasion, 
migration and angiogenesis in response to over expression of SULF1 in a variety of 
cancers like myeloma, hepatocellular cancer, head and neck cancer, breast and ovarian 
carcinomas (Safaiyan, Lindahl and Salmivirta 1998; Lai et al. 2004; Dai et al. 2005; 
Sanderson et al. 2005; Morimoto-Tomita et al. 2005; Timson et al. 2006; Lai et al. 2006; 
Narita et al. 2007; Liu et al. 2009), while some others found that over expression of 
SULF1 could result in an enhanced tumor cell progression in few different malignancies 
such as lung, pancreatic and gastric carcinomas (Abiatari et al. 2006; Lemjabbar-Alaoui 
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et al. 2010; Junnila et al. 2010). These events are due to dramatic influence of 
endosulfatase enzymes on 6-O-sulfation pattern of heparan sulfate chain. To date, the 
expression pattern of SULF1 and SULF2 in breast cancer has been described in a few 
studies, but they have not explained the functional role of editing enzymes of 6-O-
sulfation in breast carcinogenesis. Narita et al. observed that SULF1 is down regulated in 
their in situ hybridization with lobuar morphology predominance (Narita et al. 2007). 
Prior to that, they understood that the expression of SULF1 reduce angiogenesis as well 
as tumorogenesis of breast cancer in vivo (Narita et al. 2006). Later, Chen, Zhao et al. 
found that SULF1 gene is silenced due to the hypermethylation of its promoter in breast 
carcinomas (Chen et al. 2009). Functional hypermethylation of SULF1’s promoter 
provided a logical mechanistic solution for SULF1 down regulation in breast cancer as 
well as other malignancies, but how SULF1 down regulation is involved in breast 
carcinogenesis, is limited to a few simple correlations. Unlike SULF1, there are some 
evidences implying that the expression of SULF2, on the other hand, is proangiogenic in 
the breast (Morimoto-Tomita et al. 2005). Therefore, it seems that SULF1 and SULF2 
functionally behave differently in breast cancer in terms of their genomic pathway 
outcomes.     
 
As stated above, although 6-O-sulfation induced by endosulfatases may play a 
paradoxical role in different human malignancies, its involvement in the malignant 
process of many cancers and specifically in breast cancer is potentially evident. In 
addition, it was consistently observed that the activity of SULF1 is diminished in breast 
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cancer as well as other cancers. Thereby, it is inferable that 6-O-sulfation within heparan 
sulfate chain may have a reverse relationship with SULF1 expression.  
 
Herein, according to the significant involvement of SULF1 in the malignant process of 
breast carcinogenesis and based on the limited knowledge about the potential role of 
HS6ST isoforms in carcinomas, it is thus deducible that changes in the expression HS6ST 
isoforms may lead to a functional alteration of breast cancer cellular phenotypes. 
However, little is understood about the function of HS6ST isoforms in generating 
specific HS protein-binding sequences, expression pattern, and function, specifically in 
the malignant process of breast carcinogenesis.  
 
1.4 Scope of the study 
A growing body of researches has focused on the significant role of GAGs in the 
malignant process of the carcinogenesis. This study was mainly performed on the 
heparan sulfate glycosaminoglycan (HSGAG), the most diverse and biologically active 
GAG in regulating the interactions of cell to cell as well as cell to extracellular matrix 
(ECM). Modifications of heparan sulfate chain in the final stage of its biosynthesis are of 
great importance. Of several modifications, sulfation has attracted attentions, because 
sulfation critically determines the spatial configuration and thus the biding site for 
interaction of HS with other ligands such as growth factors. Recently, a few studies 
showed that 6-O-sulfation could be potentially involved in the malignant process of 
carcinogenesis. HS6STs and SULFs are the main editors of 6-O-sulfation within heparan 
sulfate chain. Similar to endosulfatases, HS6ST isoforms may similarly act on 6-O-
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sulfation within heparan sulfate chain; however, their functional outcomes may vary in 
carcinogenesis. This study was specifically restricted to represent the expression, 
functional and genomics role of HS6ST3 in breast cancer. Thus, the functional role of the 
other isoforms was not central to this study. In addition, the involvement of HS6ST3 in 
other cancers was beyond the scope of our research.  
 
1.5 Hypothesis  
1- HS6ST3 may modulate the breast cancer growth and progression. 
2-HS6ST3 expression may correlate with the clinicopathological parameters in breast 
cancer. 
3-SULF1 expression may correlate with the clinicopathological parameters in breast 
cancer. 
 
1.6 Aim of the study 
In this study, it was mainly aimed to elucidate the functional role of HS6ST3 in T47D 
and MCF7 breast cancer cell lines. Thus, the results of this study may provide a novel 
pathway map for the down-stream gene(s) involved in proliferation, cell cycle, apoptosis, 
adhesion, migration and invasion of T47D and MCF7 cell lines after silencing HS6ST3. 
Furthermore, the immunohistochemical expression of HS6ST3 and SULF1 were 
examined on clinical samples of ductal breast carcinoma by using immunohistostaining 
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technique. The latter approach may significantly contribute to introduce novel diagnostic 
and/or prognostic biomarkers for breast cancer as well as other malignancies. Together, 
specific objectives of this research are as following: 
1-To elucidate the functional roles of HS6ST3 in T47D and MCF7 breast cancer cell 
lines. 
2-To study the effect of HS6ST3 silencing on heparan sulfate synthesis in T47D and 
MCF7 cell lines. 
3-To explore a genomic pathway downstream to the HS6ST3 which regulates the cancer 
growth and progression in T47D and MCF7 breast cancer cell lines. 
4-To examine the influence of silencing of HS6ST3 on sensitizing T47D cell line to the 
cytotoxic effect of cisplatin and 5-fluorouracil. 
5- To determine the association between HS6ST3 expression and clinicopathological 
features of the patients with invasive ductal carcinoma 
6- To investigate whether the expression of HS6ST3 could be used as a novel prognostic 
or diagnostic biomarker in breast cancer. 
7- To determine the association between SULF1 expression and clinicopathological 
features of the patients with invasive ductal carcinoma. 
8- To investigate whether the expression of SULF1 could be used as a novel prognostic 




In the next chapter, the methods of experiments and materials used in this study will be 
discussed. In chapter 3, results will be presented in detail. After that, conclusion and 
discussion will be presented in chapter 4.  
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CHAPTER 2  
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2.1 Cell culture 
Non-cancerous human epithelial breast cell lines including MCF12A (ATCC no: CRL-
10782), and MCF-10A (ATCC no: CRL-10317); breast cancer cell lines including T47D 
(ATCC no: HTB-133, MCF7 (ATCC no: HTB-22) and MDA-MB 231 (ATCC no : HTB-
26) cell lines were taken from American Tissue Culture Collection (ATCC, Manassas, 
VA, USA). MCF12A, an spontaneously immortalized non-cancerous human mammary 
epithelial cell line was taken from MCF-12M, a mortal cell line which was obtained from 
a mammary tissue with focal locations of intraductal hyperplasia taken during a reduction 
mammoplasty surgery of a nulliparous female who developed a fibrocystic disease (Paine 
et al. 1992). 
 
MCF-12A cell lines was cultured in its specific culture condition, a 1:1 mixture of 
Dulbecco’s modified Eagle’s medium and F12 medium known as DMEM-F12 
(Invitrogen, Carlsbad, CA, USA) which was supplemented with 5% FBS (Hyclone, 
Logan, Utah), 0.5µg/ml hydrocortisone, 20 ng/ml EGF, 10µg/ml insulin, 40µg/ml 
gentamicin (Invitrogen, Carlsbad, CA, USA) and 100 ng/ml cholera toxin. MCF-10A was 
cultured in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and F12 medium 
known as DMEM-F12 (Invitrogen, Carlsbad, CA, USA) supplemented with 5% horse 
serum, 0.5µg/ml hydrocortisone, 20ng/ml EGF, 10µg/ml insulin, Pen/Strep (Invitrogen, 
Carlsbad, CA, USA) and 100 ng/ml cholera toxin. 
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T47D, a less invasive mammary carcinoma cell line was obtained from the pleural 
effusion sample of a 54-year-old female with invasive ductal adenocarcinoma in her 
breast (Keydar et al. 1979). T47D was cultured in RPMI 1640 medium (Sigma Aldrich, 
USA) supplemented with 10% Fetal Bovine Serum (Hyclone, Logan, UT, USA). MCF7, 
a moderately invasive breast carcinoma cell line was taken from the pleural effusion 
sample of a 69-year-old woman with metaplastic breast adenocarcinoma who had borne 
mastectomy for two times during a time span of 5 years (Levenson and Jordan 1997). 
MDA-MB 231, a highly invasive breast carcinoma cell line was taken from the pleural 
effusion sample of a 51-year-old woman with infiltrative breast adenocarcinoma 
(Cailleau, Olivé and Cruciger 1978). MCF7 and MDA-MB 231 were ordinarily cultured 
in DMEM supplemented with 10% fetal bovine serum (FBS). All of the above cell lines 
were cultured in humidified atmosphere incubator with 5% CO2. 
  
2.1.1 Thawing of human breast cancer cell lines   
The frozen tube containing human mammary carcinoma cells was taken from liquid 
nitrogen storage tank and rapidly thawed using mechanical shaking in 37ºC. Cells were 
transferred to 15ml centrifuging tube. Complete culture medium that was pre-warmed 
later added to the cells. The tube was then centrifuged at ~ 56 x g (1000 rpm) for 5min in 
order to remove the dimethyl sulphoxide (DMSO). Next, the cells were resuspended in 
5ml of complete culture medium. In the end, the cell suspension was fully transferred to 
25 cm2 culture flask and then incubated in 5% CO2, 37ºC incubator. The culture medium 
was refreshed with pre-warmed fresh complete medium every 2-3 days. 
Methods and Materials  
47  
2.1.2 Subculturing of human breast cancer cell lines 
Once the monolayer breast cancer cells became 80-90% confluent in their culturing flask, 
they were subcultued. Therefore, the old culturing medium was removed from the flask. 
Next, the cells were washed once with 1x PBS (PBS, Sigma, U.S.A.) in order to wash 
away the dead cells as well as debris. In order to detach the adherent breast cancer cells 
from the bottom of culturing flask, 1x pre-warmed trypsin-EDTA added to the cells and 
then incubated at 37ºC incubator for 5min. However, MCF-12A cells were detached 
using 5x pre-warmed trypsin-EDTA at 37ºC incubator for 5min. In order to inactivate the 
trypsin, 10% FBS-supplemented complete culturing medium was added to the tripsinized 
cells. After that, the cell suspension was centrifuged at ~ 56 x g (1000 rpm) for 5min to 
remove the trypsin. In the end, the cells were resuspended in fresh complete culturing 
medium and then incubated in 5% CO2, 37ºC incubator. 
 
2.1.3 Cryopreservation of human breast cancer cell lines 
Once the cells in culturing flask became 80-90% confluent, they were trypsinzed by 
adding of trypsin and then resuspend in 10% FBS-supplemented comlete culturing 
medium as mentioned above. Folloing of centrifuging the cell suspension at ~ 56 x g 
(1000 rpm) for 5min, the cells were resuspended in a fresh complete culturing medium 
containing 10% DMSO and 20% FBS and transferred into cryovial tubes. The cryovial 
tubes were put into Mr. Frosty container (Nalgene, Rochester, NY) to gradually 
decreasing the temperature as for 1ºC permin in a -80ºC freezer overnight. Next day, the 
cryovial tubes were finally stored in nitrogen tank for later usage. 
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2.2 Gene silencing 
2.2.1 siRNA transfection 
Firstly, T47D and MCF7 cell lines were separately cultured in 10% FBS-supplemented 
RPMI or DMEM respectively. Two pre-designed double stranded silencer siRNAs for 
targeting HS6ST3 and one negative non-targeting siRNA (scrambled siRNA) were 
ordered from Ambion (Ambion, USA). The sequences of these 21-mer siRNAs were 
shown in Table 2.1. The sense and antisense sequences of each siRNA were blasted in 
NCBI (http: //blast.ncbi.nlm.nih.gov/Blast.cgi) to confirm that they specifically target 
HS6ST3 gene. Reverse transfection method was performed based on Ambion protocol. 
Main parameters of transfection including cell seeding number, final concentration of 
transfection reagent, final siRNA concentration and duration time of exposure after 
transfection were all optimized. Three wells of 6-well culture plate were transfected with 
HS6ST3 siRNA (Ambion, USA) and the other three wells were transfected with 
scrambled siRNA. In brief, a total of 3.5x105 cells for T47D cell line and 2x105 cells for 
MCF7 cell line were seeded in each well of 6-well plate (Nunclon, Denmark) at 24 hours 
before the day of transfection. A cell confluency of 40-50% was considered as optimal 
for transfecting the cells using Oligofectamine (Invitrogen, USA) based on the 
manufacturer’s protocol. For T47D, 10µl of 20µM siRNA was diluted in 100µl Opti-
MEM I Reduced Serum Medium (Invitrogen, USA) and a mixture of 10µl 
Oligofectamine in 100µl Opti-MEM I was incubated for 5min at room temperature. For 
MCF7, 5µl of 20 µM siRNA was diluted in 180µl Opti-MEM I and then a mixture of 5µl 
Oligofectamin in 10µl Opti-MEM I was incubated at room temperature for 5min. The 
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two diluents were then combined gently and then incubated for 20min at room 
temperature to let siRNA-oligofectamine complex formation. The old culture medium of 
each well of 6-well was then removed and substituted with 780µl and 800µl Opti-MEM I 
for T47D and MCF7 respectively. A total of 220µl and 200µl siRNA-oligofectamin 
complex were finally added drop by drop into each well for T47D and MCF7 
respectively. Then, T47D and MCF7 plates were incubated in 5% CO2, 37ºC for 10 hours 
and 8 hours respectively. Following the incubation, 500µl of 30% FBS-supplemented 
RPMI and DMEM were added to each well of 6-well plate for T47D and MCF7 
respectively to stop transfection. At 24 post-transfection, the old medium of each well 
was substituted with fresh culturing medium supplemented with 10% FBS. The cells 
were incubated untill 72 hours after transfection for continuing further experiments. For 
MCF12A, reverse transfection method was performed as recommended by Ambion. 
MCF12A cells were transfected by using Ambion silencer HS6ST3 siRNA and siPORT 
Amine (Ambion, USA). For this purpose, 6.25µl of 20 µM siRNA was diluted in 93.75µl 
Opti-MEM I and a mixture of 8µl siPORT Amine in 92µl Opti-MEM I was incubated at 
room temperature for 25min. The two diluents were then combined gently and incubated 
for 10min at room temperature to allow siRNA-siPORT Amine complex formation. A 
total of 200µl of siRNA-siPORT Amine complex was finally added dropwise into 2.3ml 
(1x105 cells per ml) of MCF12A cells suspended in Opti-MEM I in each well of 6-well 
plate. MCF12A plate was then incubated in 5% CO2, 37ºC for 8 hours. Following the 
incubation, the old medium was replaced with 3ml of DMEM supplemented with 5%, 
0.5µg/ml hydrocortisone, 20 ng/ml EGF, 10µg/ml insulin, 40µg/ml gentamicin and 100 
ng/ml cholera toxin. The plate was incubated for 48 and 72 hours post transfection for 
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doing further experiments. The silencing efficiencies were measured using RT-PCR. In 
addition, transfection efficiencies were also measured by using Cy3 labeled Negative 
control siRNA (Ambion, USA) by means of overlapping bright field and fluorescent field 
under Nikon Digital Sight DS-L1 camera (Nikon, Japan). Furthermore, the percentage of 
the live cells was estimated more than 90% at 72 hours post transfection among negative 
control groups. 







Sequence 1 #40347 GGAAGACACAGUUUCUCUUtt AAGAGAAACUGUGUCUUCCtc 
Sequence 2 #40437 GGCACAUUGACUUUCUGUUtt AACAGAAAGUCAAUGUGCCtg 
 
2.2.2 shRNA Preparation 
Five sequenced of shRNA were purchased from Qiagen (Qiagen, SABioscience, USA) 
including four sequences for XAF1 knocking down and one sequence as a negative 
control.  1µL of the plasmids (30 ng/µl) were used to transform 50µl DH5α competent E. 
coli cells. The sequences of XAF1 shRNA and negative control shRNA were shown in 
Table 2.2.Transformed DH5α was spread to LB plates containing 100 µg/ml Ampicillin 
(SIGMA-ALDRICH, USA). The LB plate was incubated at 37ºC overnight. Following 
the incubation, colony-PCR was performed for each sequence by using T4 and SP6 
primers. Once the transformation of the plasmid into the DH5α was confirmed by colony-
Methods and Materials  
51  
PCR, the same colonies were picked and grown in 5ml LB medium supplemented with 
100 µg/ml Ampicillin over a shaker (200-250 rpm) at 37ºC overnight. Next day, bacterial 
stocks were provided and preserved in and then the plasmids were extracted from 
bacteria by QIAprep Spin Miniprep kit (QIAGEN, USA). The concentrations of extracted 
plasmid of each colony were measured in NanoDrop ND-1000 (Thermo Fisher Scientific, 
Wilmington, USA). 
Table 2.2. Sequences of shRNA used for silencing XAF1and negative control shRNA. 
shRNA Insert sequence 
Sequence 1 CTGTCATTATTGCAACCAAAT 
Negative control GGAATCTCATTCGATGCATAC 
 
2.2.3 shRNA transfection 
Transfection of MCF7 was carried out by using shRNA and Lipofectamine 2000. Thus, 
transfection parameters were optimized by designing several experiments.  One day prior 
to transfection, 2 x105 of MCF7 cells were seeded in each well of 24-well plate to have a 
90-95% cell confluency at the time of transfection. 0.6µg shRNA was top upped with 
Opti-MEM I to 50µl and a mixture of 1.5µl Lipofectamine 2000 in 48.5µl Opti-MEM I 
was incubated at room temperature for 5min. The two diluents were then combined 
gently and incubated for 20min at room temperature to allow shRNA-Lipofectamine 
complex formation. A total of 100µl shRNA-Lipofectamine complex were finally added 
dropwise into 400µl Opti-MEM I provided in each well of 24-well plate. The plate was 
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then incubated in 5% CO2, 37ºC for 6 hours and then the old medium was replaced with 
1ml DMED supplemented with 10% FBS and 0.125 µg/ml Puromycin (Invitrogen, 
USA). One day after transfection, the cells were reseeded as for 1x104 cells per each well 
of new 24-well plate. The old medium was replaced with similar but fresh medium 
supplemented with Puromycin every 2-3 days for two weeks to let all of untransfected 
cells be killed. Two weeks after transfection, a single colony of cells was picked from 
each wells and grown in 96-well plate. Fresh medium supplemented with 0.125 µg/ml 
Puromycin replaced again with old medium every 2-3 days for two weeks. After two 
weeks incubation, the content of each well was reseeded in 24-well plate and grown with 
similar medium until reaching to 80% cell confluency. Finally, the silencing efficiencies 
were measured using RT-PCR. The cells were cultured for proceeding further 
experiments as well as providing for frozen stock.    
 
2.3 Quantitative Real Time PCR (RT-PCR) 
2.3.1 Extraction of total RNA 
The RNA was isolated at 72 hours post-transfection from mono layer cells in the 6-well 
plate with RNeasy using mini and/or micro kit (QIAGEN, Hilden, Germany). The 
provided extraction protocol was followed from the user manual of the kit. Firstly, each 
well was washed with 1X PBS to remove the old medium. The cells were lysed with a 
mixture of 350µl RLT buffer containing 1% ß-mercaptoethanol (ß-ME). The lysed cells 
were collected by cell scrapper and homogenized with 21# gauge needle applied on 
Methods and Materials  
53  
RNase-free syringe. Similar volume of 70% ethanol added to the lysate and transferred to 
the RNeasy MicroElute spin column in 2ml provided collection tube. The column was 
centrifuged at ~ 9447 x g (13,000 rpm) for 30 sec. The flow through was discarded; 
350µl of RW1 buffer was added to the column for washing the spin column. Thus, the 
column was centrifuged at ~ 9447 x g (13,000 rpm) for 30 sec. After discarding the flow 
through, RNA was then treated with 10µl RNase-free DNase I (QIAGEN, Hilden, 
Germany) diluted in 70µl RDD buffer and incubated for 15min at room temperature in 
order to remove all genomic DNA. Next, the column was washed with 350µl RW1 
Buffer and centrifuged  at ~ 9447 x g (13,000 rpm) for 30 sec and the flow through was 
discarded. After that, 500µl RPE buffer was pipetted to the spin column and then 
centrifuged again. Following that, 500µl of 80% ethanol was applied on the column for 
further wash and centrifuged at ~ 9447 x g (13,000 rpm) for 2min. In the next step, the 
open-lid column was dried by another centrifuging at ~ 9447 x g (13,000 rpm) for 5min 
to remove any carryover of the ethanol. Then, the column was placed in provided 1.5 ml 
collection tube and finally 14µl RNase-free water (for RNeasy Micro Kit) and 30µl (for 
RNeasy Mini Kit) was pipetted onto the center of silica membrane inside the column and 
centrifuged the column at ~ 9447 x g (13,000 rpm) for 1min.  
 
2.3.2 RNA concentration and purity 
The RNA concentration and purity was measured by NanoDrop ND-1000 (Thermo 
Fisher Scientific, Wilmington, USA). Briefly, the sampling arm was opened. 1µl of RNA 
sample was pipetted onto the lower measurement pedestal.  Then the sampling arm was 
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gently closed and spectral measurement was started. The optical density (OD) ratio (260: 
280) RNA was indicating the purity and integrity. OD ratio between 1.8 and 2.2 were 
considered ideal for RNA. The RNA concentration was automatically generated by ND-
1000 software and given as ng/µl in the outputting report.  
 
2.3.3 Synthesis of first strand cDNA  
First strand cDNA was sensitized by using SuperScript III first strand synthesis system  
 (Invitrogen, USA). Firstly, a total of 2 µg of RNA was mixed with 1µl random hexamer 
primer (50ng/µl), 1µl of dNTP (10mM) and added up with DEPC-treated water up to a 
total volume of 10µl. Reverse transcription was performed in thermo cycler ( Thermo 
Hybrid, UK) based on following steps: 
Step 1: The mixture was incubated at 65 ºC for 5min and then at 4ºC for 5min. Next, the 
master mix containing 2µl  RT Buffer (10x), 4µl Mgcl2 (25mM), 2µl DTT (0.1M), 1µl 
RNase out, 1µl Superscript III RT was added to PCR tube and incubated at 4ºC for at 
least 1min. The cocktail was then sequentially incubated at 25ºC for 5min and 50ºC for 
50min followed by inactivation SuperScript III at 85ºC for 5min. 
The cDNA was diluted 10 times with autoclaved deionized water to have 0.01 µg/µl 
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2.3.4 Quantitative real time polymerase chain reaction (qRT-PCR) 
Primers were designed in Primer 3 version 0.4.0 (http://frodo.wi.mit.edu/) and Blasted in 
NCBI database (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to check their specificity. Intron-
spanning quality was considered during the primer designation. The designed primers 
were ordered to 1st Base for synthesis (First Base, Singapore). Light Cycler System 
(Roche, ID, USA) was employed for RT-PCR using Quanti Tect SYBR Green PCR kit 
(QIAGEN, Hilden, Germany). The sequence of all primers selected for qRT-PCR is 
shown in Table 2.3.  
 
A master mix solution was prepared containing 5µl SYBR Green, 1µl of diluted cDNA ( 
0.01 µg/µl), 0.5µl of each forward and reverse primers (10 µM stock) and DEPC- treated 
water to have a total volume of 10µl. The master mix was applied on RT-PCR micro 
capillary tube (Roche). 
 
The RT-PCR was performed firstly by activation of polymerase at 95ºC for 15 followed 
by amplification of the target sequence in 45 cycles of a three-step process: 
Step 1: Denaturation at 94ºC for 15 sec 
Step 2: Annealing at 60ºC for 25 sec (primer-dependent) 
Step 3: Extension at 72ºC for 12 sec (sequence-length dependent).  
At the end of each annealing step, fluorescent intensity was detected by the device. 
Melting curve analysis was then performed in order to check any unspecific 
amplification. Melting cure was generated in a plot by interfacing florescence versus 
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temperature in LightCycler software. Generated a single sharp peak confirmed the 
specificity of amplified sequence. The specificity of the products was further confirmed 
by performing a 2% agarose gel electrophoresis. 
 
2.3.5 Quantitative analysis of qRT-PCR data 
The gene expressions were analyzed by applying the given Ct values in 2^ (-∆∆ct) method 
(Livak and Schmittgen 2001) to calculate the relative fold changes of gene of interest 
against reference gene (housekeeping gene). In this method, the Ct value stands for a 
threshold cycle in which the SYBR fluorescent signal exceeds the level of background 
noise during the process of amplification. ∆∆ct is the difference of (Ct target- Ct reference) of 
treated and (Ct target- Ct reference) of control group. The results were normalized using 
GAPDH and/ or β-actin as a housekeeping genes in both groups. Finally, the relative fold 
of change was calculated by 2^ (-∆∆ct)   which is indicative of the relative expression of the 
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Table 2.3. Sequence of all primers selected for qRT-PCR.  
Gene Symbol Forward primer Reverse primer Product size (bp) 
ADD3 tttcgggaagacttggaatg gcaccaggaaggtcattgat 176 
APOL1 cctggaaatgagcagaggag gactttgccccctcatgtaa 117 
ARHGAP11A gagggacttttcaccccttc ttatcctttggggactgctg 183 
ARHGAP19 ttgccactttgctgaagatg aggaggagggagaatgagga 102 
ATL3 tccgagatcttgatgtggtg ttgaatggccactttccttc 117 
CASP1 tgttcctgtgatgtggagga  acttcctgcccacagacatt 169 
CBX5 acagtgccgatgacatcaaa tcaccacaggaatctgttgc 118 
CCL5 Ctgctgctttgcctacattg acacacttggcggttctttc 124 
CDCA7L tgcaggatttacgcagagtg ctcttcctcgctcaccaaag 109 
CEP55 tgccatcacagagccattag gctttcattgagtgcagcag 100 
CFB  Tctgcctgatgccctttatc tcttggagaagtcggaagga 136 
COL12A1 cgacctctcagcagacacag atatccacaccacgtgagca 135 
CTNNAL1 ccatgctgatcatgtggttc cgacaggtctcaacaagctg 123 
DRAM Catccccatgattgtctgtg aaaggccactgtccattcac 118 
FANCD2 tccgacttgacccaaacttc caacttctcccgaagctcag 161 
FCF1 gaccgggacctgaaaagaag aatcgaggggctccataatc 113 
GAPDH gaaggtgaaggtcggagtcaacg tgccatgggtggaatcatattgg 157 
GPC6 ggaccatgccacaaaaactt ggtccccacagatagctgaa 175 
HIF1AN tttaagccgaggtccaacag atcttcctgcccacagtgtc 134 
HMMR cagcaaaaggaggaacaagc gttcagcctccttccctttc 115 
HS6ST1 ggcccttcatgcagtacaat tacagctgcatgtccaggtc 128 
HS6ST2 ccctggtaggctgctacaac aaactcagtgaggccgaaga 115 
HS6ST3 catctcccccttcacacagt ctcgtaaagctgcatgtcca 111 
IFI27 gtcctccatagcagccaaga gaacttggtcaatccggaga 127 
IFIH1 ggggcatggagaataactca ctgcccatgttgctgttatg 133 
IFIT2 ctgcaaccatgagtgagaaca tcacgattctgaaactcagtcc 133 
IFIT3 aggaagggtggacacaactg attgccagtccagaggagaa 112 
IFITM1 tcgcctactccgtgaagtct atgaggatgcccagaatcag 156 
IGF1R Tccatctgatcatcgctctg cagaggcatacagcactcca 126 
IL1R1 aaactacccgttgcaggaga tttcagccacattcatcacg 175 
IL29 ggagctagcgagcttcaaga acctggagaagcctcaggtc 117 
KLF4 Tcccatctttctccacgttc agtcgcttcatgtgggagag 112 
MX1 ggaatcttgacgaagcctga ctcagctggtcctggatctc 143 
NFKBIA ctacaccttgcctgtgagca gacacgtgtggccattgtag 118 
NUPR1 atagcctggcccattcctac ctctcttggtgcgacctttc 111 
OAS1 tgtgtgtgtccaaggtggtaa tctctctttgacaggcttcca 180 
OAS2 cgagatccagaagtcccttg cacccagcaatgcttactca 112 
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OASL gaaacatcggccaactaagc tcccatctgtacccttctgc 121 
ODC1 gtggctttcctggatctgag cgggctcagctatgattctc 120 
PLDN cgacgcctggtttaagtgac gggcttgttttgatctctgc 138 
PRKAR2A actcagggtgaaaaggctga caatctcgacctcctggttc 115 
PRR11 agctccaggaagcactgaag tctccaggggtgatcagaac 121 
RARRES3 gtgagcaggaactgtgagca caaaagagcatccagcaaca 136 
RSAD2 ctcgccagtgcaactacaaa agaaatggctctccacctga 148 
S100A8 atcaggaaaaagggtgcaga acgcccatctttatcaccag 104 
SFXN2 Ccccgcactgtctttgtatc cagcttcttggcatacagca 123 
SHCBP1 aactctgattccgagcagga gatcttctgaccgctggaac 180 
SHISA5 ctgctgctgcctttacaaga gtggtagccctggtagcttg 142 
SLC7A11 cccagatatgcatcgtcctt cctgggtttcttgtcccata 184 
STAT1 caatggtgtggcaaagagtg gggcattctgggtaagttca 140 
TNFSF10 gcaagtcaagtggcaactcc tgtgttgcttcttcctctgg 172 
TTK cggttcacttgggcatttac catcttgtggtggcatgttc 104 
UTRN catgaagccagtcctgacaa ggtggtttcccactctttga 137 
XAF1 tcaccctccatgaggcttac cacatcgtacacccaacctg 127 
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2.3.6 Agarose gel electrophoresis for RT-PCR products 
Agarose gel electrophoresis was performed to further evaluate the specificity of amplified 
sequence by estimating the product size of each given band. The RT-PCR product was 
transferred to eppendorf tube by inverting the capillary and doing a short spin. 5 µl  of 
RT-PCR product was added to 1µl loading dye (Blue/ 6x) and loaded into the well of 
1.2% Agarose gel (0.6g Agarose and 1µl ethidium bromide in 50ml TAE which contains 
40mM Tris-acetate, 1mM EDTA, PH: 8.1-8.3). A 100 bp ladder was also pipetted in into 
the first well. The samples were run on the gel at 120V for 40min. Then, the bands were 
demonstrated by Gel Documentation Image Analysis System V6.03 (ChemiGenius 
SynGene, Cambridge, UK). Finally, the given band was compared with the ladder for 
size verification. 
 
2.4 Genome-wide expression profiling using Microarray Gen Chip 
 
2.4.1 Microarray procedure by using Affymetrix Human Gene 1.0ST arrays 
For this purpose, total RNAs were extracted from T47D cell line 72 hours after siRNA 
transfection by using RNeasy Micro Kit (N=3). The RNA concentration and purity were 
measured by NanoDrop. The silencing efficiency was checked by One-step RT-PCR kit 
(Qiagen, USA). The quality of RNAs was further determined using an Agilent 
Bioanalyzer according to Standard Operating Procedure (SOP).    
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The RNA samples were processed based on the Affymetrix recommended protocol for 
whole transcript analysis. Briefly, 300 ng of total RNA was reverse transcribed to 
produce cDNA, which was subsequently used as a template to create cRNA which was 
then converted to single stranded (ss) DNA. The ss-DNA was biotin labeled, fragmented 
and hybridized to Affymetrix Human Gene 1.0ST arrays for 16 hours at 45ºC with 
rotation at 60 rpm. Arrays were washed and stained using the FS450_0007 fluidics 
protocol and scanned using an Affymetrix 3000 7G scanner. Hybridization efficiency was 
inspected by scanned images and CEL files generated from GCOS (GeneChip Operating 
Software) were imported into Expression Console (EC) 1.1 software for array QC. RMA 
normalization was performed on the samples to generate the quality control (QC) metrics 
that routinely used to determine data quality. These include, perfect match mean 
(PM_Mean), background mean (Bgd_Mean), positive and negative probes (POS vs NEG 
AUC), bacterials spike controls, and polyA controls. Brief description for reagent used in 
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Table 2.4. Reagent used in the gene microarray profiling experiment. 
Reagent Manufacturer Lot number 
GeneChip Eukaryotic Poly-A RNA Control Kit Affymetrix 0806008 
GeneChip WT cDNA Synthesis and 
Amplification Kit 
Affymetrix 4060471 
GeneChip WT Terminal Labeling Kit Affymetrix 4060386 
GeneChip Sample Cleanup Module Affymetrix 127149657 
GeneChip Hybridization Control Kit Affymetrix 4055504 
GeneChip Hybridization, Wash and Stain Kit Affymetrix 0712009 
 
2.4.2 Microarray gene expression data analysis 
2.4.2.1 Genespring data analysis 
The Genespring 7.0 (Silicon Genetics, CA, USA) was used to normalize Affymetrix .cel 
files of the Human Gene 1.0 ST Array to the median (50 percentile) intensity of the same 
array. After that, median value of genes in control samples was used to normalize the 
intensity of corresponding gene in the silenced group. Three algorithmic models (RMA, 
PLIER, iterPLIER) were performed in Genespring for processing the .cel files.  
 
2.4.2.2 Expression console data analysis 
Expression Console version 1.1.1 (Affymetrix) was used to summarizing the probe set as 
well as checking initial data quality. Thus, by importing probe cell intensity files 
(*.CEL), probe level summarization files (*.CHP) was created. For this purpose, 
necessary library files were downloaded for the Human Gene 1.0 ST Array. By creating a 
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new study CEL files was imported and selected for analysis. RMA-Sketch was selected 
as a default method for probe summarization and then the analysis was started. By 
completing the processing, CHP files appear and intensities of all probe set were reported 
after normalization. In RMA-Sketch, the data were normalized with the median intensity 
of the same array; however, other summarization methods such as PLIER (Probe 
Logarithmic Intensity Error) and iterativePLIER (iterPLIER) were used as different 
method for background correction. In PLIER and iterPLIER, Perfect match (PM) and 
PM-GCBG were used rather than PM-MM only model. 
 
2.4.2.3 DNA-chip data analysis (dChip) 
DNA-chip Analyzer 2008 (dChip) software was used to normalizing and also 
summarizing the probe levels (Schadt et al. 2001). Thus, the .cel files were imported to 
the software. dChip normalized the probe set intensities by using a model-based approach 
to adjust the image contamination and handle the cross-hybridization by detecting the 
outliers. In this model probe level perfect match (PM) and mismatch (MM) was inspected 
by performing PM selection. Then, the normalized values were logged to base 2 and then 
the samples were compared based on stringent filtering criteria that would be discussed 
later.  
 
2.4.2.4 Robust Multi-array Analysis (RMA) 
Robust multi-array analysis (RMA) is an algorithmic method (Irizarry et al. 2003) with 
robust linear model for normalization of the intensity at probe level. RMA was used to 
minimizing the difference of probe-specific affinity by reducing the variance across the 
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dynamic change as well as increasing the sensitivity to small changes between control 
and silenced group. Adjustment of background based on PM distribution, normalization 
and summarization were three main steps performed in RMA. Thus, imported .cel files 
were processed in RMA algorithm and then converted to comparable gene expression 
values. Compared to other methods, RMA could detect the differential changes very well 
with a higher reproducibility capacity over the single array analysis.  
 
2.4.2.5 Probe Logarithmic Intensity Error Estimation (PLIER) 
Probe Logarithmic Intensity Error Estimation or PLIER is another algorithmic method 
which generates the signals based on what was experimentally observed in probe levels 
and thus, adjusting the error at low and high signal values. Unlike RMA, PLIER provides 
a higher accuracy for background adjustment but at the cost of increasing the signal 
variance. Therefore, for detecting small changes in the relative gene expression (fold of 
change), PLIER is highly sensitive with more accuracy compared to RMA; however, the 
variances are not so stable at the Log scale. The PLIER method was used in Genespring 
and Expression Console software independently. Iterative PLIER or iterPLIER is very 
similar to PLIER; however, it does not perform the summarization on all of the probes, 
but it selects the good probes regardless of bad probes (Therneau and Ballman 2008; Qu, 
He and Chen 2010; Seo and Hoffman 2006). 
 
2.4.2.6 Filtering criteria for gene selection 
Following the primary array analysis, secondary analysis was performed to filter the 
differentially expressed gens as flowing: 
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1ST filter: Present call (P call) more than 100 at least in control or silenced group. 
2nd filter: Fold of change of relative gene expression was considered at least 2. 
3nd filter: p value< 0.05 after comparing intensities of silenced group against control 
group using t-test. 
4th filter: The gene lists retrieved from several softwares by using different algorithmic 
models were overlapped. 
5th filter: The genes were categorized based on their relevant biological function by using 
Gene Ontology database, Affymetrix database and David functional annotation database. 
 
2.4.2.7 Statistical analysis 
The filtering criteria were applied using various softwares and then the filtered genes 
were overlapped.  Student t-test was performed to compare the silenced versus control 
group. P< 0.05 was considered statistically significant. 
 
2.4.2.8 Gene pathway analysis 
Extensive literature review was performed to find the relevant gene or genes justifying 
the biological cellular behaviors after silencing the HS6ST3 gene. Selected filtered genes 
were also imported to Pathway Studio Version 5 software (Ariadne Genomics) to find the 
most probable links among the identified genes. The functional linkage between HS6ST3 
and downstream genes was validated by extending of the experiments.  
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2.5 Functional Genomic analysis of HS6ST3 silencing in T47D and 
MCF7 cell lines 
2.5.1 Proliferation assay 
MTS method was performed for proliferation assay. For this purpose, each well was 
gently washed once with 1ml of 1 X PBS at 72 hours post-transfection (N=5). Next, 3ml 
complete medium (RPMI or DMEM containing 10% FBS for T47D and MCF7, 
respectively) was added to each well. Then, 600µl of AQueous One Solution (Promega, 
Madison, USA) was added (1: 5 ratio) to each well. After that, the 6-well plate was 
incubated in 5% CO2, 37ºC for 1-4 hours and the absorbances were measured at 490 nm 
wave length in SpectraMax M5 plate reader (Molecular devices, USA) at several time 
points. The measurement was based on the amount of tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-2H-tetrazolium), 
inner salt; MTS] which was converted to formazan by the mitochondria of living cells. 
The formazan quantities were proportionally expressed the number of living cells inside 
each well. Absorbance values, generated in SpectraMax software were normalized with 
blank absorbance value of similar medium in 6-well plate.  Finally, the given values of 
treated group were compared with control group by operating t-test (p< 0.05) in 
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2.5.2 Cell cycle assay  
Cell flow cytometry was employed for this assay. In the first step, the old medium was 
collected in 15ml tubes (in order to collect the dead cells) 72 hours post-transfection from 
6-well plate (N=3). Trypsin was added to the wells; and then inactivated with complete 
culture medium. The cells were transferred to the corresponding 15ml tubes and 
centrifuged at ~ 56 x g (1000 rpm) for 5min. The supernatant was discarded; the cells 
were resuspended in 5ml 1 X PBS centrifuged at ~ 56 x g (1000 rpm) for 5min; and the 
washing process repeated once again to remove the old medium. After final 
centrifugation, the pelleted cells were resuspended in 0.5ml 1 X PBS. The cell suspension 
was added dropwise to a new 15ml tubes containing 4.5ml ice-cold ethanol. The tubes 
were left at 4ºC fridge overnight. In the second step, the tubes were centrifuged at ~ 56 x 
g (1000 rpm) for 5min and the supernatants were discarded. Next, the pelleted cells were 
resuspended in 5ml 1 X PBS and centrifuged once or twice in order to remove the 
ethanol. The supernatants were completely discarded.  The cells in each tube were 
resuspended in 1ml of prepared Propidium iodide (1 mg /ml) cocktail (8ml cold 1 X PBS, 
10µl Triton-X 100, 2ml RNase A and 200µl PI). Then, the tubes were shielded from 
light. PI stained the DNA of fixed cells. Finally, the DNA contents of fixed cells were 
measured in Beckman Coulter Epics Altra (Beckman, USA) and Dako Cytomation Cyan 
LX (Dako, USA) with laser excitation in 488nm wavelength. The given data were 
imported to winMDIv2.8 and Summit 4.3 softwares and then analyzed by comparing the 
DNA content of treated versus control groups in different phases of cell cycle by 
operating t-test (p< 0.05) in GraphPad Prism 5.00 software.  
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2.5.3 Apoptosis assay 
Caspase-Glo 3/7 and 8 assays (Promega, Madison, USA) were used to measure the 
relative activity of Caspase 3/7 and 8, separately. For these purpose, the cells were firstly 
trypsinised in 6-well plate at 72 hours post-transfection and then inactivated with 
complete culture medium (N=3). The suspended cells were centrifuged at ~ 56 x g (1000 
rpm) for 5min to remove the trypsin. The supernatants were discarded. Pelleted cells 
were resuspended in complete culture medium. For T47D and MCF7 cells, 2 x 104 cells 
were reseeded in each well of white-walled 96-well plate at a total volume of 100µl 
(N=5). The content of Caspase-Glo® 3/7 Buffer bottle was totally transferred into the 
amber bottle containing Caspase-Glo® 3/7 Substrate and mixed thoroughly. Then, 100µl 
of the Caspase-Glo® 3/7 mixture was added to each well. The content of the plate was 
gently mixed at 300-500 rpm for 30 sec. Then, the plate was covered with aluminum foil 
and incubated for 1-3 hours at room temperature. The activity of Caspase 3, 7 and 8 
cleaved the luminogenic substrate containing DEVD sequence. The cleavage of caspase 
substrate released a substrate for luciferase (aminoluciferin) and resulting in luciferase 
reaction that produce a light. After this incubation, the luminescence was measured at all 
wavelengths in the SpectraMax M5 plate reader using the integration time of 1 sec. All of 
the luminescence values generated in SpectraMax software were normalized with blank 
luminescence value of similar medium in 96-well plate. The luminescence values were 
then divided by the average luminescence value of negative control group. The newly 
calculated values were finally compared in two groups by operating t-test (p< 0.05) in 
GraphPad Prism 5.00 software. 
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2.5.4 Transmission Electron Microscopy (TEM) 
Cellular morphology of T47D cells were checked by Transmission Electron Microscopy 
(TEM). For this purpose, each well was gently washed once with 1ml of 1 X PBS after 
72 hours siRNA transfection (N=3). The cells were trypsinised in 6-well plate 72 hours 
post-transfection and then inactivated with complete culture medium. The suspended 
cells were centrifuged at ~ 56 x g (1000 rpm) for 5min to remove the trypsin. The 
supernatants were discarded. Pelleted cells were washed once in 1 X PBS and centrifuged 
at ~ 56 x g (1000 rpm) for another 5min. Pelleted cells were resuspended in 0.5ml 1 X 
PBS and then 0.5ml 2.5% Glutaraldehyde in PB (pH 7.4) was added to the cell 
suspension in 1.5ml tubes. The tubes were then incubated at 4ºC for 1 hour and then 
centrifuged at ~ 503 x g (3000 rpm) for 10min. The supernatant was discarded in order to 
remove Glutaraldehyde. The cells were washed trice in 1ml 1 X PB and centrifuged at ~ 
503 x g (3000 rpm) for 10min.  Finally, 1ml 1 X PB was added over the pellet and kept at 
4ºC overnight. Next day, the cells were post-fixed 1% osmium tetroxide (OsO4, pH 7.4) 
for one hour at room temperature. The cells were then washed trice with 1 X PBS and 
centrifuged at ~ 14 x g (500 rpm) for 10min. After washing, the cells were dehydrated in 
ethanol graded series each time for 10min at room temperature. After dehydration, 100% 
Aceton was added to the cells. Aceton made the cell penetrable to resin; thus, 1: 1 ratio of 
acetone to resin was added for 30min at room temperature followed by addition of 1: 6 
ratio of acetone to resin was added at room temperature overnight. The old resin was 
changed with fresh resin for three times. For the first time, fresh resin was added to the 
cells and incubated at 45ºC for 45-60min. For second change, fresh resin was added to 
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the cells and incubated at 50ºC for 60min followed by third resin change at 55ºC for 30-
60min. Embedded cells in fresh resin polymerized at 60ºC for 24 hours. Then, specimens 
were cut in 100 nm thickness by ultra-microtone (Leica, Germany) and mounted on 
copper grids (150-mesh). Grids were double stained by uranyl acetate and lead citrate, 
and then the grids were visualized under TEM 208 transmission electron microscope 
(Philips, England) at 100 Kv. Five random fields were selected and captured from each 
sample for further analysis. Physiologic cell death (apoptosis) was assessed in control and 
silenced group by considering cytoplasm shrinkage, cell membrane asymmetry, 
chromatin condensation, aggregation of chromatin at nuclear membrane, mitochondrial 
aggregation, cytoplasmic vacuolization, formation of cell membrane budding (apoptotic 
body formation), nuclear collapse, terminal fragmentation of the cells to the smaller 
bodies, nuclear fragmentation.  Finally, physiological cell death was compared between 
control and silenced group by operating t-test (p< 0.05) in GraphPad Prism 5.00 software. 
 
2.5.5 Adhesion assay 
96-well plate (Nunclon, Denmark) was pre-coated with collagen I (20 µg/ml) or 
fibronectin (20 µg/ml) diluted in 1 X PBS in a total volume of 100µl per well and 
incubated at 4ºC overnight. Next day, the wells were washed trice with 1 X PBS and 
blocked with 100µl of 1% BSA. The wells were washed twice with 1 X PBS and air-
dried inside the hood and finally pre-warmed in 37ºC incubators for 1 hour. T47D and/or 
MCF7 cells were trypsinised in 6-well plate at 72 hours post-transfection and then 
inactivated with complete medium (N=6). The suspended cells were centrifuged at ~ 56 x 
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g (1000 rpm) for 5min to remove the trypsin. The supernatants were discarded. The 
pelleted cells were resuspended in serum-free culture medium. A total number of 2.5x 
104 cells in 100µl were seeded inside each well of 96-well plate coated with collagen I or 
fibronectin. The cells were then allowed to attach to the bottom of wells in 5% CO2, 37º 
C incubators for 30min. After that, the medium of half of the wells were gently discarded 
and washed with 1 X PBS for three times.  Each well was filled with100µl complete 
medium; then, 20µl MTS AQueous One Solution was added to each well. The 96-well 
plate was then incubated in 5% CO2, 37ºC for 1-4 hours. The absorbance was measured 
at 490 nm in the SpectraMax M5 plate reader. The absorbance of two groups was 
compared after normalization with blank group as well as unwashed wells by operating t-
test (p< 0.05) in GraphPad Prism 5.00 software.  
 
2.5.6 F-actin staining 
T47D and MCF7 cells were grown on coverslips in 6-well plate and 24 hours later the 
cells were transfected with HS6ST3 siRNA. At 72 hours post transfection, the cells were 
washed trice in 1x PBS (pH 7.6). Then, they were fixed with 4% paraformaldehyde for 
15min. Next, the cells were washed and permeabilized trice in PBS- Triton-X 0.2% 
(PBS-TX). After that, the cells were incubated with fluorescein isothiocyanate (FITC) 
conjugated with phalloidin (1:50 dilution) for 1 hour at room temperature. The coverslips 
were washed trice in1x PBS (pH 7.6) and then mounted on slides with Vectashield 
fluorescent mounting medium (Vector laboratories, USA). Five random fields were 
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selected from each replicate under Leica microscope (Leica DM 6000M, Germany).  The 
distribution pattern of F-actin was observed in both control and silenced group. 
 
2.5.7 Migration assay 
2.5.7.1 Wound healing assay (scratch assay) 
The wound healing assay was performed by scratch method on T47D cell line. Firstly, 
the cells trypsinised in 6-well plate 24 hours post-transfection and then inactivated with 
complete medium. The suspended cells were centrifuged at ~ 56 x g (1000 rpm) for 5min 
to remove the trypsin. The supernatants were discarded. The pelleted cells were 
resuspended in serum-free culture medium. 4x105 cells were seeded inside each well of 
collagen I coated (20 µg/ml) 24-well plate (Costar, Corning, NY, USA) blocked with1% 
bovine serum albumin (BSA, Sigma, St.Louis, Mo, USA). The plate was incubated in 5% 
CO2, 37ºC for 12 hours. Then, the monolayer cells were scratched by sterile 10µl plastic 
pipette tip. The suspended detached cells were gently washed by 1X PBS. The cells were 
continued to culture with complete medium in 5% CO2, 37ºC. Gap closure was monitored 
at 0, 24, 48 and 72h after scratching by using Nikon Digital Sight DS-L1 camera. The 
average of each gap size was measured at ten randomly selected sites by Image J 
software. Finally, the cell wound closure were calculated by comparing the gap-size 
difference at the mentioned time-points by operating t-test (p <0.05) in GraphPad Prism 
5.00 software.  
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2.5.7.2 Transwell Migration assay  
6.5 mm transwell polycarbonate membrane inserts with 8- µm pore size (Costar, USA) 
were used to perform cell migration assay. T47D and MCF7 cells were trypsinised in 6-
well plate 48 hours post-transfection and then inactivated with complete medium. The 
suspended cells were centrifuged at ~ 56 x g (1000 rpm) for 5min to remove the trypsin. 
The supernatants were discarded. The pelleted cells were resuspended in culture medium 
supplemented with 10% FBS. At the same time, the migration chambers were hydrated in 
culture medium (RPMI for T47D and DMEM for MCF7) in 5% CO2, 37ºC for 2 hours. A 
total number of 5x 104 cells were seeded in a total volume of 200µl into upper the 
chamber of the migration transwell. The lower chamber was filled with 600µl culture 
medium (RPMI for T47D and DMEM for MCF7) supplemented with 30% FBS. Cells 
were allowed to migrate in 5% CO2, 37ºC for 24 hours. Following the incubation, the old 
medium was gently discarded from upper and lower migration chambers. Then, the cells 
were washed thrice with 1 X PBS and fixed in 600µl of methanol for 15min. The 
chambers were gently washed with 1 X PBS and air-dried. After that, the cells were 
stained with 600µl of 0.5% crystal violet for 30min. In order to remove the excess of 
crystal violet the inserts were immersed tap water inside a beaker. Non-migrated cells on 
the upper part of polycarbonate membrane were removed by using a cotton swab. 
Migrated cells on the lower surface of polycarbonate membrane were visualized under 
stereo microscope (Nikon SMZ 1500, DXM1200F) using 9 x objective. Pictures were 
taken from five random fields. Migrated cells were then counted in control group (N=3) 
and treated group (N=3). The average of migrated number of the cells in treated group 
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was finally compared to the control group by operating t-test (p <0.05) in GraphPad 
Prism 5.00 software.  
 
2.5.8 Invasion assay 
The invasion assay was performed in BD BioCoat invasion Matrigel chamber with 8- µm 
pore size (BD Biosciences, CA, USA). The procedure of invasion assay was performed 
on T47D and MCF7 cells just similar to the procedure of migration assay discussed in 
previous section. Finally, the invaded cells were counted in control group (N=3) and 
treated group (N=3). The average of invaded number of the cells in treated group was 
compared to the control group by operating t-test (p <0.05) in GraphPad Prism 5.00 
software. 
 
2.5.9 IGF1R receptor blocking assay 
MCF7 cells were trypsinised in 6-well plate 10 hours post-transfection and then 
inactivated with complete medium. The suspended cells were centrifuged at ~ 56 x g 
(1000 rpm) for 5min to remove the trypsin. The supernatants were discarded. In order to 
remove the old serum, the pelleted cells were resuspended in 1 X PBS and centrifuged 
twice and finally resuspended in serum-free DMEM. For proliferation assay, a total 
number of 1 x 104 cells were seeded inside each well of 96 well-plate in two row for 
either silenced and control cells; then IGF1R blocking antibody (Rand D SYSTEMS, 
USA) was added to one row of either silenced and control group to reach a final 
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concentration of 10 µg/ml and then incubated in 5% CO2, 37ºC for 1 hours. Following 
the incubation, the cell’s medium was supplemented with FBS to a final concentration of 
10%. The 96-well plate was then incubated in 5% CO2, 37ºC. After 72 hours incubation, 
the proliferation assay was performed by using MTS solution as mentioned in 
proliferation assay section. The mean absorbance of IGF1R-treated cells were compared 
with untreated cells in either silenced and control groups. Similar to the proliferation 
assay, for adhesion assay the silenced and control cells were incubated with IGF1R 
antibody followed by addition of FBS and then incubated in 5% CO2, 37ºC. Following 
72 hours incubation, a total number 3x 103 MCF7 cells were seeded in each well of 96-
well plate coated with collagen I, and then adhesion assay was performed similar to what 
discussed before in adhesion assay section. Finally, the difference absorbance of washed 
and unwashed cells in silenced group was compared to control group. Similarly, in 
migration and invasion assays, the cells were incubated with IGF1R antibody followed 
by addition of FBS and then incubated in 5% CO2, 37ºC. At 48 hours post transfection, a 
total number of 5x 104 MCF7 cells were seeded in migration and invasion chambers and 
incubated in 5% CO2, 37ºC for 24 hours. During all stages of migration and invasion 
assays, the final concentration of IGF1R antibody was kept at 10 µg/ml level in cell 
culturing medium. The Migration and invasion’s procedure were carried out similar to 
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2.6 Western blotting 
2.6.1 Total protein extraction 
Protein extraction was performed on T47D and MCF7 cells at 72 hours post transfection. 
Thus, the old medium was removed from each well. The wells were washed twice with 
ice-cold 1X PBS. A total volume of 100-200µl M-PER mammalian protein extraction 
reagent (Thermo SCIENTIFIC, USA) supplemented with 10µl/ml Halt Protease Inhibitor 
cocktail (Thermo SCIENTIFIC, USA) and 10µl/ml EDTA solution was added to each 
well. Halt protease Inhibitor functioned by inhibiting a variety of proteases. In addition, 
EDTA inhibited metallo- proteases by chelating divalent cations. After that, the 6-well 
plate was gently shaken on ice for 5min and then the cells were scrapped in each well. 
The cell lysate were centrifuged in 1.5ml tube at ~ 9447 x g (13000 rpm), 4ºC, for 10min. 
The supernatant was collected and stored at -20º C. 
 
2.6.2 Quantification of total protein 
Total protein concentration was measured by BCA (bicinchoninic acid) protein assay kit 
(Thermo SCIENTIFIC, USA). In this colorimetric method, reduction of Cu2+ to Cu+ was 
induced by proteins in an alkaline medium. Chelating one cu+ with two molecule of BCA 
produced a purple-colored water-soluble product that exhibited a strong absorbance at 
562 nm. The total protein concentration is directly proportional to the measured 
absorbance. In order to plot a linear standard curve, a standard BSA (Bovine Serum 
Albumin) was diluted to a broad working range of 20 to 2000 µg/ml. The total protein 
extracted from the cells was also diluted for ten times. 25µl of protein (BSA standard 
protein and the extracted protein) was added to each well in 96-well plate. After that, 
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200µl of BCA working reaction including 50 part of BCA reagent A (sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) 
and 1 part of BCA reagent B ( 1% cupric sulfate) was added to each well and mixed 
thoroughly with the protein samples over a shaker for 30 sec . The plate was incubated at 
37ºC for 30min and then cooled at room temperature for 5min. Finally, the absorbance 
was measured at 562 nm. The absorbance was normalized with blank and plotted against 
the known concentration of BSA standard protein. The linear curve was used to 
determine the concentration of the extracted protein.    
 
2.6.3 SDS- polyacrylamide gel preparation (SDS-PAGE) 
2.6.3.1 Preparation of separating gel 
1.0 mm spacer, comb and glass plate were washed and wiped with 70% ethanol. 10ml of 
10% separating gel was prepared by addition of 4ml deionised water,  3.3ml of 30% 
acrylamide mix, 2.5ml of Tris (1.5 M, Ph 8.8), 100µl of 10% Sodium dodecyle sulfate 
(SDS ), 100µl of 10% ammonium persulfate (APS) and 4µl of N,N,N’,N’-
tetramthylenediamine (TEMED). The space between spacer and the glass plate was 
gently filled with the above mixture up to 1 cm below the comb level. Deionised water 
was pipetted over the mixture to remove bobbles and provide an even surface. The gel 
was polymerized at room temperature for 30min.      
 
2.6.3.2 Preparation of stacking gel 
When separating gel was completely polymerized, 5ml of 5% stacking gel was prepared 
by addition of 3.4ml of deionised water, 830µl of 30% acrylamide mix, 630µl of Tris 
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(1.0M, Ph 6.8), 50µl of 10% Sodium dodecyle sulfate (SDS), 50µl of 10% ammonium 
persulfate (APS) and 5µl TEMED. The deionised water over the separating gel was 
drained off by inverting the cast. Immediately, the mixture was added over the separating 
gel and then the comb was inserted into the stacking gel solution. The solution was 
allowed to polymerize for 30min.  
 
2.6.4 Electrophoresis of SDS-polyacrylamide gel  
The protein sample (20 µg of total protein) was mixed with 5x SDS gel loading buffer 
containing 10% SDS, 30% glycerol, Tris-Hcl (250mM, pH 6.8), 5% dithiothretol  (DTT) 
and 0.02% bromophenol blue. The mixture was heated at 95ºC for 5min and then allowed 
to be cooled at room temperature. Following the gel polymerization, the comb was 
removed and the electrophoresis device and was filled with 1x Tris-glycine buffer. 
Precision protein standard marker (Bio-Rad, Hercules, CA, USA) and protein samples 
were loaded to the wells. Electrophoresis was performed at 80 V until the blue line 
reached to the end of separating gel.      
 
2.6.5 Protein transfer to PVDF membrane 
A polyvinyl difluoride (PVDF) membrane (Amersham Biosciences, Germany) was 
soaked firstly in methanol for 10 sec and then hydrated in deionised water for 5min and 
finally soaked in 1x transfer buffer. From top to the bottom a Whatman’s paper, SDS-
PAGE gel, PVDF membrane and another piece of Whatman’s paper were sequentially 
placed on the cassette of Semi-Dry transfer cell (Bio-Rad, USA). A glass band was rolled 
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over the “gel-sandwich” to remove any trapped air bobble. Transferring of the protein 
was performed at 15 v for 45min. 
 
2.6.6 Incubation in primary and secondary antibody 
Following the transferring of protein, the PVDF membrane was rinsed twice in TBST 
buffer (150mM sodium chloride, 10mM Tris-Hcl; pH 7.5 and 1% Tween-20). The 
membrane was then blocked with 5% non-fat milk in 1x TBST at 4ºC overnight. The 
membrane was then incubated with primary antibody diluted in 5% non-fat milk for one 
hour at room temperature. The membrane was washed trice with 1x TBST buffer each 
time for 15min to remove the excess of primary antibody. After that, the membrane was 
incubated with secondary antibody conjugated with horseradish peroxidase (HRP) diluted 
in 5% non-fat milk for one hour at room temperature. The membrane was washed trice 
with 1x TBST buffer each time for 15min to remove the excess of secondary antibody. 
 
2.6.7 Development of the band by Enhanced Chemiluminescence (ECL)  
Enhanced Chemiluminescence method was performed by using West Femto and/ or West 
Pico Substrate System (Thermo Scientific, USA). For this purpose, peroxide solution and 
luminal solution were mixed in a 1:1 ratio. Then the mixture was incubated for 3-5min at 
room temperature. The mixture was pipetted over the PVDF membrane placed in a film 
cassette. Membrane was wrapped between the protector plastic sheets. A piece of X-ray 
film was exposed to the membrane for optimal time and then developed in Medical Film 
Processor SRX-101A (Konica MINOLTA, USA). The details of primary and secondary 
antibodies used for western blotting were summarized in the Table 2.5.    
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 Table 2.5. Dilution of primary and secondary antibodies used in western blotting. 
 
2.6.8 Densitometric analysis of the developed band   
The developed bands over the film were scanned in Image Densitometer (Bio-Rad, GS-
710, CA, USA) and the intensities were measured by using Quantity-one Image Analysis 
software version 4.62 (Bio-Rad, Ca, USA). To normalize and quantify the protein 
expression, the intensity of each band was divided by the β-actin intensity of the 












H6ST3 Poly Clonal rabbit 
IgG (Santa Cruz) 
1: 200 
Goat anti rabbit IgG HRP-
conjugated antibody ( Dako) 
1: 10 000 
IGF1R Goat recombinant 
IgG ( RandD) 
1: 1000 
Mouse anti goat IgG   HRP-
conjugated  (Millipore) 
1: 2000 
XAF1 Polyclonal Rabbit IgG                            
(Abcam)                            
1: 500 
Goat anti rabbit IgG  HRP-
conjugated antibody ( Dako) 
1: 10 000 
β-actin                       
Monoclonal mouse IgG         
(Sigma-Aldrich) 
1: 15 000 
Sheep anti mouse IgG  HRP-
conjugated (GE healthcare)  
1: 20 000 
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2.7 Immunohistochemistry (IHC) of human breast cancer 
2.7.1 Immunohistostaining procedure 
The following immunohistochemical protocol was used: 
First day  
1. 4µm thick paraffin-embedded tissue microarray sections (TMA) were dewaxed and 
hydrated with graded Series of alcohol and Histoclear. 
2. Sections were treated with 3% hydrogen peroxide (H2O2) for 30minutes to suppress 
endogenous peroxidase activity. 
3. Antigen Retrieval methods used for optimization would be discussed later (for SULF1 
staining no antigen retrieval was used, while for HS6ST3 staining heating in Sodium 
Citrate buffer for 20min was performed). 
4. Sections were blocked with 1% normal Gout serum in Tris-buffered saline (TBS) at 
pH 7.6 for 60min.  
5. Sections were incubated with primary antibody overnight at 4°C (rabbit polyclonal 
antibody for HS6ST3 and SULF1). 
Second day 
1. The excess of the primary antibody was washed trice with Tris-buffered saline each 
time for 15min. 
2. Slides were incubated with secondary antibody Polymerized with horseradish 
peroxidase (HRP) at room temperature for 20min (EnVision™ Detection Systems 
Peroxidase/DAB, Rabbit/Mouse kit for SULF1 staining and ImmPRESS™ UNIVERSAL 
polymer kit for HS6ST3 staining).  
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3. The excess of the secondary antibody was washed trice with Tris-buffered saline each 
time for 15min. 
4. Slides were incubated in 1:10 diluted DAB (3,3’-diaminobenzidine) as a chromogen 
HRP’s substrate supplemented with 33µL of H2O2 ( 6min for SULF1staining and 20min 
for HS6ST3 staining). 
5. Hematoxylin counterstaining was performed 
6. Slides were counterstained with Hematoxylin. 
7. Tissues were dehydrated with histoclear and ethanol graded Series. 
8. Slides were mounted in Permount and left to dry overnight. 
9. Quality of slides was examined under Leica DM 6000 microscope (Leica, Germany). 
Details of the primary and secondary antibodies used in the immunohistochemical 
staining were summarized in the Table 2.6. The immunohistostaing procedure was 
simultaneously performed on a single negative control breast cancer section without 
addition of the primary antibody to confirm the specificity of the IHC procedure and to 
reassure about the lack of any nonspecific background staining. 
 






dilution Secondary antibody 
Antibody 
dilution 
H6ST3 Poly Clonal rabbit 
IgG (Santa Cruz) 1: 25 
ImmPRESS™ UNIVERSAL 




SULF1 Poly Clonal rabbit 
IgG (Santa Cruz) 1: 50 
EnVision Detection Systems, Dual Link 
System-HRP (DAB+)   Peroxidase/DAB, 
Rabbit/Mouse kit  + (Dako) 
Ready to 
use 
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2.7.2 Antigen retrieval  
To restore the immunoreactivity of the paraffin-embedded tissues, proteolytic digestion 
and heat-induced antigen retrieval methods were performed. 
 
2.7.2.1 Tris-EDTA buffer and Citrate buffer antigen retrieval 
Steamer or water bath was preheated with staining dish containing Tris-EDTA Buffer or 
Sodium Citrate Buffer (pH 6) until temperature reaches 95-100 °C. Then, slides were 
immersed in the staining dish. While, the lid was loosely placed on the staining dish and 
incubated for 20-40minutes. After that, the steamer or water bath was turned off and the 
staining dish was removed to room temperature and the slides were allowed to cool for 
20minutes. Finally, the sections were rinsed twice in PBS Tween 20 each time for 2min.  
 
2.7.2.2 Proteinase K antigen retrieval 
The sections were covered with Proteinase K working solution and incubate for 10-20min 
at 37ºC humidified chamber. Then, the sections were allowed to cool at room temperature 
for 10min. Finally, the slides were rinsed twice in PBS Tween 20 each time for 2min. 
The citrate-based, Tris-EDTA-based and Proteinase K Antigen Retrieval were three 
methods that were able to break the protein cross-links, and thus enhancing the staining 
intensity by unmasking the antigens. 
 
2.7.3 Immunohistochemical scoring 
Cellular and extra cellular components including epithelial cells, stroma matrix and 
Stromal cells were examined by pathologist. The percentage of staining of the whole part 
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of each section was described from strong staining (+3), moderate staining (+2), weak 
staining (+1) to no staining (0) separately. Once the scoring was completed, 
Immunoreactivity scoring (IRS) or H-score method was hired by using the following 
formula:  (3x % strong staining) + (2x % moderatestaining) + (1x % weak staining). 
Therefore, IRS of each component ranged from minimum 0 to maximum 300. 
Additionally, Weighted Average Index (WAI) was calculated by dividing IRS of each 
component by total stained percentage of each tissue component.  
 
2.7.4 Statistical analysis  
Data management and statistical analysis were performed using Microsoft excels 2007 
and IBM PASW Statistics 18 for windows. Fisher exact test was used to find associations 
between the HS6ST3 and SULF1 immunohistochemical staining and clinicopathological 
parameters. Disease free survival (DFS) and overall survival (OS) were characterized as 
the length of time from date of diagnosis to recurrence or death respectively. The length 
of time between the dates of recurrence to death was also defined as survival after 
recurrence (SAR). Survival analysis was carried out to determine the prognostic values of 
SULF1 expression and clinicopathological parameters for DFS, OS and SAR by using 
univariate Cox regression proportional hazard model. Multivariate Cox regression 
analysis was performed to obtain hazard ratios (HRs) within 95% confidence interval 
(CI) by including known prognostic variables such as Age, tumor size, tumor side, 
histograde and lymph node status. Backward stepwise model was hired in performing 
multivariate survival analysis.  All analytical tests were set at p-value less than 0.05. 
Unavailable information was considered as missing data. 
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2.8 Immunocytochemistry (ICC) of human breast cancer cell line 
For immunocytostaining, a total 3.5x105 of T47D and 2x 105 of MCF7 cells were seeded 
over treated coverslips in 6-well plates and cultured for 24 hours. HS6ST3 was silenced in 
T47D and MCF7 by using Ambion siRNA. At 72 hours post-transfection, the old 
medium was discarded and the cells were washed trice with 1x PBS. The cells were fixed 
in 4% paraformaldehyde for 15min. After fixing, the wells were washed trice with 1x 
PBS (pH 7.6). Then, the cells were permeabilized in PBS- Triton-X 0.2% (PBS-TX) and 
gently washed trice with PBS-TX.  Next, 0.5% H2O2 diluted in methanol (200µl /well) 
was pipetted over the coverslips and incubated for 30min at room temp in the dark. H2O2 
was washed away with PBS-TX thrice each time for 5min. Coverslips were blocked with 
1% normal gout serum in 1x PBS for 1 hour and then incubated with primary antibody 
(HS6ST3, HEPSS1 and 10E4) diluted in PBS-TX  at 4o C overnight by slow shaking. 
Next day, the excess of primary antibody was washed with PBS-TX thrice. The 
secondary antibody conjugated with HRP (EnVision™ Detection Systems 
Peroxidase/DAB, Rabbit/Mouse kit for HS6ST3 staining and ABC kit for HEPSS and 
10E4) was pipetted over the coverslips and incubated for 1 hour at room temperature. 
The excess of secondary antibody was washed with 1x TBS (Ph 7.6) thrice. Following 
the secondary antibody addition, for HEPSS and 10E4 staining, ABC solution 
(400µl/well) was added and incubated for 1 hr at room temp. Wash with PBS thrice 
instead. In the next step, 400µl 1:10 diluted DAB (3,3’-diaminobenzidine) was pipetted 
to each well and incubated at room temperature (10min for HS6ST3 and 20min for 
HEPSS1 and 10E4 staining). The cells were then washed with 1x TBS once for 5min. 
Hematoxylin counterstaining was performed on coverslips. The coverslips were then 
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gently rinsed with tape water for a few seconds. Cells were dehydrated with histoclear 
and ethanol graded Series. Finally, the coverslips were mounted on glass slides by using 
permount medium. The slides were left to dry overnight. The scoring and analysis was 
performed similar to immunohistostaing. Thus, five random fields were selected from 
each replicate under Leica microscope (Leica DM 6000M, Germany).  The IRS of each 
staining was calculated and then compared between control and silenced groups (N=3) by 
operating t-test (p< 0.05) in GraphPad Prism 5.00 software. Details of the primary and 
secondary antibodies used in immunocytostainings were summarized in the Table 2.7. 
 








Primary antibody Antibody dilution Secondary antibody 
Antibody 
dilution 
H6ST3 Poly Clonal 
rabbit IgG (Santa Cruz) 1: 50 
EnVision Detection Systems, Dual 
Link System-HRP (DAB+)   
Peroxidase/DAB, Rabbit/Mouse 




mouse IgM                               
( SEIKAGAKU ) 
1: 800 ABC kit, anti-mouse secondary antibody (Vector Laboratories) 1: 200 
10E4 monoclonal 
human IgM                     
( SEIKAGAKU ) 
1: 800 ABC kit, anti-mouse secondary antibody (Vector Laboratories) 1: 200 
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2.9 Cell cytotoxicity assay 
2.9.1 LD50 (Lethal dose 50%) measurement 
Lethal dose 50% (LD50) is a drug dose in which 50% of cells could be killed. 
To find LD50, a total number of 7x 103 T47D cells were seeded in each well of 96 well 
plate. 24 hours after seeding, the cells were treated with 0, 5, 10, 15, 20, 25, 30, 35 µg/ml 
of Cisplatin (Sigma, USA) diluted in 0.9% sterile sodium chloride (N=6) and 0, 
2.5,20,40,60, 80, 100 µg/ml of 5-flurouracil (5-fu) (Sigma, USA) diluted in filtered 
DMSO (N=6) (the final concentration of DMSO was kept at 0.0025 µl/ml level in the cell 
culturing medium). Later, the cells were inculcated in 5% CO2, 37ºC for 48 hours. Then, 
MTS solution was added to each well in 1: 5 ratios and then the absorbance was 
measured at 490 nm in SpectraMax M5 plate reader following incubating of the 96-well 
plate in 5% CO2, 37ºC for 1-4 hour(s). The absorbances were normalized with blank and 
then the cytotoxic effects of Cisplatin and 5-fu was measured in Microsoft excel and 
finally dose-response curves were plotted by non-linear regression method in GraphPad 
Prism 5.00 software to find the LD50. 
 
2.9.2 Cisplatin and 5-fu cytotoxicity assay after silencing HS6ST3 in T47D 
In the first step, the old medium was discarded 12 hours after transfecting T47D cells by 
HS6ST3 siRNA in 6-well plate (N=3). Trypsin was added to the wells; and then 
inactivated with complete culture medium. The cells were transferred to the 15ml tubes 
and centrifuged at ~ 56 x g (1000 rpm) for 5min. The supernatant was discarded; the cells 
were resuspended in complete culture medium. A total number of 7x 103 of control and 
silenced T47D cells were seeded each in two rows inside 96 well plates (N=9). At 24 
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hours post-transfection, one row of the silenced and one row of control cells were treated 
with 13 µg/ml of Cisplatin (LD50 for Cisplatin) or 28 µg/ml of 5-fu (LD50 for 5-fu). The 
plates were incubated in 5% CO2, 37ºC for 48 hours. After 72 hours post-transfection, 
MTS solution was added (1: 5 ratio) to each well in 96-well plate. After that, the 
absorbance was measured at 490 nm in SpectraMax M5 plate reader following incubating 
of the 96-well plate in 5% CO2, 37ºC for 1-4 hour(s). Next, the absorbances were 
normalized with blank and then the absorbance of each drug-treated well in control and/ 
or silenced group was subtracted from the mean absorbance of the corresponding 
untreated group. Cell cytotoxicity of Cisplatin and 5-fu was measurd by substracting of 
the relative percentage of the live cells in drug-treated cells from non drug-treated cells in 
each of the silenced or control groups. The result of subtractions shows the percentage of 
dead cells due to the cytotoxic effect of Cisplatin and 5-fu. Finally, t-test (p< 0.05) was 
performed to compare the values between silenced and control group in GraphPad Prism 
5.00 software. 
 
2.9.3 Cisplatin and 5-fu cytotoxicity assay after silencing HS6ST3 in MCF12A 
To find the effect of Cisplatin and 5-fu after silencing HS6ST3 in MCF12A, similar 
procedure was designed by silencing HS6ST3 in MCF12A and treating with 13 µg/ml 
Cisplatin and/ or 28 µg/ml 5-fu. Finally, t-test (p< 0.05) was performed to compare the 
cytotoxicity effect of Cisplatin and 5-fu after silencing HS6ST3 in MCF12A between 
silenced and control group in GraphPad Prism 5.00 software.  
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2.9.4 Imatinib cell cytotoxicity assay 
To find a maximum non-toxic dose of imatinib (LC Laboratories, USA) on T47D cell 
growth, a total number of 7x 103 T47D cells were seeded in each well of 96 well plate. 24 
hours after seeding, the cells were treated with 0, 1, 2, 3, 4, 5, 6 µM of Imatinib. 
The cells were inculcated in 5% CO2, 37ºC for 48 hours. Then, MTS solution was added 
to each well in 1: 5 ratios and then the absorbance was measured at 490 nm in 
SpectraMax M5 plate reader following incubating of the 96-well plate in 5% CO2, 37ºC 
for 1-4 hour(s). The absorbances were normalized with blank and then the cytotoxic 
effects of Imatinib was measured in Microsoft excel to find the maximum ineffective 
dose of Imatinib on cell growth in T47D cell line. 
 
2.9.5 Imatinib and Cisplatin cytotoxicity assay after silencing HS6ST3 in T47D 
For this assay, the old medium was discarded 12 hours after transfecting T47D cells by 
HS6ST3 siRNA in 6-well plate (N=3). Trypsin was added to the wells; and then 
inactivated with complete culture medium. The cells were transferred to the 15ml tubes 
and centrifuged at ~ 56 x g (1000 rpm) for 5min. The supernatant was discarded; the cells 
were resuspended in complete culture medium. A total number of 7x 103 of control and 
silenced T47D cells were seeded each in four rows inside 96 well plates (N=9). At 24 
hours post transfection, one row out of four rows of the silenced and/ or control group 
was treated with 13 µg/ml of Cisplatin (LD50 for Cisplatin). The second row was treated 
with 1mM Imatinib. The third row was treated with 13 µg/ml Imatinib and 1mM 
Imatinib. The final row was left un-treated.  The plates were incubated in 5% CO2, 37ºC 
for 48 hours. After 72 hours post-transfection, MTS solution was added (1: 5 ratio) to 
Methods and Materials  
89  
each well in 96-well plate. After that, the absorbance was measured at 490 nm in 
SpectraMax M5 plate reader following incubating of the 96-well plate in 5% CO2, 37ºC 
for 1-4 hour(s). Next, the absorbances were normalized with blank and then the relative 
percentage of the live cells of each double -treated well in control and/ or silenced group 
was again normalized with the mean percentage of live cells of the corresponding 
untreated group. Finally, t-test (p< 0.05) was performed to compare the percentage of the 
live cells between Cisplatin-treated cells and Cisplatin-Imatinib-treated cells in GraphPad 
Prism 5.00 software.  
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CHAPTER 3  















In the first section of the current chapter, functional role of HS6ST3 in breast cancer 
growth and progression was examined. In addition, the influence of HS6ST3 knocked-
down on the expression of heparan sulfate was examined by immunocytostaining in 
breast cancer cell lines. In the second section, Genome-wide expression profiling was 
presented in breast cancer after silencing HS6ST3 by using Microarray Gene Chip. Based 
on gene microarray analysis, important downstream genes to HS6ST3 were verified at 
genome level, protein expression level and finally at their functional relevance. In the 
third section, the critical effect of silencing HS6ST3 was examined in breast cancer 
cellular response to Cisplatin, 5-fluracil and Imatinib. In the final sections, 
















Section 1: Functional role of HS6ST3 in growth and progression of 
T47D and MCF7  
 
3.1 HS6STs expression in T47D, MCF7 and MDA-MB-231, breast cancer cell lines 
The expression of HS6ST isoforms was measured in T47D, MCF7 and MDA-MB-231, 
relative to MCF-10A, normal epithelial breast cell line by performing two-step RT-PCR. 
Figure 3.1 shows that compared to MCF-10A, HS6ST3 was significantly up-regulated in 
T47D, MCF7 and MDA-MB-231 for more than two hundred forty, twenty two and three 
times respectively. The two other isoforms had no significant changes in T47D, while 
HS6ST1 and HS6ST2 were up-regulated in MCF7 for more than two and two hundred 
times respectively. The expression pattern of HS6ST3 in the breast cancer cell lines was 
indicative that HS6ST3 was up-regulated in breast cancer, with the highest expression in 
the less invasive cell line (T47D) and the lowest expression in the highly invasive cell 
line (MDA-MB-231). Thus, it was hypothesized that HS6ST3 might be potentially 
involved in regulating of the breast cancer phenotype. Therefore, in the next steps 
HS6ST3 was silenced in T47D and MCF7 cell lines and then the functional role of this 


























Figure 3.1. Quantitative real time PCR (RT-PCR) expression analysis of HS6ST isoforms 
in T47D, MCF7 and MDA-MB231 breast cancer cell lines (N=3). All values are relative 
to the expression of HS6ST isoforms in MCF-10A, normal epithelial breast cell 
line.GAPDH housekeeping gene was used to normalize the expression level of all the 
HS6ST isoforms.Data was shown as mean ± SE, * p <0.05, ** p <0.01, ***p<0.001, T 
test. 
 
3.2 Measurement of silencing and transfection efficiencies in T47D and MCF7 cell 
lines 
3.2.1 Silencing of HS6ST3 gene 
siRNA technology was used to elucidate the biological and functional importance of 
HS6ST3 gene expression in breast cancer. HS6ST3 gene was silenced in T47D and MCF7 












































































breast cancer cell lines by using two sequences of pre-designed HS6ST3 siRNAs. T47D 
and MCF7 cells were transfected with negatine scrambled siRNA as a control. In the first 
step, transfection efficiency was measured in order to examine the penetration of the 
siRNA into T47D and MCF7 cell lines by using fluorescent siRNA. As illustrated in 
Figure 3.2, the transfection efficiency was more than eighty percent in T47D and more 
than ninety percent in MCF7 at 72 hours post transfection. As shown in Figure 3.3, 
HS6ST3 was knocked down for more than 85% in T47D (A, B) and more than 71% in 
MCF7 cell line (C, D) on the basis of quantitative RT-PCR results. The highest silencing 
efficiency was achieved by using the first sequence of siRNA. Cell viabilities were more 
than 90% at 72 hours post-transfection in control groups. In addition, agarose gel 
electrophoresis showed a remarkable reduction in the corresponding intensity of silenced 
band compared to non-silenced (control) band (Fig. 3.4).  
 
After this stage, functional studies were sequentially performed by silencing HS6ST3 in 





Figure 3.2. Measurement of transfection efficiency in T47D (A, B) and MCF7 (C, D) cell 
lines 72 hours post-transfection using fluorescent siRNA (Cyanine 3 labeled negative 
control siRNA) (N=3). The left photos represent the bright field and the right photo 
represents the same fluorescent field. Transfection efficiency was more than 80% in 














                                                                         









Figure 3.3. Silencing efficiency of HS6ST3 genes in T47D (A, B) and MCF7 (C, D) breast 
cancer cell lines using two sequences of siRNA (N=3). The percentages were calculated 
based on the relative quantitation in RT-PCR. Data was shown as mean ± SE, * p <0.05, 
** p <0.01, ***p<0.001, T test. 
 
 
   
 
Figure 3.4 RT-PCR products were run on 1.2% 
Agarose gel 72 hours post-transfection. 100bp ladder 

































































































3.2.2 Examining the specificity of silencing HS6ST3 in T47D and MCF7 cell lines 
Expression of all HS6ST isoforms were measured after silencing HS6ST3 in T47D and 
















Figure 3.5. Using two sequences of HS6ST3 siRNAs specifically silenced HS6ST3 without 
changing the expression of HS6ST1 and HS6ST2 in both T47D (A) and MCF7 (B) cell 
lines. The values in silenced groups were compared to negative control groups 
(transfected with scrambled siRNA). Data was shown as mean ± SE, * p <0.05, ** p 






































































































3.3. HS6ST3 protein expression after silencing HS6ST3 in T47D and MCF7 
The expression of HS6ST3 was measured at protein level at 72 hours after transfecting 
T47D and MCF7 by western blotting and immunocytostaining. The expression values 
were normalized with the expression of β-actin, housekeeping protein in western blotting. 
As shown in Figure 3.6 and 3.7 the expression of HS6ST3 had a significant reduction at 









Figure 3.6. Western blotting (WB) analysis of HS6ST3 protein expression at 72 hours 
after silencing HS6ST3 gene in T47D (A) and MCF7 (B) cell lines. Silencing HS6ST3 
gene significantly reduced the protein expression by 38.5% and 55% in T47D (C) and 













































Figure 3.7. Immunocytostaining (ICC) analysis of HS6ST3 protein expression at 72 
hours after silencing HS6ST3 gene in T47D (A, B) and MCF7 (C, D) cell lines. Silencing 
HS6ST3 gene significantly reduced the HS6ST3 protein expression by 50.7% and 82.8% 























































3.4 Effect of HS6ST3-knocking down on heparan sulfate expression in breast cancer 
cells 
 
3.4.1 Analysis of HepSS1 expression after silencing HS6ST3 in T47D and MCF7 
A total 3.5x105 of T47D and 2x 105 of MCF7 cells were seeded over treated coverslips in 
6-well plates and cultured for 24 hours. HS6ST3 was silenced in T47D and MCF7 by 
using Ambion siRNA. At 72 hours post-transfection, immunocytostaining procedure 
(discussed in previous chapter) was performed. Then, the immunoreactivity score (IRS) 
was measured in five random fields of either control or silenced group. Comparison 
between the IRS of control and silenced groups showed that silencing HS6ST3 inhibited 
the expression of HepSS1 epitope on the cell surface of T47D and MCF7 by 31.62% and 















Figure 3.8. Immunocytostaining (ICC) analysis of HepSS1 epitope expression at 72 hours 
after silencing HS6ST3 gene in T47D (A, B) and MCF7 (C, D) cell lines. Silencing 
HS6ST3 gene significantly reduced the HepSS1 epitope expression by 31.62% and 
93.97% in T47D (C) and MCF7 (F) respectively (N=3). Data was shown as mean ± SE 





















































3.4.2 Analysis of 10E4 expression after silencing HS6ST3 in T47D and MCF7 
A total 3.5x105 of T47D and 2x 105 of MCF7 cells were seeded over treated coverslips in 
6-well plates and cultured for 24 hours. HS6ST3 was silenced in T47D and MCF7 by 
using Ambion siRNA. At 72 hours post-transfection, immunocytostaining procedure 
(discussed in previous chapter) was performed. Then, the immunoreactivity score (IRS) 
was measured in five random fields of either control or silenced group. Comparison 
between the IRS of control and silenced groups showed that silencing HS6ST3 reduced 
the expression of 10E4 epitope on the cell surface of T47D and MCF7 by 19.23% and 
98.14% respectively (Figure 3.9). The reduced expression of HepSS1 and 10E4 
consistently showed that silencing HS6ST3 potently diminish the expression of heparan 
sulfate on the cell surface. Thus, this observation could be suggestive of the modulatory 

















Figure 3.9. Immunocytostaining (ICC) analysis of 10E4 epitope expression at 72 hours 
after silencing HS6ST3 gene in T47D (A, B) and MCF7 (C, D) cell lines. Silencing 
HS6ST3 gene significantly reduced the 10E4 epitope expression by 19.23% and 98.14% 
in T47D (C) and MCF7 (F) respectively (N=3). Data was shown as mean ± SE 
















































3.5 Analysis of cell Proliferation after silencing HS6ST3 in breast cancer  
To test whether silencing of HS6ST3 gene is involved in breast cancer cell proliferation, 
the relative percentage of the live cells were measured at 72 hours after silencing HS6ST3 
in T47D and MCF7. Analysis showed a significant reduction in the relative percentage of 
live T47D and MCF7 cells at 72 hours after silencing HS6ST3. The silenced T47D cells 
exhibited nearly about 40.8-53.5% reduction in number of living cells compared to 
control group. Similarly, silencing HS6ST3 reduced the relative percentage of the live 
MCF7 cells by 39.4-66.2% compared to the control group (Figure 3.10).  The result 
suggested that expression of HS6ST3 may positively modulate the cell growth in breast 
cancer. One plausible reason for reduction of the viable cells after silencing of HS6ST3 is 
the regulatory effect of HS6ST3 gene on other genes that influence the cell growth. Thus, 
in the next steps flow cytometry was performed to identify the influence of HS6ST3 


































Figure 3.10. Relative percentage of the live cells cells was measured based on 
absorbance of formazan produced by T47D (A, B) and MCF7 (C, D) cells at 72 hours 
post-transfection in control and silenced group (N=5). The relative percentage of the live 
cells reduced after silencing HS6ST3 by 40.8-53.5% and 39.4-66.2% in T47D and MCF7 








































































































3.6 Analysis of cell cycle phases after silencing HS6ST3 in breast cancer   
Proliferation assay showed a significant reduction in the relative percentage of the live 
cells after silencing HS6ST3 in both T47D and MCF7. Cell cycle flow cytometry which 
is a direct reflection of cell proliferation was performed to examine whether down-
regulation of HS6ST3 influence the cell cycle progression. Therefore, this assay was 
performed at 72 hours post-transfection in T47D and MCF7 cell lines by using two 
sequences of siRNA. A total number of 10,000 cell events were acquired from control 
and silenced groups after silencing HS6ST3 in both T47D and MCF7 cell lines. As shown 
in Figure 3.11, the numbers of the cells in G0 and G1 phases were respectively increased 
by 3% and 15% in silenced group compared to control group indicating a cell cycle arrest 
in G1 as well as slight increase in the number of pre-apoptotic cells; and consequently, 
more cells were seen in S and G2 phases in control group (Figure 3.11: I, II, Figure 3.12: 
A, B). Besides, silencing HS6ST3 in MCF7 showed an induction of apoptosis pathway as 
the number of pre-apoptotic cells increased in G0 phase by 8-29%; and thus the living 
cells in G1, S and G2 phases was decreased compared to the control (Figure 3.11: III, IV, 
Figure 3.12: C, D). Furthermore, in this assay it was shown that the relative percentage of 
the live cells of all control groups (transfected with scrambled siRNA) were more than 
95% at 72 hours after silencing HS6ST3 in both T47D and MCF7 cell lines; and 
therefore, indicating that the cells in the control groups were not significantly affected by 
transfection reagent and scrambled negative siRNA. 
 
The results of cell cycle assay could confirm the observed differences in proliferation 
assay. However, as the number of the pre-apoptotic cells of G0 phase was increased in 
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Figure 3.11. Representative histograms of T47D and MCF7 cell cycle analysis 72 hours 
after silencing HS6ST3. White histogram represents the control and the red histogram 
represents the silenced group. G0, G1, S, and G2 stand for cell cycle phases. G1 arrest in 
silenced cells is remarkable in T47D (I, II), while the number of pre-apoptotic cells were 























Figure 3.12. Effect of HS6ST3 silencing on cell cycle phases in T47D  and MCF7 cell 
lines at 72 hours post-transfection (N=3). G1 arrest in silenced cells is remarkable in 
T47D (A, B), while the number of pre-apoptotic cells were increased in G0 phase in 






















































































































































































3.7 Analysis of Apoptosis assay after silencing HS6ST3 in breast cancer   
In order to find a possible reason for the observed differences between silenced and 
control group in proliferation and cell cycle assays, apoptosis assay was performed at 72 
hours after silencing HS6ST3 by using Caspase-Glo® 3/7 and 8 kits separately. Two 
sequences of siRNA were used to silence HS6ST3 in T47D and MCF7 cell lines. As 
shown in Figure 3.13, silencing HS6ST3 increased the relative activity of Caspase 3/ 7 
(A) and 8 (B) in T47D by 16-44% and 22-32% respectively. In addition, a dramatic 
increase was observed in relative activity of Caspase 3/ 7 (C) (50-172%) and 8 (D) (185-
270%) in MCF7 cell line. Thus, it seems that HS6ST3 expression could have a strong 
inhibitory effect on apoptotic pathways regulated by apoptotic genes. In the other words, 
HS6ST3 may play an important role to secure the survival of the breast cancer cells. 
Nevertheless, to find whether HS6ST3 could function as an oncogene in the progression 
of the breast cancer we performed some further experiments such as adhesion, migration 
































Figure 3.13. Effect of HS6ST3 knock down on induction of apoptosis in T47D  and MCF7 
cell lines at 72 hours post-transfection (n=5). Apoptosis assay was performed by using 
Caspase-Glo® 3/7 and 8 kits. A remarkable increase was observed in the relative activity 
of Caspase 3/7 and 8 after silencing of HS6ST3 gene in T47D (A, B) and MCF7 (C, D) 
cell lines. In addition, a dramatic increase was observed in relative activity of Caspase 3/ 
7 (C) (50-172%) and 8 (D) (185-270%) in MCF7 cell line. Data was shown as mean ± 



























































































































































3.8 Transmission Electron microscopy (TEM) analysis after silencing HS6ST3 in 
T47D 
Cell cycle and apoptosis assays revealed that silencing HS6ST3 could induce the 
apoptosis in breast cancer. To visualize this observation, cellular morphology of T47D 
cells were selected by Transmission Electron Microscopy (TEM). Five random fields 
were selected and captured from each sample for further analysis. Physiologic cell death 
(apoptosis) was assessed in control and silenced group by considering cytoplasm 
shrinkage, cell membrane asymmetry, chromatin condensation, aggregation of chromatin 
at nuclear membrane, mitochondrial aggregation, cytoplasmic vacuolization, formation of 
cell membrane budding (apoptotic body formation), nuclear collapse, terminal 
fragmentation of the cells to the smaller bodies, nuclear fragmentation (Figure 3.14). 
Analysis of the TEM-based apoptosis revealed that silencing HS6ST3 in T47D could 
increase the apoptosis by 21.8 % compared to negative control group (Figure 3.15). This 
observation was in agreement with the results of the cell cycle and apoptosis assays 






Figure 3.14. Visualization of cell morphology at 72 hours after silencing HS6ST3 in 
T47D. Silencing HS6ST3 induced apoptosis in T47D cell line. Figure B and C show 
Mitochondria Aggregation (MA). Figure E and F show Terminal Fragmentation (TF) of 
















Figure 3.15. Analysis of the cellular apoptosis percentage at 72 hours after silencing 
HS6ST3 in T47D based on TEM images. Silencing HS6ST3 increased the apoptosis in 
T47D by 21.8% compared to negative control group. Data was shown as mean ± SE, 



























3.9 Analysis of adhesion assay after silencing HS6ST3 in breast cancer   
 
Similar to the cell motility, adhesion is one of the most important characteristics of tumor 
cells for progression. Adhesion assay was performed to investigate the potential effect of 
HS6ST3 for changing the adhesion capacity of tumor cells into extracellular matrix 
(ECM). In this experiment the collagen I and fibronectin were used to coat the wells 
before seeding breast cancer cells. Analysis of the data revealed that the adhesion 
capacity of the T47D cells to collagen I was slightly increased by 5-10% in silenced 
group compared to control after silencing HS6ST3 (Figure3.16: A); while this capacity 
was interestingly enhanced by 27-36% in MCF7 cell line (Figure3.16: C). Similarly, 
silencing of HS6ST3 in T47D increased the adhesion capacity of this cell line to 
fibronectin by 9.2-14.4% (Figure3.16: B), while the similar capacity of MCF7 cells 





































Figure 3.16. Effect of silencing HS6ST3 on adhesion capacity of breast cancer cell lines. 
Silencing HS6ST3 slightly enhanced the adhesion capacity in T47D cell line toward 
collagen I and fibronectin (A, B); while, adhesion capacity of MCF7 cells remarkably 
increased toward Collagen I and fibronectin after silencing HS6ST3 (N=6) (C, D). Data 
was shown as mean ± SE, ** p <0.01, *** p<0.001, T test. 


















































































































3.10 Analysis of the cellular F-actin density in HS6ST3- knocked down cells  
Analysis of adhesion assay showed that cell adhesion increased after silencing HS6ST3 in 
breast cancer cell lines. Thus, we stained F-actin fibers in T47D and MCF7 breast cancer 
cell lines at 72 hours after silencing HS6ST3. However, it seems that silencing of HS6ST3 





Figure 3.17. Effect of silencing HS6ST3 on F-actin assembly in breast cancer cell lines. 
F-actin fibers were probed by green color of fluorescein isothiocyanate (FITC-
conjugated phalloidin). Silencing HS6ST3 did not change the distribution of F-actin in 






3.11 Analysis of Migration assay after silencing HS6ST3 in breast cancer   
This assay was performed to evaluate the functional role of HS6ST3 in breast cancer cell 
motility. Wound healing (scratch assay) and transwell migration assays were two method 
that were employed to examine the migratory behavior of breast cancer cells after 
silencing HS6ST3 with two sequence of siRNA. Firstly, migration assay was performed 
by transwell migration chambers for both T47D cell lines. Since T47D cells exhibited no 
migration through the migration inserts after silencing HS6ST3, we performed wound 
healing (scratch assay). Thus, HS6ST3-transfected T47D cells were seeded in 24 well 
plates and scratched 36 hours post-transfection and the gap sizes were measured by 
taking serial photos at 0, 24, 48 and 72 hours after scratch (Figure 3.18). The statistical 
analysis exhibited no significant differences at 24, 48 hours post-scratching; while, the 
gap size at 72 hours after scratching was significantly smaller in control compared to 
silenced group (Figure 3.19). The results showed that the scratch healing was delayed in 
silenced cells compared to control group. This change indicates that silencing of HS6ST3 
may potentially decrease the motility of cancer cells and consequently reduce the tumor 
progression; however we primarily concluded that this observed change might be 
attributable to the cellular proliferation rather than migration alone. In order to have a 
better understanding about cellular phenotype, we decided to perform invasion assay on 
MCF7 after silencing HS6ST3.  






  Control                                      Silenced             
 
Figure 3.18. Effect of HS6ST3 silencing on migration of T47D cell line at different time 
points (N=9). Although there were no significant differences at 24 and 48 hours post-
scratching, the gap closure was delayed in silenced group compared to control group at 






Figure 3.19. Silencing HS6ST3 gene delayed the migration in silenced group at 72 hours 
post-scratching compared the control group (N=9, P< 0.01). Data was shown as mean ± 





















Transwell migration inserts were employed to perform migration assay 72 hours after 
silencing HS6ST3 in MCF7. Thus, the MCF7 cells were seeded in migration inserts at 48 
hours post transfection and the cells were allowed to migrate through the inserts in 5% 
CO2, 37ºC for 24 hours (Figure 3.20: A, B and C). Analysis revealed that cellular 
migration was significantly reduced after silencing HS6ST3 compared to control group 
(Figure 3.20: D). The reduction in migratory cells confirmed the result of previous 







Figure 3.20. The effect of HS6ST3 down-regulation on migration of MCF7 cells. A total 
number of 5x 104 cells were seeded in a total volume of 200µl into upper the chamber of 
the migration transwell. The lower chamber was filled with 600µl culture medium (RPMI 
for T47D and DMEM for MCF7) supplemented with 30% FBS. Cells were allowed to 
migrate in 5% CO2, 37ºC for 24 hours. The migratory behavior of MCF7 cells were 
remarkably reduced in the silenced groups (B, C) compared to the control group (A) by 
52-69% (D) (N=3). Data was shown as mean ± SE, ** p <0.01, T test. 
 
























3.12 Analysis of breast cancer cellular invasion after silencing HS6ST3  
Invasion is clinically an important characteristic of cancer cells which leads to metastasis. 
Metastasis occurs when the tumor cells invade the basement membrane to expand their 
proliferation to adjacent tissues as well as other organs. Invasion assay was performed on 
T47D and MCF7 cell lines after silencing HS6ST3. This assay provided an in vitro 
simulation model for cancer cell invasiveness by using Matrigel coated membrane. 
Analysis revealed no invasion in silenced or control group of T47D cell line. Then we 
performed invasion assay on MCF7 cell line to examine whether HS6ST3 could affect the 
cellular invasiveness phenotype. Figure 3.21 show that silencing HS6ST3 in MCF7 







Figure 3.21.Down-regulation of HS6ST3 in MCF7 significantly reduced the cellular 
invasiveness. The number of invaded cells across the matrigel membrane was evidently 
lower in silenced group compared to control (D) (N=3). Data was shown as mean ± SE, 
*** p <0.001, T test. 
 
























Section 2: Genome-wide expression profiling in HS6ST3-knocked down 
T47D cells 
 
As stated, it was identified that HS6ST3 was highly up-regulated in breast cancer with the 
highest expression in the less invasive cell line (T47D). Thus, HS6ST3 was silenced in 
T47D and then Genome-wide microarray was performed to identify the significant 
alteration in the expression of HS6ST3-related genes to find the potential pathway(s) in 
which HS6ST3 was involved in the malignant process of carcinogenesis. T47D cells were 
transfected with negative scrambled siRNA as a negative control. 
 
3.13 RNA yield, quality and integrity for T47D cells after silencing HS6ST3 
The quality and integrity of RNA samples were important factors affecting the success of 
gene microarray hybridization. The quality of RNA samples defined by 260/ 280 
absorbance ratios and also the RNA integrity number (RIN) were summarized in Table 
3.2. All samples showed 260/ 280 absorbance ratios between 2.055 to 2.081 with 
concentration ranging from 478.52 to 970.21 ng/ μl. The mean RNA concentration of the 
silenced group was more than control group which was due to the effect of silencing 
HS6ST3 on the relative percentage of the live cells.  RIN ranged from 1 (degraded RNA) 
to 10 (intact RNA) was calculated based on the ratio of 28S/ 18S ribosomal RNA (rRNA) 
in Agilent 2100 Bioanalyzer. Analysis showed that all of the samples had a RIN of 8.2 to 
9.4 indicating that RNA samples were of good quality (Table 3.1).  
Electropherograms illustrated in Figure 3.22 (A) showed good integrity of RNA samples 
as they had two sharp peaks at18S and 28S. Furthermore, an image of depicted pseudo 
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gel revealed two specific distinct bands, one for 18S and another for 28S ribosomal 
subunit. Thus, the RNA samples were qualified to be used for next steps for synthesis of 
cDNA and cRNA in microarray procedure. 
 
 
Table 3.1. Quality and integrity of RNA samples for microarray procedure. Data was 
shown as mean ± SE. 
Sample Control Silenced 
RIN 9.66± 0.033 9.10± 0.450 
Conc.  measured 
(ng/µl) 895.67± 39.107 496.74± 13.641 
















Figure 3.22. Analysis of total RNA quality after silencing HS6ST3 in T47D by Agilent 
bioanalyzer. A) The spectrum analysis of 6 samples. Sharp peaks at 18S and 28S 
indicated highly intact RNA. B) The pseudo gel image from Agilent Bioanalyzer analysis 
showed two distinct bands (upper band: 28S subunit, lower band: 18S subunit). Samples 
include: Ladder, Control 1, Control 2, Control 3, Silenced 1, Silenced 2 and Silenced 3. 
 
3.14 Target preparation 
300 ng of each total RNA sample was used for the whole transcript assay. The 
spectrophotometric reading results of sample processing were summarized in Table 3.2. 
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and Table 3.3. At each QC stage all the samples have good purity with high 
concentration. 
 
Table 3.2. Spectrophotometric details of purified cRNA. Data was shown as mean ± SE. 
 
Sample Control Silenced 
260/280 Ratio 2.09± 0.002 2.09± 0.000 
Concentration 
(mg/ml) 5.34± 0.160 4.58± 0.228 
Yield (μg) 64.12± 1.925 54.96± 2.737 
 
Table.3.3. Spectrophotometric details of purified single stranded cDNA. Data was shown 
as mean ± SE. 
Sample Control Silenced 
260/280 Ratio 1.77± 0.017 1.84± 0.054 
Concentration 
(mg/ml) 273.55± 3.596 268.28± 11.867  
Yield (μg) 7.66± 0.101 7.51± 0.332 
 
3.15 Analysis of gene Microarray data 
Synthesized Biotin-labeled cRNA were hybridized to the Human Gene 1.0 ST Gene 
Chips. Arrays were then washed and stained and finally scanned in Affymetrix 3000 7G 
scanner. Scanning provided an image file as well as raw signal intensities for all probe 
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sets. Expression Console, Genespring and dChip softwares were hired to processing the 
microarray data. Additionally, RMA, PLIER and iterPLIER algorithms were separately 
used in Expression Console and Genespring.   
 
As discussed in method and material chapter, RMA was used to minimizing the 
difference of probe-specific affinity by reducing the variance across the dynamic change 
as well as increasing the sensitivity to small changes between control and silenced group. 
Adjustment of background based on PM distribution, normalization and summarization 
were three main steps performed in RMA. Unlike RMA, PLIER provides a higher 
accuracy for background adjustment but at the cost of increasing the signal variance. 
Therefore, for detecting small changes in the relative gene expression (fold of change), 
PLIER is highly sensitive with more accuracy compared to RMA; however, the variances 
are not so stable at the Log scale. The PLIER method was used in Genespring and 
Expression Console software independently. Iterative PLIER or iterPLIER is very similar 
to PLIER; however, it does not perform the summarization on all of the probes, but it 
selects the good probes regardless of bad probes (Therneau and Ballman 2008; Qu, He 
and Chen 2010; Seo and Hoffman 2006). 
 
 By using several stringent criteria (based on p-value, fold of change and probe intensity) 
for gene filtering in three softwares, we found significant alteration in expressions of 297 
genes (Fig. 12) after silencing HS6ST3 gene in T47D. The genes categorized into two 




Figure 3.23. Overlapping the filtered genes after using three analytical microarray 
softwares (Expression Console, Genespring and dchip). Using three different algorithmic 
analyses in Expression Console and Genespring together with the data given from dChip 
provided seven sets of data for filtered gene which were finally overlapped together. 
T47D cells were transfected with negative scrambled siRNA as a negative control. 
3.16 Functional categorization of target genes 
Visualization and Integrated Discovery (DAVID) functional annotation (DAVID, 
Bioinformatics Resources, 2008) and Affymetrix NetAffx database were hired to find the 
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functional categorization of filtered genes. Up-regulated and down-regulated genes 
together were classified based on their genomic function in Table 3.4.  
 
Table 3.4. Functional categorization of filtered genes after silencing HS6ST3 gene based 
on DAVID gene ontology and Affymetrix NetAffx database. Relative expression is fold 
change of gene after silencing HS6ST3.  Negative values in relative gene expression 
indicate Down-regulation, while positive values show Up-regulation. 




(33 genes) APOL1 apolipoprotein L, 1 27.53 8542 
 
APOL6 apolipoprotein L, 6 5.43 80830 
 
BIRC3 baculoviral IAP repeat-containing 3 6.87 330 
 
CASP1 
caspase 1, apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase) 4.58 834 
 
CCL5 chemokine (C-C motif) ligand 5 46.27 6352 
 
CD74 
CD74 molecule, major histocompatibility 
complex, class II invariant chain 10.69 972 
 
CXCR4 chemokine (C-X-C motif) receptor 4 4.64 7852 
 
DRAM damage-regulated autophagy modulator 2.33 55332 
 
EIF2AK2 
eukaryotic translation initiation factor 2-alpha 
kinase 2 2.44 5610 
 
HERC5 hect domain and RLD 5 8.34 51191 
 
IFI6 interferon, alpha-inducible protein 6 9.31 2537 
 
IFIH1 interferon induced with helicase C domain 1 11.53 64135 
 




interleukin 28A (interferon, lambda 2) /// 




IL29 interleukin 29 (interferon, lambda 1) 7.75 282618 
 
JAK2 Janus kinase 2 (a protein tyrosine kinase) 2.54 3717 
 
KLF4 Kruppel-like factor 4 (gut) 4.4 9314 
 
MX1 
myxovirus (influenza virus) resistance 1, 
interferon-inducible protein p78 (mouse) 12.6 4599 
 
MYD88 
myeloid differentiation primary response gene 
(88) 2.47 4615 
 
NFKBIA 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha 2.67 4792 
 
NUPR1 nuclear protein 1 2.35 26471 
 
OPTN Optineurin 2.95 10133 
 
PML promyelocytic leukemia 3.49 5371 
 
RARRES3 
retinoic acid receptor responder (tazarotene 




SHISA5 shisa homolog 5 (Xenopus laevis) 2.81 51246 
 
SOD2 superoxide dismutase 2, mitochondrial 2.97 6648 
 
STAT5A signal transducer and activator of transcription 5A 7.07 6776 
 
TLR3 toll-like receptor 3 4.81 7098 
 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 4.65 7128 
 
TNFSF10 
tumor necrosis factor (ligand) superfamily, 
member 10 5.8 8743 
 
TP53I3 tumor protein p53 inducible protein 3 (-)2.59 9540 
 
UBE4B ubiquitination factor E4B (UFD2 homolog, yeast) (-)2.89 10277 
 
XAF1 XIAP associated factor 1 29.84 54739 
Proliferation 
(25 genes) BST2 bone marrow stromal cell antigen 2 3.19 684 
 
CCL5 chemokine (C-C motif) ligand 5 46.27 6352 
 
CD74 
CD74 molecule, major histocompatibility 
complex, class II invariant chain 10.7 972 
 
CEP55 centrosomal protein 55kDa (-)2.62 55165 
 
CXCL10 chemokine (C-X-C motif) ligand 10 13.9 3627 
 
CXCR4 chemokine (C-X-C motif) receptor 4 4.65 7852 
 
EIF2AK2 
eukaryotic translation initiation factor 2-alpha 
kinase 2 2.44 5610 
 
IFITM1 
interferon induced transmembrane protein 1 (9-
27) 14.45 8519 
 
IGF1R insulin-like growth factor 1 receptor (-)2.37 3480 
 
IL29 interleukin 29 (interferon, lambda 1) 7.75 282618 
 
JAK2 Janus kinase 2 (a protein tyrosine kinase) 2.54 3717 
 
KLF4 Kruppel-like factor 4 (gut) 4.4 9314 
 
LAMP3 lysosomal-associated membrane protein 3 15.07 27074 
 
MYD88 
myeloid differentiation primary response gene 
(88) 2.47 4615 
 
NFKBIA 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha 2.67 4792 
 
NUPR1 nuclear protein 1 2.35 26471 
 
ODC1 ornithine decarboxylase 1 (-)3.01 4953 
 
OGFR opioid growth factor receptor 3.61 11054 
 
PML promyelocytic leukemia 3.49 5371 
 
RARRES3 
retinoic acid receptor responder (tazarotene 
induced) 3 19.11 5920 
 
SKAP2 src kinase associated phosphoprotein 2 (-)3.02 8935 
 
SOD2 superoxide dismutase 2, mitochondrial 2.97 6648 
 
STAT5A signal transducer and activator of transcription 5A 7.07 6776 
 
TTK TTK protein kinase (-)2.21 7272 
 
ZFP106 zinc finger protein 106 homolog (mouse) (-)2.17 64397 
Adhesion 
(12 genes) RND1 Rho family GTPase 1 5 27289 
 





Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain,2 2.63 10370 
 
COL12A1 collagen, type XII, alpha 1 (-)2.8 1303 
 
CTNNAL1 catenin (cadherin-associated protein), alpha-like 1 (-)3.04 8727 
 
ICAM1 intercellular adhesion molecule 1 3.05 3383 
 
LGALS3BP 
lectin, galactoside-binding, soluble, 3 binding 





lectin, galactoside-binding, soluble, 9 /// lectin, 
galactoside-binding, soluble, 9B /// lectin, 





PCDHB14 protocadherin beta 14 (-)2.85 56122 
 
PCDHB16 protocadherin beta 16 (-)2.53 57717 
 
PCDHB6 protocadherin beta 6 (-)3.18 56130 
 
STAT5A signal transducer and activator of transcription 5A 7.07 6776 
Migration 
(11 genes) ABHD2 abhydrolase domain containing 2 (-)2.8 11057 
 







/// HLA-A /// 
XXbac-
BPG181B23.1 
major histocompatibility complex, class I, C /// 
major histocompatibility complex, class I, B /// 
family with sequence similarity 20, member B /// 
MHC class I polypeptide-related sequence A /// 
similar to HLA class I histocompatibility antigen, 
B-18 alpha chain precursor (MHC class I antigen 
B*18) /// major histocompatibility complex, class 















/// HLA-A /// 
XXbac-
BPG181B23.1 
major histocompatibility complex, class I, C /// 
major histocompatibility complex, class I, B /// 
family with sequence similarity 20, member B /// 
MHC class I polypeptide-related sequence A /// 
similar to HLA class I histocompatibility antigen, 
B-18 alpha chain precursor (MHC class I antigen 
B*18) /// major histocompatibility complex, class 















major histocompatibility complex, class I, C /// 
major histocompatibility complex, class I, B /// 
MHC class I polypeptide-related sequence A /// 







hyaluronan-mediated motility receptor 
(RHAMM) (-)2.56 3161 
 
ICAM1 intercellular adhesion molecule 1 3.05 3383 
 
IGF1R insulin-like growth factor 1 receptor (-)2.37 3480 
 
PARP9 poly (ADP-ribose) polymerase family, member 9 8.07 83666 
 
SDCBP syndecan binding protein (syntenin) 2.26 6386 
 





ataxia telangiectasia mutated /// nuclear protein, 






CDCA7L cell division cycle associated 7-like (-)2.69 55536 
 
CEP55 centrosomal protein 55kDa (-)2.62 55165 
 
CITED2 
Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2 2.63 10370 
 
DSCC1 
defective in sister chromatid cohesion 1 homolog 
(S. cerevisiae) (-)2.89 79075 
 
FANCD2 Fanconi anemia, complementation group D2 (-)2.5 2177 
 


















major histocompatibility complex, class II, DR 
beta 3 /// major histocompatibility complex, class 
II, DR beta 5 /// major histocompatibility 
complex, class II, DR beta 5 /// major 
histocompatibility complex, class II, DR beta 4 /// 
major histocompatibility complex, class II, DR 
beta 1 /// hypothetical protein LOC730415 /// 
major histocompatibility complex, class II, DQ 
beta 1 /// major histocompatibility complex, class 
II, DQ beta 2 /// major histocompatibility 
complex, class II, DR beta 2 (pseudogene) /// zinc 
finger protein 749 /// ribonuclease, RNase A 













IGF1R insulin-like growth factor 1 receptor (-)2.37 3480 
 
IL1R1 interleukin 1 receptor, type I (-)2.4 3554 
 
IRF1 interferon regulatory factor 1 4.68 3659 
 
NCAPD2 non-SMC condensin I complex, subunit D2 (-)2.2 9918 
 




proteasome (prosome, macropain) subunit, beta 





proteasome (prosome, macropain) subunit, beta 
type, 8 (large multifunctional peptidase 7) 5.17 5696 
 
PSMB8 
proteasome (prosome, macropain) subunit, beta 
type, 8 (large multifunctional peptidase 7) 5.17 5696 
 
PSMB8 
proteasome (prosome, macropain) subunit, beta 
type, 8 (large multifunctional peptidase 7) 5.17 5696 
 
PSMB9 
proteasome (prosome, macropain) subunit, beta 
type, 9 (large multifunctional peptidase 2) 6.96 5698 
 
PSMB9 
proteasome (prosome, macropain) subunit, beta 
type, 9 (large multifunctional peptidase 2) 6.96 5698 
 
PSMB9 
proteasome (prosome, macropain) subunit, beta 
type, 9 (large multifunctional peptidase 2) 6.96 5698 
 
PSME1 
proteasome (prosome, macropain) activator 
subunit 1 (PA28 alpha) 2.38 5720 
 
SP100 SP100 nuclear antigen 3.98 6672 
 
STAT5A signal transducer and activator of transcription 5A 7.07 6776 
 




TTK TTK protein kinase (-)2.21 7272 
 
XAF1 XIAP associated factor 1 29.84 54739 
Signal 
Transduction 
(28 genes) ARHGAP11A Rho GTPase activating protein 11A (-)2.42 9824 
 




ataxia telangiectasia mutated /// nuclear protein, 




BIRC3 baculoviral IAP repeat-containing 3 6.87 330 
 
C3 complement component 3 6 718 
 
CASP1 
caspase 1, apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase) 4.57 834 
 
CCL5 chemokine (C-C motif) ligand 5 46.27 6352 
 
CD74 
CD74 molecule, major histocompatibility 
complex, class II invariant chain 10.7 972 
 
CLOCK clock homolog (mouse) (-)2.66 9575 
 
CXCL10 chemokine (C-X-C motif) ligand 10 13.9 3627 
 
CXCR4 chemokine (C-X-C motif) receptor 4 4.65 7852 
 
GNG12 
guanine nucleotide binding protein (G protein), 


















major histocompatibility complex, class II, DR 
beta 3 /// major histocompatibility complex, class 
II, DR beta 5 /// major histocompatibility 
complex, class II, DR beta 5 /// major 
histocompatibility complex, class II, DR beta 4 /// 
major histocompatibility complex, class II, DR 
beta 1 /// hypothetical protein LOC730415 /// 
major histocompatibility complex, class II, DQ 
beta 1 /// major histocompatibility complex, class 
II, DQ beta 2 /// major histocompatibility 
complex, class II, DR beta 2 (pseudogene) /// zinc 
finger protein 749 /// ribonuclease, RNase A 














interferon induced transmembrane protein 1 (9-
27) 14.45 8519 
 
IGF1R insulin-like growth factor 1 receptor (-)2.37 3480 
 
IRF9 interferon regulatory factor 9 2.86 10379 
 
LGALS3BP 
lectin, galactoside-binding, soluble, 3 binding 
protein 10.23 3959 
 
MX1 
myxovirus (influenza virus) resistance 1, 
interferon-inducible protein p78 (mouse) 12.6 4599 
 
OPTN Optineurin 2.95 10133 
 
PML promyelocytic leukemia 3.49 5371 
 
PRKAR2A 
protein kinase, cAMP-dependent, regulatory, type 
II, alpha (-)2.8 5576 
 




SKAP2 src kinase associated phosphoprotein 2 (-)3.02 8935 
 
STAT1 
signal transducer and activator of transcription 1, 
91kDa 4.55 6772 
 
STAT2 
signal transducer and activator of transcription 2, 
113kDa 3.34 6773 
 
STAT5A signal transducer and activator of transcription 5A 7.07 6776 
 
TLR3 toll-like receptor 3 4.81 7098 
 
TNFSF10 
tumor necrosis factor (ligand) superfamily, 
member 10 5.8 8743 
Others 
     
 
3.17 Validation of gene expression by RT-PCR 
297 genes were further filtered to 50 genes (25 down-regulated and 25 up-regulated 
genes) regarding their functional categories and the most up- and down-regulated change. 
To check the accuracy of microarray results, quantitative RT-PCR was performed on the 
50 genes. For this purpose, forward and reverse primers were designed in Primer 3 
software and then their specificity was checked in NCBI Blast.    
 
After designing specific primers, RT-PCR was performed on 50 genes out of 297 genes 
to validate their expression. The results of RT-PCR for all of the up- and down-regulated 
genes were consistent with that of microarray results (Table 3.5). For further verification, 
the direction of the regulation of the genes and the quantitative level of up- and down-
regulation (fold of change) was plotted in Figure 3.24. The main focus of this study was 
on the above mentioned gene list; however, based on the extensive literature review, 
changes of a few other genes (after silencing HS6ST3) were considered from non-
overlapped list of genes (using iterPLIER of Expression Console) which will be 
discussed in the discussion chapter.  
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Table 3.5. Validation of 50 differentially expressed genes in Microarray analysis by RT-
PCR. ↑ stands for up-regulation and ↓ stands for down-regulation. 
  Gene Symbol Gene Name Microarray RT-PCR 
Up-
regulated 
genes CFB /// C2 
complement factor B /// complement 
component 2 ↑ ↑ 
 
CCL5 chemokine (C-C motif) ligand 5 ↑ ↑ 
 
OASL 2'-5'-oligoadenylate synthetase-like ↑ ↑ 
 
IFIT3 
interferon-induced protein with 
tetratricopeptide repeats 3 ↑ ↑ 
 
IFIT2 
interferon-induced protein with 
tetratricopeptide repeats 2 ↑ ↑ 
 
XAF1 XIAP associated factor 1 ↑ ↑ 
 
APOL1 apolipoprotein L, 1 ↑ ↑ 
 
OAS2 
2'-5'-oligoadenylate synthetase 2, 
69/71kDa ↑ ↑ 
 
IFI27 interferon, alpha-inducible protein 27 ↑ ↑ 
 
S100A8 S100 calcium binding protein A8 ↑ ↑ 
 
RSAD2 
radical S-adenosyl methionine domain 
containing 2 ↑ ↑ 
 
MX1 
myxovirus (influenza virus) resistance 
1, interferon-inducible protein p78 
(mouse) ↑ ↑ 
 
RARRES3 
retinoic acid receptor responder 
(tazarotene induced) 3 ↑ ↑ 
 
IFITM1 
interferon induced transmembrane 
protein 1 (9-27) ↑ ↑ 
 
IFIH1 
interferon induced with helicase C 
domain 1 ↑ ↑ 
 
IL29 interleukin 29 (interferon, lambda 1) ↑ ↑ 
 
STAT1 
signal transducer and activator of 
transcription 1, 91kDa ↑ ↑ 
 
KLF4 Kruppel-like factor 4 (gut) ↑ ↑ 
 
SHISA5 shisa homolog 5 (Xenopus laevis) ↑ ↑ 
 
NFKBIA 
nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
inhibitor, alpha ↑ ↑ 
 
DRAM damage-regulated autophagy modulator ↑ ↑ 
 
NUPR1 nuclear protein 1 ↑ ↑ 
 
OAS1 
2',5'-oligoadenylate synthetase 1, 
40/46kDa ↑ ↑ 
 
TNFSF10 
tumor necrosis factor (ligand) 
superfamily, member 10 ↑ ↑ 
  
 CASP1 
caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, 
convertase) ↑ ↑ 
 
 







FCF1 small subunit (SSU) processome 










chromobox homolog 5 (HP1 alpha 
homolog, Drosophila) ↓ ↓ 
 
PRR11 proline rich 11 ↓ ↓ 
 
ATL3 atlastin 3 ↓ ↓ 
 
ODC1 ornithine decarboxylase 1 ↓ ↓ 
 
CTNNAL1 
catenin (cadherin-associated protein), 
alpha-like 1 ↓ ↓ 
 
IGF1R insulin-like growth factor 1 receptor ↓ ↓ 
 
COL12A1 collagen, type XII, alpha 1 ↓ ↓ 
 
PRKAR2A 
protein kinase, cAMP-dependent, 
regulatory, type II, alpha ↓ ↓ 
 
CDCA7L cell division cycle associated 7-like ↓ ↓ 
 
PLDN pallidin homolog (mouse) ↓ ↓ 
 
CEP55 centrosomal protein 55kDa ↓ ↓ 
 
ARHGAP19 Rho GTPase activating protein 19 ↓ ↓ 
 
UTRN Utrophin ↓ ↓ 
 
FANCD2 
Fanconi anemia, complementation 
group D2 ↓ ↓ 
 
HMMR 
hyaluronan-mediated motility receptor 
(RHAMM) ↓ ↓ 
 
SFXN2 sideroflexin 2 ↓ ↓ 
 
HIF1AN 
hypoxia-inducible factor 1, alpha 
subunit inhibitor ↓ ↓ 
 
ARHGAP11A Rho GTPase activating protein 11A ↓ ↓ 
 
SHCBP1 SHC SH2-domain binding protein 1 ↓ ↓ 
 
TTK TTK protein kinase ↓ ↓ 
 
SLC7A11 
solute carrier family 7, (cationic amino 
acid transporter, y+ system) member 11 ↓ ↓ 
 
GPC6 glypican 6 ↓ ↓ 
 
ADD3 adducin 3 (gamma) ↓ ↓ 































Figure 3.24. Quantitative RT-PCR agreement of the expression direction of the filtered 
genes with microarray results. Up-regulated genes revealed with positive values (A), 
while down-regulated genes illustrated with negative values (B).  Data was shown as 






























































































































































































































































3.18 Gene pathway analysis 
Extensive literature review performed to verify the function(s) of 50 selected genes. 
Then, the genes with relevant functions were further evaluated. Thus, out of 50 verified 
genes, a few of them found to be potentially involved in observed phonotypical changes 
(discussed in the first section of this chapter) after silencing HS6ST3 in the breast cancer. 
One of the most important of them was Insulin-like growth factor receptor I (IGF1R) 
gene which was down-regulated after silencing HS6ST3 in breast cancer. IGF1R is a 
transmembrane tyrosine kinase receptor comprising two extracellular alpha and two beta 
subunits which critically modulate several biological events such as growth and 
development. The other significant gene was XIAP-associated factor 1 (XAF1) which 
was considerably up-regulated in HS6ST3-knocked down T47D cells. XIAP-associated 
factor 1 or XAF1, a zinc finger protein, is known as a tumor suppressor that antagonizing 
XIAP, an antiapoptotic protein, and thus induce the cell death.  
 
Both IGF1R and XAF1 were identified as candidate genes that seemed to be potentially 
involved in cancer cell growth and progression. Therefore, in order to validate these 
findings we firstly rechecked the expression pattern of IGF1R and XAF1 genes in T47D 
and MCF7 cell lines. Then, western blotting was performed to examine IGF1R and 
XAF1 expression at the protein level after silencing HS6ST3 in T47D and MCF7. After 
that, various functional assays were performed on HS6ST3-knocked down cells after 
blocking IGF1R receptors or double silencing with XAF1 shRNA. All of the functional 
assays in latter step were performed on MCF7 cells because firstly, we found that 
blocking IGF1R receptor in MCF7 is much more effective than T47D cells by using our 
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available blocking antibody; and secondly the higher growth rate of MCF7 enabled us to 
pick a single colony for clone selection after transfecting MCF7 with XAF1 shRNA 
plasmid, while similar procedure was not feasible in T47D due to its lower growth rate 
compared to MCF7.  
 
3.19 Quantitative real time (RT-PCR) analysis of IGF1R expression after silencing 
HS6ST3 in T47D and MCF7  
Relative expression pattern of IGF1R gene was measured by performing RT-PCR at 72 
hours after silencing HS6ST3 in T47D and MCF7 cell lines in triplicate. Analysis 
revealed that IGF1R expression was significantly decreased by 47.6% and 38.4% in 









Figure 3.25. Effect of HS6ST3 silencing on relative mRNA expression of IGF1R gene in 
T47D (A) and MCF7 (B) cells (N=3). Data was shown as mean ± SE, * p <0.05, *** p 




















































3.20 Western blotting analysis of IGF1R expression in HS6ST3-knocked down cells  
The expression of IGF1R was measured at protein level at 72 hours after silencing 
HS6ST3 in T47D and MCF7 by western blotting. The expression values were normalized 
with the expression of β-actin, housekeeping protein in western blotting. As shown in 
Figure 3.26, the expression of IGF1R had a significant reduction by 46.9% at 72 hours 


































Figure 3.26. Western blotting (WB) analysis of IGF1R protein expression at 72 hours 
after silencing HS6ST3 gene in T47D (A) and MCF7 (C) cell lines. Silencing HS6ST3 
gene significantly reduced the IGF1R protein expression by 46.9% and 68% in T47D (B) 
and MCF7 (D) respectively (N=3). Data was shown as mean ± SE, ** p <0.01, *** p 





































3.21 Analysis of the effect of IGF1R receptor blocking on cell proliferation  
Insulin-like growth factor I receptor (IGF1R) is a transmembrane tyrosine kinase receptor 
that critically modulate several biological events such as growth and promotion of 
malignant cells. It is understood that restoration of IGF1R expression increases the 
malignant cell proliferation, migration and invasion; while it reduces the  apoptosis (Tang 
et al. 2007; Cullen et al. 1990; Werner and Le Roith 1997; Burtscher and Christofori 
1999;  Yanochko and Eckhart 2006; Carboni et al. 2005; Dunn et al. 1998; Sachdev et al. 
2004; Samani et al. 2004; Sachdev et al. 2010; Zhang et al. 2010; Kang et al. 2010; 
Linnerth et al. 2009; Avnet et al. 2009; Párrizas, Saltiel and LeRoith 1997; Guvakova and 
Surmacz 1999) . 
 
Non-transfected T47D and MCF7 cells were washed and incubated in FBS-free medium 
in 5% CO2, 37ºC for 1 hour. Serial recommended concentration of IGF1R antibody was 
used to find the dose at which 50% of the cell survived. Following the incubation, FBS 
was added at a final concentration of 10% in culture medium and incubated in 5% CO2, 
37ºC for 72 hours. Finally, cell proliferation assay was performed by adding MTS 
solution and then the absorbances were measured at 490 nm. Figure 3.27 revealed the 




















Figure 3.27. Effect of IGF1R blocking antibody on the relative percentage of live T47D 
(A) and MCF7 (B). Various recommended concentration (0, 0.001, 0.01, 1 and 10 µg/ml) 
of IGF1R blocking antibody were used on T47D cells; however, a maximum 
recommended dose of 10 µg/ml was much more effective in MCF7 compared to T47D 
cells (N=3). Data was shown as mean ± SE, * p <0.05, ** p <0.01, ***p<0.001, T test. 
 
3.22 Analysis of the effect of blocking IGF1R receptor on the relative percentage of 
live HS6ST3-knocked down MCF7 cells 
MCF7 cells were transfected for silencing HS6ST3. At 10 hours post-transfection, the 
IGF1R receptors on the cell surface were blocked with 10 µg/ml of blocking antibody in 
a serum-free culture medium. Next, serum (FBS) was added at a final concentration of 
10% and then the cells were incubated in 5% CO2, 37ºC for 72 hour. Then, the relative 
percentage of the live cells was measured by using MTS method. There was no 
significant difference in the relative percentage of live HS6ST3-silenced group which 
were blocked for IGF1R receptor, while non-silenced group revealed reduction in their 
relative percentage of live cells by 37.8% after blocking IGF1R receptor (Figure 3.28). 
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The observed difference might be due to the lower expression of IGF1R receptor after 








Figure 3.28. Effect of IGF1R blocking antibody on the relative percentage of the live 
HS6ST3-knocked down MCF7. While IGF1R blocking antibody had no influence on 
relative percentage of live silenced cells, it reduced the relative percentage of live cells in 
negative siRNA-transfected MCF7 cells by 37.8% (N=3). Data was shown as mean ± SE, 
***p<0.001, T test. 
 
 3.23 Analysis of adhesion assay after blocking IGF1R receptor in HS6ST3-silenced 
MCF7 
MCF7 cells were transfected for silencing HS6ST3. At 10 hours post-transfection, the 
IGF1R receptors on the cell surface were blocked with 10 µg/ml of blocking antibody in 
a serum-free culture medium. Next, serum (FBS) was added at a final concentration of 
10% and then the cells were incubated in 5% CO2, 37ºC for 72 hour. Adhesion assay was 
performed in 96-well plate coated with collagen I (discussed in previous chapter). 
Interestingly, adhesion of both silenced and control group were increased at 72 hours 
after silencing HS6ST3 and blocking IGF1R receptor in MCF7; however, statistically no 
significant difference was observed between silenced and control group (Figure 3.29). 
























































Figure 3.29. Effect of IGF1R blocking antibody on adhesion of HS6ST3-knocked down 
MCF7. IGF1R blocking antibody increased the cell adhesion at 72 hours after blocking 
IGF1R in MCF7 for both control and silenced groups. However, no statistical difference 
was observed between silenced and control groups (N=3). The control group was 
transfected with negative control siRNA and treated with IGF1R antibody. Each group of 
the control or silenced group was normalized to its corresponding un-washed cells 
during the adhesion assay. Data was shown as mean ± SE, T test. 
 
 
3.24 Analysis of migration and invasion assays after blocking IGF1R receptor in 
HS6ST3-silenced MCF7 
MCF7 cells were transfected for silencing HS6ST3. At 10 hours post-transfection, the 
IGF1R receptors on the cell surface were blocked with 10 µg/ml of blocking antibody in 
a serum-free culture medium. Next, serum (FBS) was added at a final concentration of 
10% and then the cells were incubated in 5% CO2, 37ºC. At 48 hours post transfection, a 
total number of 5x 104 MCF7 cells were seeded in migration and invasion chambers and 
incubated in 5% CO2, 37ºC for 24 hours. During all stages of migration and invasion 






















culturing medium. Both migration (Figure 3.30 A, B) and invasion (Figure 2.31 A, B) 
were evidently decreased in control and silenced groups compared to non-IGF1R blocked 
cells. However, no significant differences were found between silenced and control group 
in both migration (Figure 3.30 C) and invasion (Figure 3.31 C) assays. This observation 




Figure 3.30. Effect of IGF1R blocking antibody on migration of HS6ST3-knocked down 
MCF7 cells (N=3). The control group was transfected with negative control siRNA and 
treated with IGF1R antibody. Data was shown as mean ± SE, T test. 
 
 
Figure 3.31. Effect of IGF1R blocking antibody on invasion of HS6ST3-knocked down 
MCF7 cells (N=3). The control group was transfected with negative control siRNA and 















































3.25 Quantitative real time (RT-PCR) analysis of XAF1 expression after silencing 
HS6ST3 in T47D and MCF7  
Relative expression pattern of XAF1 gene was measured by performing RT-PCR at 72 
hours after silencing HS6ST3 in T47D and MCF7 cell lines in triplicate. Analysis 
revealed that XAF1 was significantly over-expressed by 253 and 3472 times in HS6ST3-









Figure 3.32. Effect of HS6ST3 silencing on relative mRNA expression of XAF1 gene in 
T47D (A) and MCF7 (B) cells (N=3). Data was shown as mean ± SE, * p <0.05, ** p 
<0.01, T test. 
 
3.26 Western blotting analysis of XAF1 expression in HS6ST3-knocked down cells  
The expression of XAF1 was measured at protein level at 72 hours after silencing 
HS6ST3 in T47D and MCF7 by western blotting. The expression values were normalized 
with the expression of β-actin, housekeeping protein in western blotting. At 72 hours 
after silencing HS6ST3 gene, the expression of XAF1 significantly increased by 102% 








































































Figure 3.33. Western blotting (WB) analysis of XAF1 protein expression at 72 hours 
after silencing HS6ST3 gene in T47D (A) and MCF7 (C) cell lines. Silencing HS6ST3 
gene significantly up-regulated XAF1 protein expression in T47D (B) and MCF7 (D) 









































3.27 Quantitative real time (RT-PCR) analysis of XAF1 expression after silencing in 
MCF7  
XIAP-associated factor 1 or XAF1, a zinc finger protein, is known as a tumor suppressor 
that antagonizes XIAP, an antiapoptotic protein, and thus induce the cell death. XAF1 
could be detected ubiquitously in many tissues; however, its expression is suppressed in 
vitro and in vivo in several cancers such as gastric cancer, skin cancer, colorectal cancer, 
prostate cancer, blood cancer, kidney cancer, bladder cancer, liver cancer and testicular 
cancer (Sakemi et al. 2007; Ng et al. 2004; Byun et al. 2003; Ma et al. 2005; Chen et al. 
2006; Lee et al. 2006; Gao et al. 2006; Zou et al. 2006; Shibata et al. 2007; Yu et al. 
2007; Chung et al. 2007; Li et al. 2007; Kempkensteffen et al. 2007; Li et al. 2008; 
Kempkensteffen et al. 2008; Pinho et al. 2009; Huang et al. 2010). Researchers 
understood that loss of XAF1 expression was associated with poor prognosis in several 
malignancies (Chen et al. 2006; Huang et al. 2010). On the other hand, over-expression 
of XAF1 could redistribute the cytosolic XIAP into nucleus and therefore trigger the 
apoptosis pathway and induce cell cycle arrest at specific check points (Liston et al. 
2001; Wang et al. 2009). 
 
XAF1 was silenced in MCF7 using shRNA plasmid. Thus, the mRNA of transfected cells 
was extracted and then quantitative real time PCR (RT-PCR) was performed to compare 
the silencing efficiency. Analysis of RT-PCR data showed that XAF1 was silenced in 













Figure 3.34. Silencing efficiency of XAF1 genes in MCF7 cell line using shRNA (N=3). 
The percentages were calculated based on the relative quantitation in RT-PCR. Negative 
control group was transfected with negative shRNA. Data was shown as mean ± SE, ** p 




3.28 Western blotting analysis of XAF1 expression after silencing XAF1 in MCF7  
The expression of XAF1 was measured at protein level in XAF1-knocked down MCF7 by 
western blotting. The expression values were normalized with the expression of β-actin, 
housekeeping protein in western blotting. Analysis revealed that the expression of XAF1 
protein significantly diminished by 56.6% in MCF7 after silencing XAF1 by shRNA 

































Figure 3.35.Western blotting (WB) analysis of XAF1 protein expression hours after 
silencing XAF gene in MCF7 cell lines. Silencing XAF1 gene significantly reduced XAF1 
protein expression in MCF7 (N=3) Negative control group was transfected with negative 
control shRNA. Data was shown as mean ± SE, * p <0.05, T test. 
 
 
3.29 Analysis of proliferation assays after silencing XAF1 in MCF7 
This assay was performed to evaluate of the effect of silencing of XAF1 gene on MCF7 
proliferation. Thus, a total number of 1X 104 of XAF1-silenced MCF7 and negative 
shRNA transfected cells were seeded in 96 well plate. Proliferation assay was performed 
at 72 hours after seeding MCF7cells, by using MTS method. The proliferation of XAF1-




















(Figure 3.36). The result of this assay could be indicative of an inhibitory role of XAF1 







Figure 3.36. Effect of silencing XAF1 on proliferation of MCF7. Negative control group 
was transfected with negative control shRNA. In the other group cells were silenced with 
XAF1 shRNA (N=5). Data was shown as mean ± SE, * p <0.05, T test. 
 
3.30 Analysis of proliferation assays after silencing HS6ST3 in XAF1-knocked down 
MCF7 
This assay was performed for evaluating the effect of silencing HS6ST3 gene on the 
proliferation of XAF1-silenced MCF7. For this purpose, a total number of 2 X 105 of 
XAF1-silenced MCF7 and negative shRNA transfected cells were seeded in two 6-well 
plates separately. HS6ST3 was silenced in both groups by using HS6ST3 siRNA. 
Negative control groups were transfected with negative control siRNA. At 72 hours post-
transfection, proliferation assay was performed by using MTS method. Analysis of the 
data showed that silencing HS6ST3 in XAF1-silencved MCF7 severely reduced the 
relative percentage of the live cells by 78% ( Figure 3.37: B), while silencing HS6ST3 in 
negative control shRNA-transfected cells reduced the relative percentage of the live cells 


























(Figure 3.37: A). The result of this experiment was contradictory to the results of 
previous observation; however, the reduction in the relative percentage of the live cells 










Figure 3.37. Effect of double silencing XAF1 and HS6ST3 on proliferation of MCF7 
cells. A) Negative shRNA-transfected MCF7 cells were transfected by negative control 
siRNA (Negative) or HS6ST3 siRNA (Silenced) (N=3). B) XAF1-silenced MCF7 cells 
were transfected by negative control siRNA (Negative) or HS6ST3 siRNA (Silenced) 
(N=3).   Data was shown as mean ± SE, ** p <0.01, T test. 
 
3.31 Analysis of adhesion assays after silencing HS6ST3 in XAF1-knocked down 
MCF7 
Adhesion assay was performed to investigate the potential effect of XAF1 for changing 
the adhesion capacity of tumor cells into extracellular matrix (ECM) in HS6ST3-knocked 
down MCF7. This assay was performed at 72 hours after silencing HS6ST3 in XAF1-
silenced MCF7 cells. In this experiment collagen I and fibronectin were used to coat the 
wells before seeding breast cancer cells. Analysis of the data revealed that double 





















































and fibronectin (B) and thus no significant differences were observed between control 










Figure 3.38. Effect of double silencing XAF1 and HS6ST3 on adhesion of MCF7. SS: 
Single silenced for XAF1, Negative controls were just silenced for XAF1. DS: Double 
silenced for XAF1 and HS6ST3. Each group of the control or silenced group was 
normalized to its corresponding un-washed cells during the adhesion assay (N=6). Data 
was shown as mean ± SE, T test. 
 
3.32 Analysis of migration assays after silencing HS6ST3 in XAF1-knocked down 
MCF7 
Migration assay was performed for evaluating the effect of double silencing XAF1 and 
HS6ST3 on migration capacity of MCF7 cells compared to the cells silenced just for 
HS6ST3 in negative shRNA-transfected MCF7. Thus, XAF1-silenced MCF7 and also 
negative control shRNA-transfected cells were silenced for HS6ST3. At 48 hours after 
silencing HST6ST3, the cells were re-seeded into migration chambers and allowed to 
migrate for 24 hours (discussed in previous chapter). As shown in figure 3.39, double 












































silencing XAF1 and HS6ST3 interestingly increased the migratory capacity of MCF7 cells 









Figure 3.39. Effect of double silencing XAF1 and HS6ST3 on migration of MCF7. SS: 
Single silenced for HS6ST3, DS: Double silenced for XAF1 and HS6ST3. Double 
silencing MCF7 cells considerably increased the migration of MCF7 cells through 
migration inserts (N=3).   Data was shown as mean ± SE, *** p <0.001, T test. 
 
3.33 Analysis of invasion assays after silencing HS6ST3 in XAF1-knocked down 
MCF7 
Migration assay was performed to assess the effect of double silencing XAF1 and 
HS6ST3 on migration capacity of MCF7 cells compared to the cells silenced just for 
























HS6ST3 in negative shRNA-transfected MCF7. Thus, XAF1-silenced MCF7 and also 
negative control shRNA-transfected cells were silenced for HS6ST3. At 48 hours after 
silencing HST6ST3, the cells were re-seeded into invasion chambers and allowed to 
migrate for 24 hours (discussed in previous chapter). Similar to migration assay, silencing 
XAF1 and HS6ST3 significantly enhanced the cellular invasiveness by 90% compared to 









Figure 3.40. Effect of double silencing XAF1 and HS6ST3 on invasiveness of MCF7. SS: 
Single silenced for HS6ST3, DS: Double silenced for XAF1 and HA6ST3. Double 
silencing XAF1 and HS6ST3 transformed the MCF7 nature to a highly invasive cells 
(N=3).   Data was shown as mean ± SE, * p <0.05, T test. 

























Section 3: Analysis of the effect of silencing HS6ST3 on sensitivity of 
T47D breast cancer cell line to Cisplatin and 5-fluorouracil 
 
3.34 Measurement of LD50 concentration of cisplatin and 5-Flurouracil (5-fu) 
To find LD50, a total number of 7x 103 T47D cells were seeded in each well of 96 well 
plate. 24 hours after seeding, the cells were treated with 0, 5, 10, 15, 20, 25, 30, 35 µg/ml 
of Cisplatin and 0, 2.5,20,40,60, 80, 100 µg/ml of 5-flurouracil (5-fu). Later, the cells 
were inculcated in 5% CO2, 37ºC for 48 hours. Then, relative percentage of live cells was 
measured by using MTS method. The absorbances measured in MTS assay were then 
normalized with blank and then the cytotoxic effects of Cisplatin and 5-fu was measured 
in Microsoft excel and finally dose-response curves were plotted by non-linear regression 
method in GraphPad Prism 5.00 software to find the LD50. Non-linear model is generally 
used for the response of specific drugs such as antimetabolites which influence the cell 
cycle phases and finally lead to a plateau for their cytotoxicity effect that means the 
greater doses does not result in more cell death. Using non-linear regression analysis, we 
found high coefficients of correlation that showed strong negative relationships between 
doses versus cell survival (R2 > 0.9). LD50 of 28 ug/ml and 13 ug/ml were determined 





Figure 3.41.Logarithmic curves illustrating LD50 of 5-Flurouracil (A) and Cisplatin (B) 
in dose-response model by using non-linear regression method (N=6). 
 
3.35 Analysis of Cisplatin and 5-fu cytotoxicity assay after silencing HS6ST3 in 
T47D 
T47D cells were silenced by two sequence of HS6ST3 Ambion siRNA. At 12 hours post-
transfection, a total number of 7x 103 of control and silenced T47D cells were seeded 
each in two rows inside 96 well plates. At 24 hours post-transfection, one row of the 
silenced and one row of control cells were treated with 13 µg/ml of Cisplatin (LD50 for 
Cisplatin) or 28 µg/ml of 5-fu (LD50 for 5-fu). The plates were incubated in 5% CO2, 
37ºC for 48 hours. After 72 hours post-transfection, relative percentage of the live cells 
was measured using MTS method. Cell cytotoxicity of Cisplatin and 5-fu was measurd 
by substracting of the relative percentage of the live cells in drug-treated cells from non 
drug-treated cells in each of the silenced or control groups. Analysis of the results 
showed that silencing HS6ST3 in T47D sensitized the cancer cells to the cytotoxic effect 
of Cisplatin and 5-fu. Thus, HS6ST3-knocked down T47D cells were killed by 9.05-
11.75% more than control after treating with 13 µg/ml of Cisplatin (Figure 3.42). 
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Similarly, HS6ST3-knocked down T47D cells were killed by 18.31-23.2% more than 










Figure 3.42. The cytotoxic effect of Cisplatin after silencing HS6ST3 in T47D. The values 
of treated groups with Cisplatin were normalized with the values in non-treated control 










Figure 3.43. The cytotoxic effect of 5-fu after silencing HS6ST3 in T47D. The values of 
treated groups with Cisplatin were normalized with the values in non-treated control or 



















































































3.36 Analysis of Cisplatin and 5-fu cytotoxicity assay after silencing HS6ST3 in 
MCF-12A 
MCF12-A, normal epithelial cell line was silenced by two sequences of Ambion HS6ST3 
siRNA. At 10 hours post-transfection, a total number of 7x 103 of control and silenced 
MCF-12A cells were seeded each in two rows inside 96 well plates (N=9). At 24 hours 
post-transfection, one row of the silenced and one row of control cells were treated with 
13 µg/ml of Cisplatin (LD50 for Cisplatin) or 28 µg/ml of 5-fu (LD50 for 5-fu). The 
plates were incubated in 5% CO2, 37ºC for 48 hours. After 72 hours post-transfection, the 
relative percentage of the live cells was measured using MTS method. Unlike T47D, 
analysis of the results showed that silencing HS6ST3 in MCF12-A did not statistically 
change the sensitivity of the cells to Cisplatin (Figure 3.44). It was also found that 
silencing HS6ST3 in MCF-12A did not sensitized the normal epithelial cells to 5-fu 








Figure 3.44. The cytotoxic effect of Cisplatin on HS6ST3-silenced MCF-12A. The values 
of treated groups with Cisplatin were normalized with the values in non-treated control 





















































Figure 3.45. The cytotoxic effect of 5-fu on HS6ST3-silenced MCF-12A. The values of 
treated groups with Cisplatin were normalized with the values in non-treated control or 
silenced groups (N=6). Silencing HS6ST3 in MCF-12A by first sequence siRNA made the 
cells more resistant to 5-fu by 13% compared to control. Data was shown as mean ± SE, 
**p<0.01, T test. 
 
3.37 p63/ p73-mediated cytotoxicity 
Activation of BCL2 superfamily might be mediated by p63/ p73 network in response to 
cisplatin treatment .TAp63 promote the survival of the breast cancer cells, while TAp73 
induce apoptosis by activating BCL2 superfamily (Carroll et al. 2006). However, TAp73 
and TAp63 may co-express in the cancer cells and then bind to each other. Dissociation 
of these proteins is a determining factor that could regulate the relative percentage of the 
live cells (Leong et al. 2007). Imatinib is a drug that inhibits the dissociation of TAp63 
from TAp73. In order to find if the sensitization of T47D cells to Cisplatin after silencing 
HS6ST3 is mediated by p63/ p73 network, imatinib was used to inhibit the dissociation of 











































3.38 Analysis of Imatinib cell cytotoxicity on T47D cell line 
To remove the cytotoxic effect of Imatinib as a confounding factor, a maximum non-
toxic dose of Imatinib was measured on T47D. For this purpose, a total number of 7x 103 
T47D cells were seeded in each well of 96 well plate. 24 hours after seeding, the cells 
were treated with 0, 1, 2, 3, 4, 5, 6 µM of Imatinib. The cells were inculcated in 5% CO2, 
37ºC for 48 hours. Then, the relative percentage of the live cells was measured by using 
MTS method. The absorbances were normalized with blank and then the cytotoxic effects 
of Imatinib was measured in Microsoft excel to find the maximum ineffective dose of 
Imatinib on cell growth in T47D cell line. The result of this experiment showed that the 
maximum dose of 1 µM was non-toxic to the live cells (Figure 3.46). Thus, this dose was 
used for next cytotoxicity assay during treating HS6ST3- silenced T47D cells with 










Figure 3.46. The cytotoxic effect of Imatinib on T47D cell line. T47D cells were treated 
by serial concentration of Imatinib in 96-well plate. The absorbance values of treated 
cells were normalized with non-treated T47D cells (N=5). Data was shown as mean ± 
SE, *p<0.05, **p<0.01, T test. 
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3.39 Analysis of Imatinib effect on cisplatin sensitivity pathway in HS6ST3-silenced 
T47D cells 
T47D cells were silenced by two sequence of HS6ST3 Ambion siRNA. At 12 hours post-
transfection, a total number of 7x 103 of control and silenced T47D cells were seeded 
each in four rows inside 96 well plates. At 24 hours post-transfection, one row of the 
silenced and/ or control cells were treated with 13 µg/ml of Cisplatin. The second row 
was treated with 1mM Imatinib. The third row was treated with 13 µg/ml Imatinib and 
1mM Imatinib. The final row was left un-treated. The plates were incubated in 5% CO2, 
37ºC for 48 hours. After 72 hours post-transfection, cell relative percentage of the live 
cells was measured using MTS method. Analysis of this assay showed that Imatinib 
reduced the cytotoxic effect of Cisplatin on non-silenced T47D by 11-17% (Figure 3.47: 
A, C), while Imatinib had no significant effect on the cytotoxicity of Cisplatin in 
HS6ST3-silenced T47D (Figure 3.47: B, D). These observations were indicative of the 
influence of down regulation of HS6ST3 on the Imatinib pathway. On the other hand, 
reviwing our microarray data revealed that Tap73 was significantly up-regulated by 58% 
(p<0.01) after silencing HS6ST3 in breast cancer, while no significant change occoured in 
the expression of Tap63. Thus, it could be postulated that silencing HS6ST3 could 






























Figure 3.47. The cytotoxic effect of Cisplatin and Imatinib on HS6ST3-silenced T47D. 
Two sequences of siRNA were used to silence HS6ST3 in T47D. Figure A, C) T47D was 
transfected with negative control siRNA. Figure B) T47D was silenced using first 
sequence of siRNA. Figure D) T47D was silenced using second sequence of siRNA. The 
absorbance values of treated cells were normalized with non-treated T47D cells (N=5).  
Data was shown as mean ± SE, *p<0.05, T test. 
 
Section 4: Immunohistochemical analysis of human HS6ST3 expression 
in human clinical breast cancer sections of ductal carcinoma 
 
3.40 Clinicopathological features of breast cancer sections  
In this cohort study, immunohistostaining was performed on a total of 258 paraffin 
embedded tissue microarray cases (TMA) of archival blocks of diagnosed cases of breast 
adenocarcinoma which were collected in the Department of Pathology of Singapore 






























































































General Hospital, between 1998 and 2004. In addition to the study population, 43 
sections were collected from non cancerous (normal) breast biopsies. Clinicopathological 
features of cases including race, age, tumor side, tumor size, histotype, histograde, lymph 
node status, associated ductal carcinoma in situ (DCIS) nuclear grade, associated DCIS 
nuclear grade extent as well as immunohistochemical markers such as estrogen receptor, 
progesterone receptor and HER2 were collected. Other information such as diagnosis 
date, recurrence date and also date of death were retrieved from patient’s records. The 
study follow up was set up from January 1998 to the end of June 2009. This study was 
ethically approved by Institutional Review Board, Singapore General hospital. 
 
In this study, most of the breast cancer specimens were from Chinese. In addition, 
majority of the cancer sections were diagnosed as ductal adenocarcinoma. The age of the 
breast cancer patients ranged from 23 to 88, with a mean age of 57.52. Tumor size was 
distributed from 1mm to 140mm among cases with median of 30mm. Details of 
clinicopathological features of all cases are summarized in Table 3.6. It must be 
mentioned that nearly all of the specimens were collected prior to any therapy. Thus, the 













Table 3.6. Clinicopathological features of 258 cases of breast cancer. Data represented 
the number and percentage of cases. 
 
 
Clinicopathological features Clinicopathological features 





Involved Lymph nodes 
(LN)   
≤ Mean age (57.5) 147 57 LN = 0 118 45.7 
> Mean age (57.5) 111 43.0 ≥1 LN 4 < 64 24.8 
Race 
  
≥ 4 61 23.6 
Chinese   214 82.9 Unavailable 15 5.8 
Malay     21 8.1 Associated nuclear grade of DCIS   
Indians      7 2.7 None 110 42.6 
Others        16 6.2 Low 9 3.5 
Laterality 
  
Intermediate 56 21.7 
Right 121 46.9 High 81 31.4 
Left 137 53.1 Unavailable 2 .8 
Unavailable 0 0 DCIS nuclear grade  extent   
Tumor size (TS) 
  
 None 28 10.9 
TS ≤ 20 64 24.8 Minimal 61 23.6 
> 20  186 72.1 Extensive 25 9.7 





IDC 231 89.5 Negative 96 37.2 
Non-IDC 6 2.3 Positive 158 61.2 





1 23 8.9 Negative 116 45.0 
2 97 37.6 Positive 138 53.5 
3 129 50.0 Unavailable 4 1.6 
Unavailable 9 3.5 HER2 expression   
    
Negative 169 65.5 
    Positive 81 31.4     Unavailable 8 3.1 
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3.41 Expression of HS6ST3 in normal and cancerous human breast tissue 
In benign human breast tissues, HS6ST3 expresses itself both in the cytoplasm of 
epithelial cells as well as extracellular compartments including stroma matrix and stromal 
cells (Figure 3.49: A). In invasive ductal adenocarcinoma, HS6ST3 seemed to be 
differentially expressed in epithelial and stromal components of human ductal 
adenocarcinoma (Figure 3.48). Although HS6ST3 basically expressed in cytoplasm of 
epithelial cells, the cytoplasmic expression of HS6ST3 positively correlates with its 
stromal existence (p< 0.01). 
 
Figure 3.48. Immunohistochemical staining of HS6ST3 in tissue microarray sections of 
breast cancer. (A) 0 or negative epithelial staining (B) +1 or weak staining (C) +2 or 
moderate staining (D) +3 or strong staining.  
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3.42 Immunohistochemical expression of HS6ST3 in epithelial and stromal 
components of breast ductal adenocarcinoma 
HS6ST3 expresses itself both in the cytoplasm of epithelial cells as well as extracellular 
compartments including stroma matrix and stromal cells of normal and breast cancer 
cells. Analysis revealed that the mean staining intensity of stroma matrix of normal 
tissues (42.209 ± 3.290) were discriminatively higher than cancer sections (15.969 ± 
1.338) (Figure 3.49); however, no significant difference was found for the similar 
comparison in epithelial and stromal cell components (Table 3.7). 
 
Table 3.7. Immunoreactivity scoring (IRS) among all tissue sections, T test.  














Normal  44.651 5.602 33.627 55.675 
0.853 
Cancer 45.775 2.287 41.275 50.276 
Stroma 
matrix 
Normal  42.209 3.290 35.735 48.683 
0.000* 
Cancer 15.969 1.338 13.336 18.602 
Stromal 
cells 
Normal  42.791 4.275 34.379 51.203 
0.433 








Figure 3.49. A) Normal breast tissue. B) IDC grade I C) IDC grade II D) IDC grade III. 
Arrows indicating the expression of HS6ST3 which was significantly reduced in stroma 












3.43 Association analysis of HS6ST3 immunoreactivity with clinicopathological 
parameters 
The staining intensity of different tissue compartments were compared with 
clinicopathological features. Data shown in Table 3.8, 3.9, and 3.10 represented 
associations between the expression of HS6ST3 and clinicopathological parameters of 
breast cancer patients such as age, tumor size, histograde, histotype, lymph node status, 
estrogen receptor and progesterone receptor. The results suggested that patients whose 
ages were above the mean of age expressed more HS6ST3 in their epithelial cell and 
stromal cells, while no associations were found in stroma matrix. In addition, tumors 
smaller than 20mm showed to have higher staining intensities in their stroma matrix. 
Furthermore, histograde 2 had a significantly higher staining intensity compared to 
histograde 1 and 3 in stroma matrix (Table 3.8). Invasive ductal carcinoma (IDC) 
exhibited more HS6ST3 in their stromal cells compared to DCIS. Tumor which 
metastasized to more than three lymph nodes had also a higher staining intensity in their 
stroma matrix. Interestingly, HS6ST3 expressed more in stroma matrix compartments of 
breast cancer specimens which were positive for estrogen and progesterone receptors. 
There was no significant association between the expression of HS6ST3 and tumor side, 










Table 3.8. Correlations between expression of HS6ST3 using IRS cut off 25 and 
clinicopathological features of breast cancer, Fisher’s exact test. 
 
Clinicopathological 
parameter      
IRS     
Epithelial cells P value 
    IRS    
Stroma matrix P value 
    IRS    
Stromal cell P value 
    ≤25 >25   ≤25 >25   ≤25 >25   
Age 






> mean (57.5) 43 68 86 25 21 90 
Race 






Others 20 24 35 9 12 32 
Laterality 






Left 62 75 109 28 39 98 
Tumor size 






> 20mm 82 104 155 31 47 139 
Histograde 





0.173 Grade 2 40 57 70 27 21 76 
Grade 3 56 73 110 19 40 89 
Histotype 






DCIS 1 5 4 2 3 3 
Lymph node 
involvement 






> 3 nodes 23 38 45 16 11 50 
Associated nuclear 
grade of DCIS 






Low 6 3 8 1 2 7 
Intermediate 23 33 48 8 16 40 
High 32 49 62 19 26 55 
DCIS nuclear 
grade extent 





0.846 Minimal 25 36 52 9 18 43 
Extensive 6 19 18 7 8 17 
Estrogen receptor 






Positive 70 88 118 40 40 118 
Progesterone 
receptor 






Positive 56 82 103 35 34 104 
HER2 


















Table 3.9. Correlations between expression of HS6ST3 using IRS cut off 45 and 









parameter      
    IRS  
Epithelial cells P value 
    IRS    
Stroma matrix P value 




    ≤45 >45   ≤45 >45   ≤45 >45   
Age 






> mean (57.5) 51 60 100 11 46 65 
Race 






Others 25 19 40 4 22 22 
Laterality 






Left 72 65 124 13 70 67 
Tumor size 






> 20mm 103 83 173 13 87 99 
Histograde 





0.143 Grade 2 52 45 87 10 47 50 
Grade 3 68 61 121 8 68 61 
Histotype 






DCIS 4 2 6 0 6 0 
Lymph node 
involvement 






> 3 nodes 33 28 52 9 25 36 
Associated nuclear 
grade of DCIS 






Low 7 2 9 0 6 3 
Intermediate 30 26 54 2 26 30 
High 40 41 72 9 43 38 
DCIS nuclear 
grade extent 





0.681 Minimal 32 29 58 3 36 25 
Extensive 9 16 20 5 13 12 
Estrogen receptor 






Positive 94 64 142 16 75 83 
Progesterone 
receptor 






Positive 76 62 122 16 66 72 
HER2 










Table 3.10. Correlations between expression of HS6ST3 using WAI cut off 1 and 







parameter      
         WAI  
Epithelial cells P value 
          WAI   
Stroma matrix P value 
          WAI  
Stromal cell P value 
    ≤1 >1   ≤1 >1   ≤1 >1   
Age 






> mean (57.5) 11 100 108 3 109 2 
Race 






Others 1 43 44 0 44 0 
Laterality 






Left 13 124 134 3 136 1 
Tumor size 






> 20mm 15 171 183 3 184 2 
Histograde 





0.882 Grade 2 2 95 95 2 96 1 
Grade 3 12 117 127 2 128 1 
Histotype 






DCIS 1 5 6 0 6 0 
Lymph node 
involvement 






> 3 nodes 4 57 59 2 60 1 
Associated nuclear 
grade of DCIS 






Low 2 7 9 0 9 0 
Intermediate 3 53 56 0 56 0 
High 4 77 78 3 79 2 
DCIS nuclear grade 
extent 





0.413 Minimal 4 57 60 1 59 2 
Extensive 2 23 23 2 25 0 
Estrogen receptor 






Positive 9 149 156 2 158 0 
Progestrone receptor 






Positive 7 131 137 1 138 0 
HER2 






Positive 5 76 79 2 80 1 
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3.44 Survival analysis of HS6ST3 expression in breast ductal carcinoma 
Kaplan-Meier survival analysis was primarily performed in all of the possible strata of 
the histopathological parameters. Then, Univariate Cox regression proportional analysis 
was performed on strata which were detected as a significant factor (p< 0.05) for 
predicting the prognosis by Kaplan-Meier survival analysis. Disease free survival (DFS) 
and overall survival (OS) were defined as the length of time from date of diagnosis to 
recurrence or death respectively. The length of time between the dates of recurrence to 
death was also defined as survival after recurrence (SAR). Univariate Cox regression 
proportional analysis showed that staining intensity of tissue compartments is predictive 
of OS, DFS and SAR. The prognostic factors associated with the expression of HS6ST3 
are summarized in Table 3.11. The survival analysis revealed that age, tumor size, 
histograde, progesterone and HER2 are predictive of the breast cancer prognosis. Thus, 
the OS of breast cancer cases whose ages were younger than 57.5 were significantly 
higher than those who developed breast cancer after 57.5. In addition, bigger tumors (> 
34.1mm) were associated with poorer OS, DFS and SAR. As expected, higher histograde 
was associated with worse DFS, while lymph node metastasis could not significantly 
predict the prognosis. Unlike lymph node status, histograde was able to predict DFS; 
however, none of them was predictive of OS, while HS6ST3 expression was interestingly 
predictive of OS, DFS and SAR. In the other words, higher expression of HS6ST3 in 
stroma matrix of breast cancer predicted a worse prognosis for OS and DFS. Similarly, 
higher HS6ST3 expression in stroma matrix of breast cancer patients with tumor size 
bigger than 20mm or involvement of more than 3 lymph nodes or progesterone negativity 
was predictive of a shorter DFS. In contrast, higher expression of HS6ST3 of the stromal 
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cells predicted a longer survival for patients with less than 4 lymph node involvement or 
intermediate nuclear grade. Furthermore, higher expression of HS6ST3 in stromal cells of 
breast cancers in histograde 1 and histograde 2 predicted a better outcome in terms of 
their DFS, while it was predictive of worse SAR in breast cancer cases with positive 
HER2. The trends of survivals are shown in Figure 3.50 using Kaplan-Meier survival 
analysis.   
 
Using a multivariate survival analysis interestingly revealed that the IRS and WAI of 
stroma matrix could independently be predictive of OS and DFS. In addition, it was 
shown that IRS of stromal cell compartment could independently predict the DFS of the 
breast cancer patients; however, none of the IRS or WAI was found predictive of SAR 













Table 3.11. Univariate Cox regression analysis for prognostic clinicopathological factors in 
breast  cancer. 
  
Overall survival Disease-free survival Survival after recurrence 
HR      95% CI p Value HR      95% CI 
p 
Value HR      95% CI 
p 
Value 
Age                                                           
≤Mean (57.5) vs > Mean (57.5) 1.949 1.071-3.547 0.029* 1.406 0.876-2.255 0.158 1.798 0.990-3.266 0.054 
Tumor size (Mean)                                         
≤ 34.1mm vs > 34.1mm 2.746 1.450-5.200 0.002* 2.039 1.261-3.298 0.004* 2.185 1.152-4.146 0.017* 
Histograde 1.654 0.989-2.767 0.055 1.577 1.068-20328 0.022* 1.242 0.744-2.072 0.408 
Lymph node status (metastasis) 
≤ 3 nodes vs >3 nodes 1.199 0.832-1.727 0.33 1.212 0.908-1.617 0.192 1.069 0.737-1.551 0.724 
Estrogen receptor                                         
Neg vs Pos 1.134 0.588-2.185 0.708 0.883 0.536-1.455 0.625 1.488 0.772-2.869 0.235 
Progesterone receptor                                 
Neg vs Pos 0.529 0.283-0.989 0.046* 0.584 0.360-0.945 0.029* 0.643 0.341-1.210 0.171 
HER2                                                            
Neg vs Pos 0.387 0.171-0.875 0.022* 0.844 0.496-1.435 0.53 0.323 0.142-0.738 0.007* 
WAI stroma matrix                                       
≤1 vs >1 4.593 1.101-19.129 0.036* 4.626 1.443-14.826 0.010* 2.01 0.428-8.377 0.338 
IRS stroma matrix in ≤ 3 lymph nodes 
involvement                                                 
≤25 vs >25 
0.163 0.022-1.207 0.076 0.282 0.087-0.913 0.035* 0.207 0.028-1.534 0.123 
IRS stromal cell in intermediate 
nuclear grade                                                        
≤25 vs >25 
0.29 0.040-2.132 0.224 0.213 0.059-0.768 0.018* 0.789 0.072-8.7.6 0.847 
IRS stroma matrix in tumor size > 
20mm                                                     
≤45 vs >45 
2.077 0.805-5.354 0.13 2.723 1.334-5.557 0.006* 1.065 0.403-2.814 0.900 
IRS stroma matrix in ≥ 4 lymph nodes 
involvement                                                 
≤45 vs >45 
2.145 0.682-6.743 0.192 3.357 1.356-8.309 0.009* 0.942 0.279-3.184 0.924 
IRS stroma matrix in PR negative                                               
≤45 vs >45 2.439 0.570-10.441 0.23 3.89 1.358-11.144 0.011* 1.094 0.254-4.714 0.905 
IRS stromal cells in histograde 1, 2               
≤45 vs >45 0.412 0.149-1.135 0.086 0.448 0.208-0.967 0.041* 0.513 0.186-1.415 0.197 
IRS stromal cells in HER2 positive             








Table 3.12. Multivariate Cox regression analysis for prognostic clinicopathological factors in 
breast cancer using backward stepwise model. 
Predictor HR      95% CI p Value 
Overall survival (OS)    
Tumor size_34.1 (mean) 2.892 1.509-5.545 0.001* 
PR 0.509 0.267-0.971 0.040* 
HER2 0.293 0.128-0.671 0.003* 
WAI stroma matrix                               ≤ 1 vs > 1   5.882 1.349-25.654 0.018* 
Disease free survival (DFS)    
Tumor size_34.1mean 1.743 1.060-2.866 0.028* 
Progesterone receptor (PR) 0.619 0.375-1.022 0.060* 
WAI stroma matrix                               ≤ 1 vs > 1 5.054 1.556-16.417 0.007* 
IRS stroma matrix in ≤ 3 lymph nodes  
involvement                                         ≤ 25 vs > 25 0.306 0.094-0.995 0.049* 
IRS stromal cells in intermediate nuclear grade                                
                                                             ≤ 25 vs > 25     0.214 0.060-0.764 0.017* 
Histograde 1.640 1.015-2.649 0.043* 
IRS stroma matrix in tumor size > 20mm                                           
                                                             ≤ 45 vs > 45    2.648 1.189-5.894 0.017* 
IRS stroma  matrix in PR negative                                      
                                                             ≤ 45 vs > 45     3.909 1.359-11.247 0.011* 
IRS stromal cells in histograde 1, 2                          
                                                            ≤ 45 vs > 45   0.443 0.203-0.966 0.040* 
Survival after recurrence (SAR)    
Tumor size_ mean (34.1) 107800.291 0.000-8.00E150 0.946 
IRS stromal cells in HER2 positive                       




















Figure 3.50. Kaplan-Meier survival analysis of the breast cancer using HS6ST3 as a 
biomarker. Survival analysis revealed that HS6ST3 staining in stroma matrix and stromal 
cells could predict the prognosis of the breast cancer. Thus, HS6ST3 staining in different 
tissue compartments was predictive of OS and DFS.  
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Section 5: Immunohistochemical analysis of human SULF1 expression 
in human clinical breast cancer sections of ductal carcinoma 
 
3.45 Clinicopathological features of breast cancer sections  
Human SULF1 is an enzyme known by its arylsulfatase activity that specifically removes 
sulfate group from carbon 6 position in heparan sulfate chain. In recent studies, it was 
identified that human SULF1 expression is dysregulated in several cancers. It lost its 
expression in cancers such as breast cancer, ovarian cancer, hepatocellular carcinoma and 
myeloma, while it is up-regulated in gastric cancer and primary pancreatic 
adenocarcinoma (Li et al. 2005; Lai et al. 2004; Lai et al. 2003; Narita et al. 2007; 
Abiatari et al. 2006; Narita et al. 2006; Staub et al. 2007; Junnila, 2010). 
 
In this study, immunohistostaining was performed on a total of 267 paraffin embedded 
tissue microarray slides (TMA) of archival blocks of diagnosed cases of breast 
adenocarcinoma which were collected in the Department of Pathology of Singapore 
General Hospital, between 1998 and 2004. In addition to the study population, 39 
sections were collected from non cancerous (normal) breast biopsies. Clinicopathological 
features of cases including race, age, tumor side, tumor size, histotype, histograde, lymph 
node status, associated ductal carcinoma in situ (DCIS) nuclear grade, associated DCIS 
nuclear grade extent as well as immunohistochemical markers such as estrogen receptor, 
progesterone receptor and HER2 were collected. Other information such as diagnosis 
date, recurrence date and also date of death were retrieved from patient’s records. The 
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study follow up was set up from January 1998 to the end of June 2009. This study was 
ethically approved by Institutional Review Board, Singapore General hospital. 
 
In this study, most of the breast cancer specimens were from Chinese. In addition, 
majority of the cancer sections were diagnosed as ductal adenocarcinoma. The age of the 
breast cancer patients ranged from 23 to 88, with a mean age of 57.26. Tumor size was 
distributed from 1mm to 140mm among cases with median of 30mm. Details of 
clinicopathological features of all cases are summarized in Table 3.13. It must be 
mentioned that nearly all of the specimens were collected prior to any therapy. Thus, the 




























Table 3.13.Clinicopathological features of 267 cases of breast cancer. Data represented 

























Clinicopathological features Clinicopathological features 





Involved Lymph nodes (LN) 
   
≤ Mean age (56) 136 50.9 LN = 0 127 47.6 
> Mean age (56) 131 49.1 ≥1 LN 4 < 66 24.7 
Race 
  
≥ 4 61 22.8 
Chinese   218 81.6 Unavailable 13 4.9 
Malay     21 7.9 Associated nuclear grade of 
DCIS    
Indians      11 4.1 None 109 40.8 
Others        17 6.4 Low 11 4.1 
Laterality 
  
Intermediate 59 22.1 
Right 132 49.4 High 85 31.8 
Left 135 50.6 Unavailable 3 1.1 
Unavailable 
  
DCIS nuclear grade  extent 
   
Tumor size (TS) 
  
 None 30 11.2 
 ≤20 75 28.1 Minimal 61 22.8 
>20  185 69.3 Extensive 29 10.9 
 ≤30 (mean) 148 55.4 Unavailable 147 55.1 
>30 (mean) 112 41.9 ER expression 
   
Unavailable 7 2.6 Negative 98 36.7 
Histotype 
  
Positive 164 61.4 
IDC 239 89.5 Unavailable 5 1.9 
Non-IDC 27 10.1 PR expression 
   
Unavailable 1 .4 Negative 124 46.4 
Histograde 
  
Positive 138 51.7 
1 27 10.1 Unavailable 5 1.9 
2 102 38.2 HER2 expression 
   
3 128 47.9 Negative 177 66.3 
Unavailable 10 3.7 Positive 81 30.3 
      Unavailable 9 3.4 
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3.46 Expression of SULF1 in normal and cancerous human breast tissue 
In benign human breast tissues, SULF1 strongly expresses itself both in the cytoplasm of 
epithelial cells as well as extracellular compartments including stroma matrix and stromal 
cells (Figure 3.51, D). In ductal adenocarcinoma, SULF1 seemed to be differentially 
expressed in epithelial and stromal components of human ductal adenocarcinoma. 
Although SULF1 basically expressed in cytoplasm of epithelial cells, the cytoplasmic 
expression of SULF1 positively correlates with its stromal existence (p< 0.001). 
 
Figure 3.51. Immunohistochemical staining of SULF1 in tissue microarray sections of 
breast cancer. (A) 0 or negative epithelial and stromal staining (B) +1 or weak staining 
(C) +2 or moderate staining (D) +3 or strong staining. Picture A, B and C belong to 
cancer sections, while picture D was captured from normal breast tissue. 
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3.47 Immunohistochemical expression of SULF1 in epithelial and stromal 
components of breast ductal adenocarcinoma 
SULF1 expresses itself both in the cytoplasm of epithelial cells as well as extracellular 
compartments including stroma matrix and stromal cells. However, the mean of staining 
intensity was evidently higher in epithelial cells (126.925±3.929) and stroma matrix 
(97.772±3.120) than stromal cells (66.498±2.790) among cancer specimens (P<0.001). 
Analysis of tissue microarrays revealed that the average staining intensity of normal 
tissues was overall stronger than cancer sections in extra cellular matrix; thus, this 
difference was significant in stroma matrix and stromal cells by 95% and 90% confidence 
interval respectively (Table 3.14). 
 











Bound P value 
Epithelial 
cells 
Normal 113.077 9.743 93.905 132.249 
0.144 
Tumor 126.929 3.724 119.601 134.256 
Stroma 
matrix 
Normal 112.564 8.164 96.498 128.630 
0.016* 
Tumor 97.772 3.120 91.631 103.912 
Stromal cells 
Normal 69.103 7.300 54.738 83.467 
0.073 






3.48 Association analysis of SULF1 immunoreactivity with clinicopathological 
parameters 
The staining intensity of different tissue compartments were compared with 
clinicopathological features. Data shown in Table 3.8 represent associations between the 
expression of SULF1 and clinicopathological parameters of breast cancer patients such as 
age, tumor size, histograde, lymph node status, estrogen receptor, progesterone receptor 
and HER2. The results suggested that patients whose ages were above the mean of age 
express more SULF1 in their stromal cell, while no associations were found in epithelial 
cells and stroma matrix. In addition, tumors bigger than 20mm showed to have higher 
staining intensities in their epithelial cells. In contrast, WAI-based analysis at 1.2 cut off 
showed that SULF1 staining intensity is higher in stroma matrix of tumors which were 
smaller than 20mm (p=0.007) In addition, the latter analysis revealed that histograde 1 
and 2 together have a significantly lower staining intensity compared to histograde 3 in 
stromal cell compartment (Table 3.15). Further, analysis revealed that the expression of 
SULF1 was higher in stroma matrix of the sections with higher lymph node metastasis 
(Table 3.16). There was no significant association between the expression of SULF1 and 
estrogen and progesterone receptors in tissue compartments. However, interestingly, 
SULF1 expressed more in epithelial cells and stroma matrix compartments of breast 







Table 3.15. Correlations between expression of SULF1 using IRS and clinicopathological 
features of breast cancer, Fisher’s exact test. 
Clinicopathological 
parameter      
    IRS 
Epithelial cells P value 
    IRS   Stroma 
matrix P value 
    IRS   
Stromal cell P value 
    ≤50 >50   ≤50 >50   ≤50 >50   
Age 






> mean (56) 17 113 16 115 36 95 
Race 






Others 5 44 4 45 18 31 
Laterality 






Left 19 115 24 111 56 79 
Tumor size 






> 20mm 16 167 27 158 67 118 
Histograde 






Grade 3 12 114 20 108 46 82 
Histotype 






DCIS 3 4 1 6 2 5 
Lymph node 
involvement 
≤ 3 nodes 25 168 0.248 27 166 0.273 74 119 0.436 
> 3 nodes 5 54 6 55 22 39 
Associated nuclear 
grade of DCIS 






Low 3 8 1 10 4 7 
Intermediate 4 55 8 51 23 36 
High 9 74 11 74 29 56 
DCIS nuclear 
grade extent 





0.582 Minimal 6 53 8 53 20 41 
Extensive 4 25 4 25 10 19 
Estrogen receptor 






Positive 19 143 20 144 66 98 
Progesterone 
receptor 






Positive 15 121 16 122 56 82 
HER2 
















Table 3.16. Correlations between expression of SULF1 using WAI 
andclinicopathological features of breast cancer, Fisher’s exact test. 
 
 
3.49 Survival analysis of SULF1 expression in breast ductal carcinoma 
Kaplan-Meier survival analysis was primarily performed in all of the possible strata of 
the histopathological parameters. Then, Univariate Cox regression proportional analysis 
was performed on strata which were detected as a significant factor (p< 0.05) for 
predicting the prognosis by Kaplan-Meier survival analysis. Univariate Cox regression 
Clinicopathological 
parameter      
   WAI 
Epithelial cells P value 
   WAI   
Stroma matrix P value 
   WAI   
Stromal cell P value 
   ≤ 1.2 >1.2  ≤1.2 >1.2  ≤1.2 >1.2   
Age 






> mean (56) 33 98 82 49 107 24 
Race 






Otheres 9 40 24 25 44 5 
Laterality 






Left 40 95 82 53 114 21 
Tumor size 






> 20mm 46 139 119 66 150 35 
Histograde 






Grade 3 27 101 74 54 99 29 
Histotype 






DCIS 2 5 4 3 6 1 
Lymph node 
involvement 






> 3 nodes 16 45 26 35 50 11 
Associated nuclear 
grade of DCIS 






Low 3 8 7 4 10 1 
Intermediate 13 46 32 27 49 10 
High 23 62 46 39 68 17 
DCIS nuclear 
grade extent 





0.556 Minimal 15 46 37 24 47 14 
Extensive 8 21 14 15 23 6 
Estrogen receptor 






Positive 44 120 98 66 134 30 
Progestrone 
receptor 






Positive 38 100 85 53 114 24 
HER2 






Positive 17 64 43 38 63 18 
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proportional analysis showed that staining intensity of tissue compartments significantly 
associated with overall survival (OS), disease-free survival (DFS) as well as survival 
after recurrence (SAR). The prognostic factors associated with the expression of SULF1 
are summarized in Table 3.10. The survival analysis revealed that age, tumor size, tumor 
laterality and the number of lymph node involvement are predictive of prognosis. Thus, 
the OS and SAR of breast cancer cases whose ages were younger than 60 were 
significantly higher than those who developed breast cancer after 60. In addition, bigger 
tumors (> 30mm) were associated with poorer SAR. As expected, more lymph node 
involvement was associated with worse OS and SAR. Interestingly, SULF1 expression 
was the only factor which was able to predict DFS in addition to OS in breast cancer. 
Therefore, higher expression of SULF1 in epithelial cells of grade1 of breast cancer 
predicted a better prognosis for DFS. Similarly, higher SULF1 expression in stroma 
matrix of breast cancer patients with less than 4 lymph node involvements was predictive 
for a longer OS and DFS. In contrast, higher expression of SULF1 in stromal cells of 
breast cancer patients below 60 years old predicted a worse outcome in terms of their 
DFS. The trends of survivals are shown in Figure 3.52 using Kaplan-Meier survival 
analysis.  
 
Using a multivariate survival analysis interestingly revealed that the IRS of all of the 
tissue compartments could independently be predictive for OS and DFS; however, it was 




Table 3.17. Univariate Cox regression analysis for prognostic clinicopathological factors in 
breast  cancer. 
 
 
Table 3.18. Multivariate Cox regression analysis for prognostic clinicopathological factors in 
breast cancer using backward stepwise model.  
Predictor HR 95% CI p Value 
Overall survival (OS)    
IRS Stroma matrix in PN1 to pN3           ≤50 vs > 50 0.157 0.049-0.506 0.002* 
Tumor side                                               Right vs Left 0.315 0.098-1.009 0.052 
IRS Stroma matrix                                    ≤50 vs > 50 0.461 0.209-1.017 0.055 
Age                                                            ≤60 vs > 60 2.456 1.292-4.666 0.006* 
Tumor side                                                Right vs  Left 0.352 0.176-0.705 0.003* 
Disease free survival (DFS)    
IRS Epithelial cell in Grade 1                  ≤50 vs > 50 0.02 0.001-0.465 0.015* 
Lymph node status                              6.272 1.080-36.414 0.041* 
IRS Stroma matrix in PN1 to pN3          ≤50 vs > 50 0.201 0.073-0.554 0.002* 
IRS Stromal cell in Age  below 60          ≤50 vs > 50 3.021 1.307-6.986 0.010* 
  
Overall survival Disease-free survival Survival after recurrence 
HR 95% CI p Value HR 95% CI 
p 
Value HR 95% CI 
p 
Value 
Age                                                          
≤60 vs >60 
        
2.266 1.222-4.202 0.009* 1.613 
0.976-
2.666 0.062 1.862 
1.007-
3.443 0.048* 
Tumor size (mm)                                          
≤ Median (30) vs > 
Median (30)  
         
0.984 0.490-1.978 0.964 1.046 
0.626-
1.749 0.884 1.793 
1.030-
3.121 0.039* 
Tumor side                                          
Right vs Left 
        
0.412 0.213-0.796 0.008* 0.639 
0.385-
1.060 0.083 0.45 
0.232-
0.871 0.018* 
Lymph node metastasis                  
pN0 vs  PN1 to pN3 
        
1.909 1.053-3.463 0.033* 1.323 
0.836-
2.092 0.23 1.916 
1.054-
3.482 0.033* 
IRS Epithelial in Grade 1  
≤50 vs  > 50 
         
0.196 0.027-1.405 0.105 0.181 
0.036-
0.904 0.037* 0.227 
0.032-
1.613 0.138 
IRS Stroma matrix in 
PN1 to pN3   ≤50 vs  > 50 
         
0.249 0.085-0.729 0.011* 0.231 
0.087-
0.616 0.001* 0.377 
0.119-
1.192 0.097 
IRS Stromal cell in Age  
below 60  ≤50 vs  > 50 
         
1.634 0.621-4.299 0.32 2.63 
1.191-







Figure 3.52. Kaplan-Meier analysis of the breast cancer survival using SULF1 as a 
biomarker. Analysis revealed that SULF1 positivity in epithelial cells and stroma matrix 
was associated with a longer survival, while similar expression in stromal cells was 








3.50 Analysis of the expression of HS6ST3 and SULF1 in breast cancer 
The staining intensities of HS6ST3 and SULF1 of various tissue compartments revealed 
to have significant associations with clinicopathological parameters such as age, tumor 
size, histograde, histotype, lymph node status, estrogen receptor, progesterone receptor 
and HER2.  
 
The breast cancer patients whose ages were above the mean of age expressed more 
HS6ST3 and SULF1 in their epithelial cells and stromal cells respectively. Tumors which 
were smaller than 20mm expressed more HS6ST3 in their stroma matrix, while they 
expressed less SULF1 in their epithelial cells. Similarly, tumors which were smaller than 
20mm expressed more SULF1 in stroma matrix compartment. Besides, HS6ST3 
expressed more in stroma matrix of the histograde 2 compared to histograde 1 and 
histograde 3.  SULF1 expressed more in stromal cells of histograde 3 compared to 
histograde 1 and histograde 2. It was also identified that the expression of HS6ST3 was 
higher in stromal cells of invasive ductal carcinoma (IDC) compared to ductal carcinoma 
in situ (DCIS). However, there was no significant association between the expression of 
SULF1 and histotype. On the other hand, SULF1 expression was found higher in the 
epithelial cells and stroma matrix of tumors which were positive for HER2, while no 
association was identified between the expression of HS6ST3 and HER2. Furthermore, 
the analysis interestingly showed that the higher expression of HS6ST3 and SULF1 in 




Survival analysis showed that the expression of both HS6ST3 and SULF1 in different 
tissue compartments could independently predict the prognosis of the breast cancer 
patients. 
 
Although the expression of HS6ST3 in epithelial cell was not predictive of prognosis, the 
similar expression in extracellular components could predict the prognosis of the breast 
cancer patients. Lower expression of HS6ST3 in stroma matrix of the breast cancer cells 
was predictive of a better survival; however, in tumors with less lymph node metastasis 
(≤ 3 lymph nodes involvement), higher expression of HS6ST3 was able to predict a 
longer survival. On the other hand, less staining of HS6ST3 in stromal cell compartments 
with positive HER2 was predictive of a better survival, while a higher expression of 
HS6ST3 in stromal cells of histograde 1, 2 sections were associated with a prolonged 
survival.  
 
The expression of SULF1 in various tissue compartments was also predictive of survival 
of the breast cancer patients. Unlike the expression of HS6ST3, the expression of SULF1 
in epithelial cells was predictive of the breast cancer survival. It was identified that higher 
expression of SULF1 in epithelial cells of the histograde 1 was associated with a better 
survival. Similarly, a higher expression of SULF1 in stroma matrix of the tumors with 
less lymph node metastasis (≤ 3 lymph nodes involvement) was associated with a longer 
survival. On the other hand, the expression of SULF1 in stromal cell compartment was 
able to predict the breast cancer prognosis. Thus, it was interestingly revealed that the 
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lower staining of SULF1 in the stromal cells of the patients below 60 years old was 

















CHAPTER 4  























4.1 Expression analysis of HS6ST3 in breast cancer cell lines 
This study was mainly aimed to highlight the significance of HS6ST3 in breast cancer 
behavior. Thus, the modulatory role of HS6ST3 was examined in T47D and MCF7 breast 
cancer cell lines by performing several functional experiments such as proliferation, cell 
cycle, apoptosis, adhesion, migration and invasion assays. The current research is the first 
comprehensive study which was performed to elucidate the potential role of HS6ST3 in 
the malignant process of carcinogenesis. Hence, little is known about the involvement of 
HS6ST3 in cancer in the literature. In addition, the function of other HS6ST isoforms was 
rarely studied in cancer. Seko et al. firstly showed that HS6ST2 was over-expressed in 
mucinous adenocarcinomas, while HS6ST3 was down-regulated in the same carcinomas 
(Seko et al. 2002).  Later, labbe et al. revealed that targeting TGF-beta and Wnt signaling 
could increase the expression of HS6ST2 in mammary and intestinal carcinomas (Labbé 
et al. 2007). Recently, song et al. found the significant involvement of HS6ST2 in 
pancreatic cancer. They understood that shRNA silencing of HS6ST2 diminished the 
growth, progression and angiogenesis of the pancreatic carcinoma. In addition, they 
proposed that HS6ST2 could trigger the Notch signaling in PC. (Song et al. 2011). 
 
In the current study, proliferation assay showed that silencing HS6ST3 decreases the 
number of viable T47D and MCF7 cells in culture medium. It was postulated that 
HS6ST3 knock down could result in diminished relative percentage of the live cells. 
However, this change might be attributable to diminished rate of cell proliferation or 
activation of apoptotic pathway(s). Whether this observed effect is due to diminished 
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proliferation or activation of apoptotic cascade, the finding indicates that silencing 
HS6ST3 could potentially change the interactions between heparan sulfate and a variety 
of growth factors and cytokines. Consequently, cell signaling which is influenced by the 
latter process could potentially affect the relative percentage of the live cells. Lai et al. 
showed that the expression of SULF1, a heparan sulfate 6-O-sulfation editing enzyme, 
could reduce the proliferation and induce the apoptosis in the ovarian carcinoma (Lai et 
al. 2003). Therefore, it is plausible that 6-O-hypo sulfation of the heparan sulfate by 
inhibiting HS6ST(s) or over-expression of SULF1 could potentially alter the interaction 
of the heparan sulfate chain with other significant signaling molecules which regulate the 
cellular processes. 
 
In order to find why the relative percentage of the live cells was diminished after 
silencing HS6ST3, cell cycle assay and apoptosis assays were performed respectively. 
Thus, cell cycle assay was carried out at 72 hours after HS6ST3 knock down. Analysis 
revealed that the cellular population percentages of cell cycle phases were shifted after 
silencing HS6ST3 in both T47D and MCF7. In T47D, this shift was remarkably obvious 
in G0 and G1 phases. In G0 phase which is indicative of pre-apoptotic cells, the cellular 
percentage was significantly increased after silencing HS6ST3. Similar trend was 
observed in G1 phase suggesting that HS6ST3 knock down induced a G1 arrest. In other 
words, the percentage of viable cells in G1 was remarkably increased. As a result of G1 
arrest, cellular transition from G1 to G2 phase was reduced in T47D; and in turn the 
relative number of viable cell was significantly diminished in S and G2 phases. In MCF7, 
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the shift in G0 was more prominent as the number of pre-apoptotic cells remarkably 
increased. However, G1 arrest was not observed after silencing HS6ST3 in MCF7. These 
changes were consistent with the result of proliferation assay. Performing cell cycle assay 
showed that down regulation of HS6ST3 may decrease the relative percentage of the live 
cells through various pathways in T47D and MCF7 as it mainly induced apoptosis and on 
the other hand, caused G1 arrest in the cell cycle.   
 
Cell cycle assay showed that the numbers of pre-apoptotic cells increased after silencing 
HS6ST3; however, in order to verify the direct influence of apoptosis on the relative 
percentage of the live cells, apoptosis assay was performed. In this assay, the activity of 
caspase 3, 7 and caspase 8 were measured in T47D and MCF7. These caspases were 
previously chosen from the list of the genes which were up-regulated after silencing 
HS6ST3 in gene microarray analysis. Luminescence measurement showed that the 
activity of these caspases was increased by knocking down HS6ST3. This observation 
was in agreement with the observations of proliferation and cell cycle assay and was 
indicative of the potential ability of HS6ST3 knocked down on activation of apoptotic 
pathways. In other words, restoration of HS6ST3 expression prevented the activation of 
the cascade of caspases. 
 
Adhesion is an important characteristic of most cells. Malignant cells tend to have weaker 
adhesion compared to non-malignant cells; therefore, cancer cells may easily metastasize 
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into adjacent tissues of the involved organ as well as other organs (Ruoslahti 1984; Pauli 
et al. 1983; Sebestyén et al. 2000). In this study, we performed adhesion assay using 
collagen I or fibronectin coated plates. Analysis of this assay demonstrated a significant 
increase in cell adhesion after silencing HS6ST3 in T47D and MCF7. This finding 
suggested that down-regulation of HS6ST3 may result in over expressing adhesion 
molecule(s) which tends to adhere into collagen I and/ or fibronectin; and consequently, 
enhances the cellular adhesion.  For example, based on our microarray data we identified 
that ICAM1 and paxillin, adhesion molecules, were overexpressed by 205.5% (p< 0.001) 
and 50% (p< 0.05) respectively after silencing HS6ST3 in the breast cancer. Kawai et al. 
revealed that restoration of ICAM1 expression in lymphatic endothelial cells enhanced 
the adhesion of cancer cells to the lymphatic endothelial cells (Kawai et al. 2009). On the 
other hand, Schröder et al. explained that the expression of ICAM1 may increase the cell 
migration and invasion in the breast cancer (Schröder et al. 2011). However, the critical 
role of ICAM1 in the malignant process of tumorogenesis is still unknown.  
 
Paxillin is another adhesion molecule that mechanically regulates the integrin bonds in 
vascular cell adhesion by contributing in the assembly of focal adhesion (Manevich et al. 
2007). Chen et al. revealed that silencing of paxillin inhibited the cellular adhesion in the 
breast cancer (Chen and Kroog 2010).  
 
Our microarray analysis showed that by silencing HS6ST3, the expression of several 
integrins such as alpha 3 (p< 0.01), alpha 2b (p< 0.05), beta 2 (p< 0.05), alpha 9 (p< 
0.05), beta 8 (p< 0.05), alpha 8 (p< 0.01), beta 7 (p< 0.01), and alpha M (p<0.05) 
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increased. All of these observations could be suggestive of the potential effect of HS6ST3 
silencing in enhancing the cellular adhesion in the breast cancer. As an example, 
Slambrouck et al. showed that inhibition of integrin alpha 2 led to a poor adhesion and 
enhanced the invasion of the cells in prostate cancer (Van Slambrouck et al. 2009). 
 
Malignant cells may move from their original location and reach to the blood vessels as 
well as lymphatic vessels and hence could potentially facilitate the metastasis of the 
cancer cells into the other tissues or organs (Brown and Bicknell 2001; Simpson et al. 
2010; Moutasim, Nystrom and Thomas 2011). To assess how the cell motility was 
affected by HS6ST3 knock down, migration assay was perform using wound healing or 
scratch assay. For this purpose, serial photos were captured at 12, 24, 48 and 72 hours 
after scratching the T47D cells. Analysis shows no significant different between silenced 
cells and control group at 12, 24 and 48 hours. On the other hand, significant difference 
was observed at 72 hours post scratch indicating that the wound healing was delayed in 
silenced cells compared to control group. However, since the time lag between scratch 
and cell motility at 72 hours after that was quite long, the observed difference could be 
attributable to cellular proliferation. In order to confirm whether the latter is due to 
proliferation or cell motility a different migration assay was performed by using 
migration inserts. The results of the transwell migration assay revealed no cellular 
migration through the inserts in either silenced or control groups of T47D cells. Unlike 




Invasiveness of the tumor cell is as a result of pathological interaction of the malignant 
cells with the other cells as well as extracellular matrix (ECM). Invasive cancers may 
metastasize to the adjacent tissues as well as other organs. These malignant cells are 
capable to invade the basement membrane that lines the epithelial or endothelial cells and 
infiltrate into the other tissues. In order to simulate this condition, we performed invasion 
assay by using matrigel invasion chambers (Kramer, Bensch and Wong 1986; Kleinman 
and Jacob 2001). Similar to the migration chamber, the results of the invasion assay 
revealed no cellular invasion through the inserts in either silenced or control group. 
However, silencing HS6ST3 in MCF7 resulted in an interesting decrease in cellular 
invasiveness. The observed differences in migration and invasion between T47D and 
MCF7 cell lines might be due to their nature, size or other unknown factors (Karey and 
Sirbasku 1988; Edwards et al. 1989; Sheridan, Francis and Horwitz 1989; Ryde, Nicholls 
and Dowsett 1992; Mooney et al. 2002). 
 
In addition, we found that silencing HS6ST3 in T47D and MCF7 could significantly 
diminish the expression of heparan sulfate on the cell surface. The latter was revealed in 
immunocytostaining (ICC) by using two anti-heparan sulfate antibodies (10E4 and 
HepSS-1). Suppression of heparan sulfate synthesis could further justify the observed 
phenotypic alterations after silencing HS6ST3 in T47D and MCF7; because cell surface 
heparan sulfate regulates a variety of signal transduction by interacting with several 
ligands such as growth factors, matrix components and cytokines (Lo et al. 2011; Iozzo 
1988; van den Born et al. 2005; Pilkington et al. 1997; Fujita et al. 2010). In 2004, Maeda 
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et al. realized that over-expressing the syndecan-1 could enhance the tumoral 
proliferation in breast cancer (Maeda, Alexander and Friedl 2004). Park et al. understood 
that syndecan-2 was involved the process of tumorogenesis and this involvement was 
mediated by Focal Adhesion Kinase (FAK) in fibrosarcoma (Park et al. 2005). Later, 
Choi et al. examined the role of syndecan-2 on the cancer progression. They showed that 
over-expression syndecan-2 increased the collagen adhesion, migration and invasion of 
the rate intestinal epithelial cells (RIE1) (Choi et al. 2009). Earlier to these findings, 
Farooq and his colleagues found that the syndecan-3 could induce cell cycle arrest at G1; 
and thus they showed that by inhibiting the expression of syndecan-3, cellular 
proliferation could increase in Hep 3B (Farooq et al. 2003). Nikolova et al. showed that 
the syndecan-1 differentially expressed in the different stages of the breast cancer and 
therefore regulating the breast cancer progression (Nikolova et al. 2009).  
 
In our microarray data we found that silencing HS6ST3 did not affect the expression of 
any of the syndecans, while it significantly reduced the expression of the expression of 
glypican-6 (p< 0.001) by 61 % and increased the expression of glypican 1 (p< 0.05) and 
glypican 2 (p< 0.01) by 49% and 64% respectively. Therefore, we may deduce that 
during the process of carcinogenesis the expression of the glypican 1 and glypican 2 was 
diminished and the expression of the glypican 6 was increased so that it composed the 
major content of the heparan sulfate on the cell surface of the breast cancer cells. Thus, 
significant reduction of cell surface heparan sulfate after silencing HS6ST3 in T47D and 
MCF7 could be attributable to the reduction in the content of the cell surface glypican 6. 
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Furthermore, we one possible way to justify the observed phenotypic change after 
silencing HS6ST3 is the regulatory role of glypican 6 in the malignant process of 
carcinogenesis. 
 
Herein, we proposed two hypotheses: Firstly, the phenotypic alterations consistently 
indicated that silencing HS6ST3 could significantly influence the interactions between 
heparan sulfate and several growth factors. This in turn affects the growth factor signals 
that adjust the cell growth, adhesion, apoptosis, migration as well as invasion; and thus 
diminish breast cancer progression. In our microarry analysis it was identified that 
silencing HS6ST3 reduced the expression of IGF1R which will be fully discussed in the 
next section.  Secondly, it might be possible that HS6ST3 gene have a direct or indirect 
positive regulation on breast cancer oncogene(s) and a negative regulation on the breast 
cancer tumor suppressor gene(s). Thus, silencing HS6ST3 may minimize the positive 
regulation of the oncogene(s), while tumor suppressor(s) could be activated and 
consequently these alterations influenced the cancer growth and progression. Osborne et 
al. introduced a number of oncogenes (such as Cyclin D1, Cyclin E) and tumor 
suppressor genes (such as CHK2) which could potentially contribute in breast cancer 
tumorogenesis (Osborne, Wilson and Tripathy 2004). 
 
In the microarray analysis, we found that the expression of Cyclin D1 and Cyclin E, 
breast cancer oncogenes diminished by 40% (p< 0.01) and 37% (p< 0.05) respectively 
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after silencing HS6ST3. On the other hand, silencing HS6ST3 over-expressed CHK2, a 
breast cancer suppressor gene, by 30% (p< 0.05). 
 
These finding are of considerable significance since they have introduced an interesting 
gene which regulates breast cancer behavior. The significance of the current study is not 
restricted to the regulatory role of HS6ST3 in breast cancer because it could be also used 
as a novel prognostic and/ or diagnostic biomarker in breast cancer. In addition, it might 
be useful as an effective therapeutic target for treating breast cancer as well as other 
malignancies. However, the results of our study were restricted to breast cancer cell line 
in vitro. Therefore, a direct extension of this study is required to explore the consistency 
of these findings in vivo. Applying similar studies in vivo could reveal the clinical 
significance of HS6ST3 in breast cancer as well as other malignancies. 
 
4.2 Insulin-like growth factor 1 receptor (IGF1R) 
Based on our microarray analysis, we found that IGF1R was down-regulated after 
silencing HS6ST3. This finding was further confirmed by RT-PCR in T47D and MCF7 
breast cancer cell lines. Then, the downstream relationship of IGF1R and HS6ST3 was 
validated by designing several functional studies. After that, we found that blocking 
IGF1R with blocking antibody diminished the cellular proliferation, migration and 




IGF1R is a transmembrane tyrosine kinase receptor comprising two extracellular alpha 
and two beta subunits which critically modulate several biological events such as growth 
and development. Hadsell et al. examined the role of insulin-like growth factor I on the 
development of mammary. They showed that targeting insulin-like growth factor I could 
result in incomplete breast development, diminished mammary gland branching and loss 
of secretory lobules (Hadsell et al. 1996; Richards et al. 2004). On the other hand, IGF1R 
is a key regulator of several cell processes in malignant cells, and thus play an important 
role in growth and progression of the cancers (Tang et al. 2007). Cullen et al. was firstly 
explained the expression and function of IGF1R in breast cancer. They concluded that 
IGF1R ubiquitously express in breast carcinoma and suggested a mitogenic function for 
this receptor (Cullen et al. 1990). Hence, the existence or even up-regulation of IGF1R 
seems to be essential for transforming  the non-tumoral cellular phenotype into a 
malignant behavior (Werner and Le Roith 1997; Burtscher and Christofori 1999). 
Activation of IGF1R was shown to enhance the cellular proliferation and inhibit the 
apoptosis in several cell lines such as breast epithelial cells. (Yanochko and Eckhart 
2006). Carboni et al. revealed that activation of IGF1R in transgenic mice could develop 
breast cancer, and then they detected the higher expression level of IGF1R in the 
mammary tumor at 8 weeks of age (Carboni et al. 2005). Jones et al. injected the breast 
cancer cells over-expressed for IGF1R into the mammary gland of wild type mice. After 
about two weeks they found a prominent tumor which was palpable in the mammary 
gland, while the control mice had the palpable tumor after about 12 weeks. Additionally, 
based on their microarray analysis they found that suppression of IGF1R diminished the 
expression of cyclin D1 protein in vivo and in vitro. Thus, they proposed that some 
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proliferative functions of IGF1R might be regulated by cyclin D1 as a downstream 
signaling factor (Jones et al. 2008). Cyclin D1 was reported to be aberrantly expressed in 
breast cancer as well as other cancer. High expression level of cyclin D1 associated with 
poorer prognosis in breast cancer cases. Over-expression of cyclin D1 was associated 
with invasive malignant transformation of non-invasive epithelial cells of the mammary 
gland (Wang et al. 2007). On the other hand, suppression of Cyclin D1 expression in 
breast cancer inhibited the tumor cell growth by inducing a G1 arrest in cell cycle and 
also promoted the apoptosis of the breast cancer cells (Wei et al. 2011).  In our study, 
cyclin D1 was remarkably down-regulated by 40% (p< 0.01) after silencing HS6ST3 in 
the breast cancer; therefore, we postulate that the suppression of cyclin D1 could be due 
to the down-regulation of IGF1R which occurred after silencing HS6ST3 in breast cancer 
cell line. Therefore, we may also presume that the suppression of the growth and 
development of the tumor cells in HS6ST3 knocked down cells were partly due to the 
down-regulation of the cyclin D1. 
 
In estrogen receptor expressing (ER) cell lines such as MCF7, IGF1R was shown to be 
involved in a crosstalk which synergistically leads to promote the cell cycle progression. 
Thus, the estrogen potentiates the effect of IGF1R signaling and enhances the cellular 
proliferation (Dupont and Le Roith 2001).  
 
Metastasis of the breast cancer cells is a process in which the tumor cells invade the 
basement membrane and then migrate to the adjacent tissues or different organs. Apart 
from proliferation, IGF1R was reported to have a robust regulatory influence on the 
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migration and invasion of the breast carcinoma as well as other cancers. Suppression of 
IGF1R was firstly shown to reduce the invasion and thus the metastasis of the cancer 
cells (Dunn et al. 1998; Sachdev et al. 2004). Samani et al. revealed that genetically 
engineering of highly invasive cancer cells that expressed truncated IGF1R subunits 
could considerably neutralized the invasive characteristics of the malignant cells by 
blocking the IGF1R mediated signal transduction in vivo. In addition, they found that this 
method increased the disease free survival (DFS) of the mice comparing with the controls 
(Samani et al. 2004). Sachdev et al. found that IGF1R promotes the metastasis and 
survival of the tumor cells in breast cancer independent to the role which it has for 
primary tumor proliferation. The latter indicated that IGF1R is able to regulate multiple 
phenotypes in the process of tumorogenesis (Sachdev et al. 2010). The functional role of 
IGF1R has been extensively studied in breast carcinoma; however, similar scenario was 
observed in other cancers such as bladder cancer, colorectal cancer, Ewing tumor, lung 
cancer, prostate carcinoma and bone malignancies (Zhang et al. 2010; Kang et al. 2010; 
Linnerth et al. 2009; Avnet et al. 2009).   
 
Insulin-like growth factor I (IGF-I), a potential specific ligand for IGF1R is similarly able 
to potentiate the cellular proliferation, while it inhibits the apoptosis via multiple signal 
transduction pathways such as kinase pathways (Párrizas, Saltiel and LeRoith 1997). The 
association between serum IGF1 levels and IGF1 binding proteins and increased risk of 
breast cancer was described in a few epidemiological studies (Goodwin et al. 2002). The 
risk of developing breast cancer was further increased when activation of IGF1R 
accompanied p53 mutation.  In addition, clinical studies showed that IGF1R is a valuable 
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independent predictor of breast carcinoma specifically at its earlier stages (Mulligan et al. 
2007; Toniolo et al. 2000). 
 
Decreasing cellular adhesion is another important characteristic of invasive cells in 
different malignancies. It was reported in a few studies that expression of IGF1R was 
necessary for the cellular adhesion (Dunn et al. 1998; Mauro et al. 2003), while 
Guvakova et al. found that activation of the IGF1R induced disassembly of actin filament 
as well as tyrosine deposphorylation of paxillin and Focal adhesion kinase (FAK) in 
mammary epithelial cells. In their study, activation of IGF1R was associated with 
decreasing of the cell adhesion. They further found that increased activity of IGF1R 
promoted the cellular motility in MCF7 (Guvakova and Surmacz 1999). In another study, 
Mauro et al. showed that the expression of E-cadherin as a junctional protein is needed 
for IGF1R-dependent cell to cell adhesion in MCF7. They found that the assembly of E-
cadherin (E-cad) was stimulated by over-activation of IGF1R in MCF7 but not in 
negative E-cad cell lines. Thus, they deduced that co-expression of E-cad and IGF1R 
could increase the intercellular adhesion (Mauro et al. 2001). 
 
In the current study, we found that down-regulation of IGF1R in HS6ST3-silenced T47D 
cells increased the cellular adhesion. Based on our microarray analysis, we noticed that 
silencing HS6ST3, upregulated the paxillin by 50% (p< 0.05), while there was no 
statistically significant change in the expression of E-cad and FAK. This finding had a 
consistency with the other findings regarding the growth and progression of tumor cells 
in breast cancer. 
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Targeting IGF1R in breast cancer has been suggested as a novel therapeutic method in 
many studies. In antisense therapy, an anti sense RNA or oligonucleotide could target the 
genomic expression of IGF1R and decreases its expression in order to inhibit the tumoral 
growth and progression (Yang, Elliott and Head 2002; Samani et al. 2004). Recently, the 
scientist revealed that targeting IGF1R may induce the tumor supression, while it does 
not totally eradicate the preneoplastic changes in mammary tumor. Although they knew 
that targeting IGF1R could be an effective antitumor therapy, co-targeting IGF1R with 
other molecules was reported to be more potent against cancer growth and progression 
(Jones, Petrik and Moorehead 2010). For example, Chakraaborty et al. found that co-
targeting IGF1R and HER2 dramatically inhibited the cell proliferation and efficiently 
induced the apoptosis in the breast cancer cells. Therefore, targeting IGF1R in 
combination with other signaling molecules might be beneficial in developing of anti-
cancer treatment (Chakraborty, Liang and DiGiovanna 2008).  
 
In this study, we showed that knocking down of HS6ST3 down-regulated IGF1R 
expression in breast cancer. This effect may occur through inactivation of IGF1R 
transcription regulator. Alternatively, silencing HS6ST3 might change the growth factor 
signaling due to possible alteration in 6-O sulfation pattern and this may down-regulate 
IGF1R expression. Overall down-regulation of IGF1R mediated the reduction in growth 






4.3 X chromosome-linked inhibitor of apoptosis protein (XIAP)-associated factor 1 
(XAF1) 
Analysis of our microarray data showed that XAF1 was strongly up-regulated after 
silencing HS6ST3. Performing RT-PCR confirmed that the expression of XAF1 
significantly increased by 102% and 670.8% in T47D and MCF7 cell lines respectively. 
Then, the downstream relationship of XAF1 and HS6ST3 was validated by designing 
several functional studies. After that, we found that silencing XAF1 enhance the cellular 
growth in MCF7. In addition, by performing double silencing for XAF1 and HS6ST3 it 
was unraveled that the suppression of XAF1 might be involved in cell proliferation, 
adhesion, migration and invasion in breast cancer.  
 
XIAP-associated factor 1 or XAF1, a zinc finger protein, is known as a tumor suppressor 
that antagonizing XIAP, an antiapoptotic protein, and thus induce the cell death. XIAP is 
an important member of intrinsic factors which diminish the apoptosis both in vitro and 
in vivo. The inhibition function of XIAP is done by binding to the caspase 3, 7, 8 and 9 
(Chai et al. 2001; Huang et al. 2001; Riedl et al. 2001; Fong et al. 2000; Groebner et al. 
2010). However, XAF1 prevent XIAP of binding to the caspases. For this purpose, XAF1 
could bind to XIAP and facilitate degradation of Survivin which is an important anti-
apoptotic protein (Arora et al. 2007). In our microarray analysis, we found that XIAP was 
significantly down-regulated by 31% (p<0.01) in HS6ST3-silenced breast cancer cells. 
When the changes in the expression of XAF1 and XIAP was identified in HS6ST3-
knocked down cells, we luminometrically measured the activity of different caspases 
after silencing HS6ST3 to evaluate whether the observed apoptosis was due to the 
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enhanced caspase(s) activity. Then, we found that the activity of caspase 3, 7 and 8 was 
remarkably increased after silencing HS6ST3 in T47D and MCF7. This observation might 
be attributable to the over-expression of XAF1 after silencing HS6ST3 or the direct 
influence of HS6ST3-knocked down on the expression of the caspases. Douglas et al. 
suggested that the up-regulation the XAF1 might be potently mediated by INF-beta and 
this up-regulation sensitized the cells to induce apoptosis; however, we found no 
significant change in the expression of INF-beta after silencing HS6ST3 in breast cancer. 
Therefore, we hypothesized that up-regulation of XAF1 was occurred in HS6ST3-
knocked down cells independent to INF-beta (Leaman et al. 2002; Wang et al. 2006; 
Micali et al. 2007). On the other hand, Sun et al showed that the promoter of the XAF1 
might be activated by the transcription regulator STAT1 in colon cancer (Sun et al. 
2008). In this regards, we found that STAT1 was up-regulated up to 354% (p< 0.001) 
after silencing HS6ST3 in breast cancer based on the microarray data. Hence, we could 
postulate that the over-expression of XAF1 might be mediated by activation of STAT1 in 
HS6ST3-knocked-down cells in breast cancer. 
 
Association between the absences of programmed cell death and carcinogenesis has been 
widely examined in many studies. It was proposed that the disrupted balance between 
XIAP and XAF1 expression might be a key element in cancer growth and progression 
(Fong et al. 2000; Yin, Cheepala and Clifford 2006).  XAF1 could be detected 
ubiquitously in many tissues; however, its expression is suppressed in vitro and in vivo in 
several cancers such as gastric cancer, skin cancer, colorectal cancer, prostate cancer, 
blood cancer, kidney cancer, bladder cancer, liver cancer and testicular cancer (Sakemi et 
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al. 2007; Ng et al. 2004; Byun et al. 2003; Ma et al. 2005; Chen et al. 2006; Lee et al. 
2006; Gao et al. 2006; Zou et al. 2006; Shibata et al. 2007; Yu et al. 2007; Chung et al. 
2007; Li et al. 2007; Kempkensteffen et al. 2007; Li et al. 2008; Kempkensteffen et al. 
2008; Pinho et al. 2009; Huang et al. 2010). Researches explained that low expression of 
XAF1 in tumor cells was attributable to the aberrant promoter hypermethylation which 
contribute in tumor progression (Jang et al. 2005; Murphy, Perry and Lawler 2008). They 
further found an inverse correlation between low XAF1 expression and mutation of p53 
indicating that loss of XAF1 expression may accompany the p53 mutation in the process 
of carcinogenesis in malignancies such as gastric cancer (Byun et al. 2003). On the other 
hand, XAF1 and p53 which are known as tumor suppressors could modulate the 
expression of each other in cancer cells. In other words, it was shown that the over-
expression of XAF1 suppressed the expression of p53 and the restoration of p53 inhibited 
the XAF1 transcription in gastrointestinal cancer (Zhang et al. 2010). However, in Zou’s 
study it was revealed that over-expression of XAF1 resulted in activation of wild-type 
p53 and accumulation of wild type p53 led to apoptosis (Zou et al. 2011). In our 
microarray results it was noticed that tumor protein p53 inducible nuclear protein 2 
(TP53INP2) was slightly up-regulated, while other p53-related proteins such as 
TP53RKB, TP53BP2, TP53I11, TO53I3, TP53TG1, PERP and PDRG1 were 
significantly down-regulated  after silencing HS6ST3 in breast cancer. Although we could 
not rule out the mutation of p53 in breast cancer, we may primarily hypothesize that over-
expression of XAF1 reduced the growth and progression of breast cancer independent to 
p53. In a recent study, it was revealed that the autophagic cell death function of XAF1 
was mediated by Beclin-1 in gastric cancer (Sun et al. 2011). Herein, we found that 
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autophagy/ beclin-1 regulator 1 (AMBRA1) was significantly up-regulated by 80% after 
silencing HS6ST3 in our microarray data (p< 0.001). Hence, we think that Beclin-1 may 
also mediate the regulatory effect of XAF1 on tumoral growth and progression in breast 
cancer. Recently, Xing et al. examined the regulatory influence of somatostatin on XAF1. 
They realized that somatostatin inhibit the cell proliferation and induced the cellular 
apoptosis via regulating XAF1 (Xing et al. 2010). Somatostatin was found up-regulated 
after silencing HS6ST3 in breast cancer by more than 50 %. Thus, it is postulated that 
somatostatin is an up-stream gene which inhibit the tumoral growth and progression by 
modulating XAF1 expression in breast cancer.    
 
Researchers further examined the significance of XAF1 and found that up-regulation of 
XIAP or loss of XAF1 expression was associated poor prognosis in acute leukemia and 
pancreatic cancer (Chen et al. 2006; Huang et al. 2010). Similar to IGF1R, XAF1 was 
introduced as an independent prognostic factor which could predict the survival in gastric 
adenocarcinoma (Shibata et al. 2008). On the other hand, over-expression of XAF1 could 
redistribute the cytosolic XIAP into nucleus and therefore trigger the apoptosis pathway 
and induce cell cycle arrest at specific check points (Liston et al. 2001; Wang et al. 
2009). Qiao et al. examine the role of XAF1 in the process of angiogenesis. They 
revealed that restoration of XAF1 expression inhibited the angiogenesis in the mouse 
endothelial cells (Qiao et al. 2008).  
 
As discussed growing body of researches has been elucidated the critical role of XAF1 in 
programmed cell death; however, the potential role of the XAF1 and XIAP in other 
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cellular processes is still immature. Our findings importantly contributed in elucidating 
the role of XAF1 in critical cellular processes such as proliferation, cell cycle, adhesion, 
migration and invasion of the breast cancer.  
 
Restoration of XAF1 expression has been shown as a potent inhibitor of tumor growth 
and progression in many cancers (Tu et al. 2009); therefore, regardless of its diagnostic 
and prognostic values it could be considered as an important therapeutic candidate for 
treating the malignancies in future (Liston et al. 2001; Holcik, Gibson and Korneluk 
2001; Yang et al. 2003); however, further research should attempt to investigate the 
molecular mechanisms suppressing XAF1 expression in cancers and then examine the 
functional values of XAF1 in cancer growth and progression.  
 
In the current study, it was revealed that XAF1 could mediate the behavior of the tumor 
cells after silencing HS6ST3 in the breast cancer by changing the expression of several 
genes such as caspases, STAT1, p53-related proteins, Beclin-1, Somatostatin. Herein, we 
proposed that targeting HS6ST3 might be useful therapeutic tool for treatment of breast 
cancer. This study elucidated the role of HS6ST3 in breast cancer cell lines in vitro; 
however, in vivo examining of the influence of HS6ST3 in regulating the breast cancer 
cell could be complementary to this work. On the other hand, HS6ST3 might be a 
potential therapeutic target for malignancies other than breast cancer. Therefore, further 





4.4 Identification of a novel molecular pathway in relation with HS6ST3 
We identified the potential role of HS6ST3 for regulating the cell phenotypes in breast 
cancer. Herein, we show a schematic diagram for the relationship of HS6ST3-related 
genome-wide genes which is based on our experimental observations and in agreement 
with the extensive literature review. (Appendix: Figure 4.1). 
 
4.5 Analysis of the drug sensitivity of the breast cancer after silencing HS6ST3  
We hypothesized that HS6ST3 is involved in cancer growth and progression by 
modulating several relevant genes. Extensive analysis of our microarray data revealed 
that the regulation of some of the potential genes might sensitize tumor cells to 
chemotherapeutic reagents. We examined the candidacy of XAF1 as a tumor suppressor 
in breast cancer therapy. Therefore, we found that silencing HS6ST3 in T47D modulated 
the cellular response to Cisplatin and 5-fluorouracil (5-fu) in breast cancer. In specific, it 
was identified that breast cancer cells were sensitized to the cytotoxic effect of cisplatin 
and 5-fu by silencing HS6ST3. 
 
As discussed, suppression of the growth and progression of the breast cancer was mainly 
mediated by down-regulation of IGF1R and up-regulation of the XAF1 after silencing 
HS6ST3 as its downstream factors. In addition to this significant discovery, we noticed 
that the down-regulation of IGF1R and up-regulation of XAF1 were reported to sensitize 
the malignant cells to several chemotherapeutic reagents (Hellawell et al. 2003). IGF1R 
was over-expressed in many malignancies such as prostate cancer, melanoma ovary 
cancer and renal carcinoma and thus modulating the cancer growth and progression. 
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Therefore, several researchers hypothesized that IGF1R expression may contribute in 
tumor resistance to chemotherapy (Eckstein et al. 2009; Yavari et al. 2010; Zuo and Luo 
2010). Liu et al. showed that stimulation of IGF1R in esophageal carcinoma induced 
chemoresistance to cisplatin, 5-fluorouracil (5-fu) and camptothecin (Liu et al. 2002). 
Other researchers understood that inhibition of IGF1R may enhance the cytotoxic effect 
of chemotherapeutic agents such as 5-fu on several cancers such as colorectal carcinoma 
and renal cancer (Dallas et al. 2009; Zeng et al. 2009; Yuen et al. 2009). Rochester et al. 
found that down-regulation of IGF1R sensitized the prostate cancer cells to DNA-
damaging drugs (Rochester et al. 2005). Later, other researchers observed an enhanced 
chemosensitivity to cisplatin after silencing IGF1R in melanoma, ovary cancer,  lung 
cancer, renal carcinoma, teratoid/ rhabdoid tumor, mesothelioma and skin tumors (Yeh, 
Bohula and Macaulay 2006; Gao et al. 2008; Dong et al. 2008; Yuen et al. 2009; D'cunja 
et al. 2007; Kai et al. 2009; Liu et al. 2010). Furthermore, the potent influence of IGF1R 
silencing on cancer chemosensitization was exhibited both in vitro and in vivo (Zeng et 
al. 2009). 
 
Cisplatin is a chemotherapeutic drug which has been used in anti-tumor therapy for more 
than four decades. Although it is not included in traditional regime used for treatment of 
the breast cancer, it has been effectively used on several cancers in human. Cisplatin 
could induce the apoptosis by formation of DNA adducts and causing DNA damage 
(Milosavljevic et al. 2010; Maiani, Diederich and Gonfloni 2011). Although several 
theories were hypothesized for cisplatin function, its direct and indirect function on the 
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tumoral protein expression is still unclear (Gibson 2009; Krause-Heuer et al. 2009; 
Tabata et al. 2011).  
 
Cyclin A2, an indicator of poor prognosis in several cancers, was introduced in Suzuki’s 
study as an important factor which modulate the aggressiveness of tumor cells by 
activation of PI3K pathway and induced resistance to cisplatin (Suzuki et al. 2010). 
Herein, we noticed that cyclin A2 was down-regulated after silencing HS6ST3 in our 
microarray data by more than 40% (p< 0.01). Thus, sensitization of tumor cells to 
cisplatin in the current study might be attributable to down-regulation of cyclin A2 after 
silencing HS6ST3 in breast cancer. The Wilson disease protein (ATP7B) is an ATPase 
which adjusts copper transportation and hence regulates the copper homeostasis in the 
cells. Expression of ATP7B was shown to be associated with chemoresistance to cisplatin 
(Dmitriev 2011). Our microarray analysis revealed that ATP7B was down-regulated in 
HS6ST3-knocked down cells by 36% (p< 0.05). Therefore, the observed down-regulation 
might be another possible reason for sensitizing the breast cancer cells to cisplatin. 
Rouette et al. showed that cisplatin induce cell death by activating B-cell-lymphoma 2 
(BCL2). They further indicated that over-expression of BCL2 could promote the 
treatment efficiency of cisplatin on endometrial cancer (Rouette et al. 2011). In the 
current study, we noticed that BCL2L1 and BCL2L14 which are the facilitator of the 
cellular apoptosis was up-regulated in HS6ST3- knocked down cells by 60% (p< 0.001) 
and 46% (p< 0.05) respectively. We think that the alteration in the expression of BCL2 
subsets could potentiate the cisplatin function in breast cancer. Leong et al. showed that 
activation of BCL2 superfamily might be mediated by p63/ p73 network in response to 
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cisplatin treatment. TAp63 promote the survival of the breast cancer cells, while TAp73 
induce apoptosis by activating BCL2 superfamily. However, TAp73 and TAp63 may co-
express in the cancer cells and then bind to each other. Dissociation of these proteins is a 
determining factor that could regulate the relative percentage of the live cells. Breast 
cancers expressing both TAp63 and TAp73, exhibited cisplatin sensitivity that was 
closely TAp73-dependent. Cisplatin induces the dissociation of TAp73 from TAp63 
through phosphorylating TAp73 and thus by activating BCL2 family induce the cell 
death (Leong et al. 2007; Carroll et al. 2006). By reviewing our microarray data we 
understood that TAp73 was up-regulated by 58% (p<0.01) after silencing HS6ST3 in 
breast cancer, while no significant change occurred in the expression of TAp63. Hence, it 
is presumable that up-regulation of TAp73 induced an imbalance between TAp63 and 
TAp73 and therefore, over-expression of TAp73 could further augment the cytotoxic 
effect of cisplatin in breast cancer.  
 
Imatinib is able to inhibit dissociation of TAp63 from TAp73. As stated, we found that 
silencing HS6ST3 sensitized the breast cancer cells to the cytotoxic effect of cisplatin. In 
order to examine whether the observed sensitivity was occurred via p63/ p73 network, we 
tried to treat the breast cancer cells with maximum non-toxic dose of imatinib to inhibit 
the dissociation of TAp63 from TAp73. Then, it was identified that treating HS6ST3-
silenced cells with imatinib and cisplatin was not significantly different from HS6ST3-
silenced cells which was treated with cisplatin only, while the relative percentage of the 
live cells were significantly increased in control group which treated with imatinib and 
cisplatin compared to the control group which was treated with cisplatin only. This 
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observation indicates that silencing HS6ST3 strongly promoted the dissociation of TAp63 
from TAp73 in p63/ p73 pathway so that imatinib was not able to increase the cell 
survival by inhibiting of the dissociation. On the other hand, we further propose that up-
regulation of Tap73 could independently enhance the cytotoxic effect of cisplatin on the 
breast cancer cells (Appendix: Figure 4.2). 
 
As discussed, XAF1 has been shown to be down-regulated in many cancers. Over-
expression of XAF1 was also shown as a potent inhibitor of cancer growth and 
progression. A few studies, examined the critical role of XAF1 expression on the 
sensitivity of the cancer cells to chemotherapeutic agents. Lee et al. understood that 
restoration of XAF1 expression sensitized the urogenital cancers (kidney, bladder and 
prostate) to the cytotoxic effect of etoposide and 5-fluorouracil (5-fu) (Lee et al. 2006). 
This effect was further confirmed in Pinho’s study that examined the role of XAF1 
expression on chemotherapy response of the bladder cancer (Pinho et al. 2009).   
During the last decade, 5-fluorouracil (5-fu) has been widely used as a classic anti-tumor 
drug for treatment of solid tumor such as breast cancer, gastric cancer, colorectal cancer, 
prostate cancer, pancreatic cancer and urogenital carcinomas. 5-fu specifically acts on 
thymidydlate synthase (TYMS) during the S phase and thus inhibiting the cell cycle by 
damaging DNA and RNA synthesis (Shahrokni, Rajebi and Saif 2009). Thymidydlate 
synthase is an important enzyme which is actively involved in synthesis of DNA. 
(Longley, Harkin and Johnston 2003; Salk, Grogan and Chang 2006; Parker and Stivers 
2011) Researchers suggested TYMS as a useful serological biomarker which could 
evaluate the chemotherapy responsiveness in colorectal cancer (Shebzukhov et al. 2005; 
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Gusella et al. 2009; Tan et al. 2011). TYMS was introduced as a critical gene which 
could modulate the chemoresistance to 5-fu and methotrexate. Three polymorphisms 
were discovered for thymidydlate synthase gene so that they could affect the expression 
of TYMS in several cancers (Shahrokni, Rajebi and Saif 2009; Fujishima et al. 2010). 
Kumar et al. revealed that polymorphisms of thymidydlate synthase gene significantly 
influenced the chemoresponsiveness of 5-fu in breast cancer (Kumar, Vamsy and Jamil 
2010). Over-expression of TYMS was shown to be associated with resistance to 5-fu in 
several cancers such as colorectal cancer and esophageal cancer (Lecomte et al. 2004; 
Marsh 2005; Langer et al. 2007; An et al. 2007; Jensen et al. 2008; Peters et al. 2009; 
Martinez-Balibrea et al. 2010; Watson et al. 2010). Ichikawa et al. found that low 
expression of TYMS was associated with tumor shrinkage as well as longer survival of 
gastric cancer after chemotherapy (Ichikawa et al. 2006). Takagi et al. showed that a 
reduction in the expression of TYMS enhanced the chemosensitivity to 5-fu. More 
importantly, they understood that the expression of TYMS was regulated by cyclin-
dependent kinase (CDK). Then, they concluded that inhibition of CDK expression by 
specific drug resulted in suppression of TYMS in a dose-dependent manner and 
sensitized the cancer cells to 5-fu in colorectal cancer (Takagi et al. 2008).  
 
Our microarray analysis showed that by silencing HS6ST3, the expression of CDK-
related genes (CDK2, CDK4, CDK7, CDK8, CDK9, CDK10, CDKAL1, CDKL3, 
CDKL5, CDK5RAP3, CDK2AP2, CDKN2AIP, and CDK5RAP2) was significantly 
decreased, while the expression of CDK-inhibitor genes (CDKN2B, CDKN2D and 
CDKN1C) was increased in breast cancer. Furthermore, we noticed that the expression of 
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TYMS was reduced by 53% (p<0.01) after silencing HS6ST3 in breast cancer. Therefore, 
we may propose that silencing HS6ST3 directly inhibited the expression of TYMS or 
indirectly by up-regulating the CDK-inhibitor genes and consequently down-regulation 
of CDK-related genes that modulates the TYMS expression. Together, it might be 
concluded that low expression of TYMS in HS6ST3-silenced breast cancer cells could 
effectively enhance the cell mediated cytotoxicity of 5-fu in vitro. 
 Silencing of HS6ST3 showed that it could alter the expression of the several genes which 
are critical for chemosensitivity of the breast cancer cells to the cytotoxic effect of 
cisplatin and 5-fu. The significant role of HS6ST3 on the treatment of breast cancer was 
unraveled in vitro in the current pre-clinical study; thus a direct extension of this work 
should be accomplished in vivo. In addition, the results of these findings should be 
validated on the other cancer cell lines. Together, the inclusion of HS6ST3-targeted 
treatment in chemotherapeutic regimes could provide an effective therapy for breast 
cancer as well as the other malignancies. 
 
4.6 Expression analysis of HS6ST3 in clinical specimens of breast ductal carcinoma 
HS6ST3 is a heparan sulfate sulfotransferase that specifically transfers sulfate group from 
3’-phosphoadenosine 5’- phosphosulfate (PAPS) to C6 position of N-acetylglucosamine 
(GlcNAc) residues of heparan sulfate chain. HS6ST3 was shown to play an important 
role in modifying a tissue-specific 6-O-sulfation in heparan sulfate chain (Habuchi et al. 
2000). Changes of the expression of HS6ST3 were reported to be associated with an 
altered heparan sulfate domain structure that may affect the molecular interactions and 
signaling processes (Do et al. 2006).  
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Several studies have demonstrated that 6-O-sulfotransferases are involved in important 
biological processes such as embryonic organogenesis, postnatal growth and 
development (Kamimura et al. 2001; Sedita, Izvolsky and Cardoso 2004; Habuchi et al. 
2007; Izvolsky et al. 2008). Tissue-specific expression of HS6ST3 at different time points 
of embryonic period indicates that their timely expression is significantly required for 
growth factor-related development during organogenesis (Sedita, Izvolsky and Cardoso 
2004). In addition to the embryonic development, HS6ST isoforms seem to influence the 
anticoagulant characteristic of heparan sulfate during its biosynthesis (Zhang et al. 2001).  
 
Recently, researchers have shown an increased interest in identifying the potential role of 
6-O-sulfotransferases in the malignant process of carcinogenesis. Of the few studies, 
remarkable over-expression of HS6ST2 has been demonstrated in serous, papillary, clear 
cell carcinoma of ovary as well as cervical and corpus cancer of uterine (Kanoh et al. 
2006; Seko et al. 2009). However, the potential role of HS6ST3 has not been studied in 
any of the human malignancies. Thus, the significance of HS6ST3 was extensively 
explored on 258 cases of the breast cancer in the current study. In this study, it was 
revealed that HS6ST3 expressed in epithelial and extracellular matrix compartments with 
expression being the strongest in epithelial and stromal cell compartments. 
Immunoreactivity staining (IRS) analysis revealed that the expression of HS6ST3 was 
significantly diminished in stroma matrix of the breast adenocarcinoma compared to the 
normal sections. Analysis showed that by 95% confident interval, the lower and upper 
bound (13.336-18.602) of the staining intensity of HS6ST3 in the matrix stroma of the 
cancer sections had no overlapping with the lower and upper bound (35.735-48.683) of 
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similar staining in the normal section (p< 0.001). This finding was strongly suggestive of 
the diagnostic characteristics of HS6ST3 as a sensitive test for early detecting of the 
breast cancer. 
 
Significant correlations were detected between the expression of HS6ST3 and several 
clinicopathological factors among all of the tissue compartments; however, it seems that 
the biological significance of HS6ST3 is compartment-specific in the cancer tissues as it 
differentially expressed in various tissue compartments. Analysis of the immunoreactivity 
staining (IRS) of the HS6ST3 showed a significant correlation between the expression of 
the HS6ST3 in stroma matrix of the cancer sections and histograde. In specific, the 
expression of HS6ST3 was significantly enhanced by increasing the histograde with 
expression being the weakest in histograde 1. On the other hand, immunoreactivity 
staining of HS6ST3 in epithelial and stromal cells revealed no correlation with 
histograde, while analysis of weighted average intensity (WAI) of the HS6ST3 of 
epithelial cells represented a significant correlation with histograde (p=0.016). In other 
words, the expression of HS6ST3 was enhanced by increasing the histograde with 
expression being the weakest in histograde 1. This finding was consistent with results we 
discussed earlier regarding the correlation of immunoreactivity staining of stroma matrix 
with histograde of the cancer sections. By moving from histograde 1 to histograde 2, the 
IRS and WAI were remarkably increased; however, by shifting from histograde 2 to 
histograde 3, a slight reduction occurred in the expression of the HS6ST3 in epithelial 
cells and matrix stroma of the breast cancer sections.  
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Survival analysis showed breast cancers were associated with poorer prognosis in older 
ages, bigger tumors, progesterone or HER2 negativity. Histograde weakly predicted the 
disease free survival (DFS) of the breast cancer patients, but it was not predictive for 
overall survival (OS) and survival after recurrence (SAR). In addition, we did not find 
any prognostic value for lymph node metastasis, estrogen receptor status and other 
clinicopathological parameters.  
 
On the other hand, univariate survival analysis revealed that staining intensity of HS6ST3 
in various tissue compartments could potentially predict the OS, DFS and SAR of the 
breast cancer patients. Performing multivariate survival analysis further confirmed that  
IRS and WAI of the tissue compartments could be used as a valuable prognostic factor 
for breast cancer. While multivariate analysis showed that the expression level of 
HS6ST3 could strongly predict the prognosis of the breast cancer patients in terms of OS 
and DFS, it was not independently able to predict the SAR of the breast cancer patients. 
Survival analysis interestingly showed that higher expression of HS6ST3 in stroma 
matrix resulted in shorter survival, while similar expression in stroma matrix of the 
tumors with less than three lymph nodes involvements was predictive of a better survival. 
On the other hand, it was identified that the higher expression of HS6ST3 in stromal cells 
of lower histograde and intermediate nuclear grade could valuably predict a longer 
survival for breast cancer patients. Therefore, we may hypothesize that during the process 
of carcinogenesis, the expression of HS6ST3 was firstly diminished in stroma matrix. By 
progressing of the tumor histograde, the epithelial and stromal cells expressed more 
HS6ST3; and thus the expression of the HS6ST3 increased in stroma matrix of the 
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cancerous tissue. Although by increasing of the higher histograde, the expression pattern 
of the HS6ST3 had an ascending trend in the epithelial cells and stroma matrix 
compartments, a slight reduction was observed in the expression of HS6ST3 of the 
histograde 3 compared to the histograde 2. Thus, it is postulated that the expression of 
HS6ST3 in stroma matrix could be regulated by epithelial and stromal cells. In other 
words, the expression of HS6ST3 in stromal matrix could be a consequent of HS6ST3 
expression in epithelial or stromal cell. However, we think that the expression of the 
HS6ST3 in stroma matrix could directly play a crucial role in the malignant process of 
carcinogenesis because it could potentially edit the 6-O-sulfation of the cell surface and 
stroma matrix heparan sulfates and thus change the interactions of the heparan sulfate 
chain with a several ligands such as growth factors. This alteration in turn could affect the 
growth factor signaling pathway(s) which enhance the tumoral growth and progression. 
 
This study was the first research which unraveled the clinical significance of the HS6ST3 
in breast cancer. Herein, we understood that HS6ST3 was up-regulated in the breast 
cancer and could potentially regulate the growth and progression of this malignancy. 
Although the underlying molecular mechanisms are unclear, we think that HS6ST3 might 
have an important contribution in the malignant process of carcinogenesis. This 
contribution could be possibly due to the alteration of 6-O-sulfation of heparan sulfate 
chain which could potentially change the interactions between heparan sulfate molecules 
with a variety of signaling ligands such as growth factors. 
Together, the current study is of valuable importance in terms of diagnosis the breast 
cancer at any grade or stage. In addition, it was provided a clinically significant insight 
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for clinician to predict the breast cancer prognosis and then decide about the timely ideal 
therapy.  
 
This study was restricted to unravel the diagnostic and prognostic values of HS6ST3 in 
the breast cancer; but we did not explore the role of HS6ST3 in other malignancies. Thus, 
to achieve this goal further research is required.  
 
4.7 Expression analysis of SULF1 in clinical specimens of breast ductal carcinoma 
A variety of molecular changes has been identified in breast cancer; however, their 
clinical significance is poorly understood. SULF1 is a potent sulfation modifying 
enzymes which specifically edit 6-O-sulfation on the cell surface and extracellular matrix 
by removing the sulfate group from C6 position of N-acetylglucosamine in heparan 
sulfate chain and thereby modulating the biological activity of heparan sulfate (Holst et 
al. 2007). SULF1 is dysregulated in breast cancer as well as several other cancers. DNA 
methylation and histone acetylation are two proposed mechanisms for down regulation of 
SULF1 gene in epithelial cells of cancers such as ovarian, breast and hepatocellular 
carcinoma (Castro et al. 2008). Although, this alteration could potentially be a significant 
stage in tumorogenesis of breast cancer, the molecular basis for the involvement of 
SULF1 expression in malignant process is still unknown.  
 
In this study, we have shown that SULF1 expresses in epithelial cells as well as 
extracellular matrix with expression being the weakest in stromal cells. Significant 
correlations were detected between the expression of SULF1 and several 
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clinicopathological factors among all of the tissue compartments; however, it seems that 
the biological significance of SULF1 is specific to tissue compartments since localization 
of this enzyme has a multimodal nature in different tissue compartments. In particular, 
we identified that the expression of SULF1 is differentially associated with various 
clinicopathological parameters in different tissue compartment of breast cancer 
specimens.  
 
In this study, the clinical significance of SULF1 was extensively explored on 267 cases 
of the breast cancer. SULF1 was differentially expressed in epithelial cells and extra 
cellular matrix compartments. The expression of SULF1 in majority of epithelial cells of 
the cancer sections had an obvious reduction; however, due to the large variation in the 
expression of this enzyme in different grades we did not find any significant difference 
amongst the histogrades. Unlike the epithelial cells, the expression of SULF1 in stromal 
cells was statistically lower than other tissue compartments both in normal and cancer 
sections. This expression significantly increased when the breast cancer shifted from 
histograde 2 to the highest histograde (3) (P=0.049). Additionally, it was revealed that the 
stronger SULF1 expression in stromal cells is predictive of a poorer prognosis for breast 
cancer survival; while, a similar expression of SULF1 in epithelial cells and stroma 
matrix was observed to have a longer survival in breast cancer patients (Table 3.18). 
SULF1 express weaker in stromal cells than other tissue compartments; however, it 
seems that increasing the expression of SULF1 in stromal cells is clinically of great 
importance as a novel prognostic factor. Although SULF1 is less expressed in matrix 
stroma of breast cancer compared to normal breast tissue, it is postulated that increasing 
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SULF1 expression in stromal cells of more invasive cancers is concomitant with 
increasing the SULF1 shedding in stroma matrix. Thus, interpreting SULF1 staining 
intensity in all of the tissue compartments could be a more useful tool for predicting a 
cancer state specifically with regards to clinicopathological associations.  
 
Survival analysis in our study showed that more lymph node infiltration and bigger tumor 
size were associated with poorer OS and DFS. However, we could not distinguish any 
association between histograde and survival of breast cancer patients. On the other hand, 
while none of the histopathological features were able to predict DFS in univariate 
survival analysis, the expression of SULF1 was able to significantly function as a 
valuable prognostic factor for predicting both OS and DFS. Tumor laterality was another 
prognostic factor which suggests that left sided breast cancer are significantly associated 
with a better prognosis. This observation might be due to the anatomical differences in 
vascular distribution between left and right auxiliary regions.  Multivariate survival 
analysis further confirmed that the IRS of tissue compartments could be used as a 
valuable prognostic factor. 
 
All together, these observations suggest a potential role for involvement of SULF1 in 
malignant process of carcinogenesis in breast cancer. Since, the expression of SULF1 is 
generally higher in normal breast tissue compared to cancerous tissue; we postulate that 
down regulation of SULF1 in breast cancer epithelial cells as well as other cancers could 
be a starting point in the chain of cancer tumorogenesis. A possible explanation is that 
under-expression or non-functionality of expressing SULF1 in epithelial cells of breast 
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tissue could result in over-sulfation of carbon 6 positions in heparan sulfate chain which 
in turn entertains a variety of signaling growth factors on the cell membrane of epithelial 
cells. Therefore, in the process of tumorogenesis, normal epithelial cells present invasive 
phenotype. However, once the cancer cells transform to higher histogrades, stromal cells 
might be reactivated in response to the malignant state of stroma matrix 
microenvironment and thus the expression of SULF1 would be enhanced by stromal cells 
in order to modulate the malignant state by suppressing heparin-binding growth factor 
signaling. Besides, due to the rapid turnover of reactive stromal cells, the SULF1 content 
of stroma matrix is increased in higher grades of breast cancer (Appendix: Figure 4.3). 
Although, stromal cells may attempt to repress the rapidly growing rate of epithelial cells 
by expressing SULF1 (Lai et al. 2004), this inhibitory mechanism might not be strong 
enough to completely repress the uncontrolled invasive phenotypes of the tumor cells. 
 
The newly developed biomarkers during the last decades have played an important role in 
identifying signaling pathway(s) involved in malignant process of breast tumorogenesis. 
In addition, some of these biomarkers have served as novel diagnostic or prognostic 
detection markers in breast cancer as well as other cancers. In fact, identifying new 
cancer biomarkers lead to early detection of cancer besides receiving optimal treatment. 
On the other hand, they could be potentially targeted as therapeutic molecule(s) to inhibit 
the pathological process of tumorogenesis (Shao et al. 2011). Currently, optimal 
treatment for breast cancer basically depends on the stage of disease at the time of 
diagnosis. An effective treatment further depends on availability of several biomarkers 
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profile such as estrogen receptor, progesterone receptor and HER2 (Alvarez Goyanes et 
al. 2010). 
This study greatly has contributed to exploring an important prognostic role for SULF1 in 
breast cancer as it has provided guidelines for determining breast cancer survival. 
However, interpretation of interesting correlations of HER2 and tumor size with SULF1 
expression which were observed in this study has remained unknown due to the lack of 
current knowledge about the biological role of SULF1 in human. Thus, we would like to 
suggest this study as a preliminary basis for further research on using human SULF1 as a 
diagnostic biomarker in breast cancer. Therefore, in the future, using SULF1 expression 
as a powerful tool may enable clinicians to decide their therapeutic strategies ranging 
from less invasive therapies to very invasive therapies such as total mastectomy as well 
as combinational chemotherapy and radiotherapy. However, further research is required 
to uncover the underlying molecular mechanisms for the involvement of SULF1 in breast 
carcinogenesis. Meanwhile, a direct extension of this work should be considered on other 
cancers as this study was mainly restricted to breast cancer. 
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In this study, we showed that that silencing HS6ST3 could significantly diminish the 
tumor growth and progression in breast cancer by reducing the proliferation, migration 
and invasion, while inducing the apoptosis and enhancing the adhesion. Genome wide 
microarray analysis revealed that the expression of a number of genes was changed after 
silencing HS6ST3 in the breast cancer. By performing extensive literature review, we 
found a few critical up- and down-regulated genes which might be involved in the 
malignant process of carcinogenesis in the breast cancer. Out of a few recognized genes, 
we understood that the functional role of IGF1R and XAF1 had of great importance in the 
HS6ST3 pathway. IGF1R was significantly down-regulated, while XAF1 was up-
regulated after silencing HS6ST3 in the breast cancer. To validate our hypothesis, several 
functional experiments were designed by silencing HS6ST3 and blocking IGF1R or 
silencing XAF1 in the breast cancer. Then, it was found that IGF1R and XAF1 
significantly could modulate the phenotypic behavior of the tumor cells in mammary 
cancer. Thus, we found that IGF1R and XAF1 critically mediated the modulatory 
function of the HS6ST3 in the breast cancer.  
 
Additionally, it was shown that silencing HS6ST3 could diminish the expression of the 
heparan sulfate on the cell surface. Our microarray data revealed that the expression of 
glypican 6 was significantly reduced after silencing HS6ST3 in the breast cancer, while 
syndecans bore no significant difference. Since silencing HS6ST3 diminished the 
cytoplasmic heparan sulfate expression, it is plausible that glypican 6 comprised the 
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major content of heparan sulfate on the cell surface of the breast cancer cell line and thus 
silencing HS6ST3 affected the expression of the glypican 6 in the breast cancer.  
 
Our findings indicated that HS6ST3 could regulate the breast cancer phenotypic behavior 
by regulating the expression of critical genes directly and/ or influence the interactions 
between heparan sulfate and several growth factors on the cell surface. 
 
Based on our microarray data, we further noticed that changing the expression of specific 
genes might sensitize the tumoral cell to specific chemotherapeutic drugs. Then, by 
performing cytotoxicity assays it was identified that silencing HS6ST3 could sensitize the 
breast cancer cells to the cytotoxic effect of Cisplatin and 5-fu.  
 
Therapeutic targeting of IGF1R and XAF1 has attracted attentions in many studies. 
Herein, we found an important gene which could regulate IGF1R and XAF1 and thus 
could target both of them at the same time while it could sensitize the breast cancer to 
Cisplatin and 5-fu. Thus, a new pathway was introduced that could be used as an 
effective therapy for the breast cancer.  
 
The immunohistochemical findings on heparan sulfate editing enzymes using HS6ST3 
and SULF1 antibodies in the breast cancer showed that the expression of SULF1 and 
HS6ST3 were dysregulated in breast cancer. Besides, it was identified that HS6ST3 could 
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be used as a novel diagnostic and prognostic tool for breast cancer, while SULF1 could 
be used as a prognostic factor in breast carcinoma.  
   
These finding are of considerable significance since they have introduced an interesting 
gene which regulates breast cancer behavior. The significance of the current study is not 
limited to the regulatory role of HS6ST3 in cellular processes because it could be also 
used as a novel prognostic and/ or diagnostic biomarker in breast cancer. In addition, it 
might be useful as an effective therapeutic target for treating breast cancer as well as 
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Figure 4.1. Proposed schematic pathway analysis for the genomic functions of HS6ST3 in 
the breast cancer. Silencing HS6ST3 significantly diminished the tumoral growth and 
progression in the breast cancer. Green color reveals the down-regulation and red color 
reveals the up-regulation of the gene(s). Arrow indicates the positive regulation and the 





Figure 4.2. Schematic diagram for p63/ p73 pathway. Dissociation of the Tap73 activates 
the BCL-2 family which results in apoptosis. Arrow reveals the positive regulation and 




Figure 4.3. Expression of SULF1 in stromal cells of the breast cancer tissue. Expression 
of SULF1 in reactive stromal cells (arrow) enhanced in response to the cancer 
microenvironment, while this expression in epithelial cells reduced. (A) Breast ductal 
carcinoma histograde 2 (B) Breast ductal carcinoma histograde 3. SULF1 expression of 
reactive stromal cells increase when grade 2 shift to grade 3; however, due to the high 
turnover of stromal cells around malignant epithelial cells, SULF1 expression may 
increase in stroma matrix. 
